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1. Zusammenfassung 
Natürliche Killerzellen (NK) sind Effektorzellen des angeborenen Immunsystems, die in der Tumorabwehr 
eine wichtige Rolle spielen. Die Aktivierung von NK-Zellen wird durch ein Zusammenspiel von Signalen 
hemmender Rezeptoren, die zumeist MHC Klasse I erkennen, und aktivierender Rezeptoren bestimmt. 
Neben zielgerichteter Eliminierung von Zellen, können NK-Zellen zusätzlich Botenstoffe freisetzen, die 
Entzündungen bewirken und somit Immunantworten des angeborenen und des adaptiven Immunsystems 
auslösen. 
In unserer Studie charakterisierten wir NK-Zellantworten gegen MHC Klasse I defiziente Lymphome in 
Mäusen. Unsere Untersuchungen zeigten, dass nach subkutaner Injektion von RMA-S Zellen NK-Zellen, 
die in den Tumor eingewandert sind, einen geringen Reifungsgrad (CD27high) aufweisen. Zusätzlich zeigte 
diese Population einen aktivierten Phänotyp, der sich durch hohe Expression von B220, MHC Klasse II 
und zytotoxischen Effektormolekülen widerspiegelt. Genexpressionsanalysen mittels Microarrays machten 
deutlich, dass Tumor-infiltrierende NK-Zellen ein stark unterschiedliches Transkriptionsprofil aufweisen als 
NK-Zellen im Blut von Tumor-tragenden Mäusen. NK-Zellen im Tumor zeigten neben einem verringerten 
Ausmaß von aktivierenden NK-Zellrezeptoren zusätzlich einen Anstieg von hemmenden Molekülen. Die 
meisten dieser Änderungen auf Transkriptionsebene konnten ebenso auf Proteinebene bestätigt werden.  
Tumor-infiltrierende NK-Zellen exprimierten ein höheres Ausmaß von Mitgliedern der B7-Proteinfamilie 
verglichen mit NK-Zellen aus dem Blut. Hierzu zählen der aktivierende Rezeptor CD28 und die 
hemmenden Rezeptoren CTLA-4 und B7-H1, die alle an B7-1 binden. Die Funktion dieser Moleküle ist in 
T-Zellen gut verstanden, in NK-Zellen allerdings größtenteils unbekannt. sere Daten zeigten, dass die 
Expression von CD28 und CTLA-4 mittels IL-2 auf NK-Zellen induzierbar ist bzw. sich die Expression von 
B7-H1 erhöhen lässt. Eine Stimulierung von in vitro expandierten NK-Zellen mit einem B7-1 IgG 
Fusionsprotein führte zu Proliferation von NK-Zellen und deren IFNγ-Produktion. Mit Hilfe von knockout 
Mäusen zeigten wir, dass nach Stimulation von NK-Zellen mittels B7-1 IgG IFNγ-Produktion durch CD28 
vermittelt und diese durch die CLTA-4 und B7-H1 Rezeptoren negativ reguliert wird. Im Gegensatz dazu 
wurden B7-1 exprimierende Zielzellen durch IL-2 expandierte NK-Zellen unabhängig von CD28, CTLA-4 
und B7-H1 lysiert. Zudem beobachteten wir, dass in einer Ko-Kultur von NK-Zellen und B7-1 
exprimierenden Zellen, darunter transduzierte Tumorzelllinien sowie reife dendritische Zellen, einen 
interzellulären Transfer von B7-1 der Zielzellen zu NK-Zellen bewirkt. Dieser Prozess ist teilweise 
abhängig von CD28. Schliesslich wiesen unsere Experimente darauf hin, dass wiederholte Applikation von 
IL-2 das Wachstum von B7-1+ Melanome in T- /B-Zell defizienten Mäusen hemmt. Dieser Effekt konnte 
durch gleichzeitige CTLA-4 Blockierung noch geringfügig verbessert werden.  
 
Zusammenfassend zeigen unsere Daten, dass Tumor-infiltrierende NK-Zellen einen unterschiedlichen 
Phänotyp als NK-Zellen aus dem Blut aufweisen. Dies spiegelt sich sowohl in ihrem Reifungsgrad, der 
Expression von aktivierenden und inhibierenden Molekülen als auch in ihrem umfassenden 
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Transkriptionsprofil wider. Wir beobachteten, dass bestimmte Rezeptoren der B7-Familie unterschiedlich 
exprimiert sind, die die Effektorfunktionen von NK-Zellen in vitro regulieren. Unsere Experimente deuten 
darauf hin, dass Mitglieder der B7-Proteinfamilie während der Tumorentwicklung eine wichtige Rolle bei 
der Kontrolle von NK-Zellantworten spielen. Unsere Ergebnisse sollten bei Immuntherapien gegen 
Tumore, die auf der Wirkung von NK Zellen beruhen, mit einbezogen werden. 
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2. Summary 
Natural killer (NK) cells are innate immune effector cells that play an important role in anti-tumor defense. 
A delicate balance of signals delivered by activating ligands and inhibitory molecules, mainly MHC class I, 
expressed by target cells, determinates the NK cell activation. Besides direct killing of target cells, NK cells 
release mediators that induce inflammation and exert immunoregulatory effects influencing both innate 
and adaptive immune responses. Although efficient at eliminating metastazing cells and small tumor 
grafts, the eradication of larger solid tumors by NK cells is usually not efficient, despite the low expression 
of MHC class I by tumor cells in many cases.  
In our study, we characterized the in vivo NK cell response against the MHC class I deficient mouse 
lymphoma. We demonstrate that after subcutaneous injection of RMA-S tumor cells, NK cells infiltrating 
the tumor tissue (TINs) correspond to the less mature CD27high NK cell population. At the same time, the 
subset of TINs displays a phenotype of activating state, which is reflected in the elevated expression of 
B220, MHC II and cytotoxic effector molecules. Gene expression profiling using whole genome 
microarrays, revealed a strikingly different transcription profile of tumor infiltrating compared to blood NK 
cells of tumor bearing mice. TINs downregulated activating NK cell receptors, which was accompanied by 
upregulation of inhibitory molecules. We confirmed that most of the molecules that were differentially 
regulated at the mRNA level were also differentially expressed at the protein level. 
As compared to NK cells from the blood, expression of several members of the B7 protein family was 
elevated in TINs, including the activating receptor CD28 and the inhibitory receptors CTLA-4 and B7-H1, 
which all bind the B7 family ligand B7-1. Our data demonstrate that the expression of CD28 and CTLA-4 
can be induced and expression of B7-H1 elevated on NK cells by IL-2. Stimulation of in vitro expanded NK 
cells with a B7-1 IgG fusion protein induced NK cell proliferation and IFNγ production. Using gene deficient 
NK cells, we demonstrated that B7-1 dependent IFNγ production was mediated by CD28, and negatively 
regulated by CTLA-4 and B7-H1 receptors. The lysis of B7-1 expressing target cells by IL-2 expanded NK 
cells was independent of CD28, CTLA-4 and B7-H1 expression. We observed that co-incubation with B7-1 
expressing cells, including transduced tumor cell lines and mature dendritic cells, led to the intercellular 
transfer of B7-1 from target cells to the NK cells, in a process that partially depended on CD28. Our 
experiments indicated that therapeutic responses to B7-1+ melanoma, mediated by IL-2 in T and B cell 
deficient mice, could be moderately improved by CTLA-4 blockade. 
In summary, our data reveal that NK cells infiltrating solid tumors display a phenotype different from NK 
cells found in blood, including their maturation state, expression of activating and inhibitory molecules and 
global transcription profile. We demonstrate that certain receptors of the B7 family that were differentially 
expressed by TINs, regulated NK cell effector responses in vitro. Our results suggest that members of the 
B7 protein family can be involved in the complex control of NK cell responses during tumor progression 
and should be considered as potential targets in NK cell based anti-cancer immunotherapy. 
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3. Introduction 
 
3.1. The immune system 
The immune system represents the complex network of molecules, cells, tissues and organs evolved to 
protect the organism from pathogens. The main property enabling the immune system to accomplish its 
function is the ability to recognize non-self molecules as well as “altered-self” state. “Altered-self” 
recognition and possibility to sense any kind of cellular stress enables the immune system to detect both 
infected and transformed cells and potentially prevents the development of malignancy. Any molecule that 
can be recognized by the immune system leading to the activation of protective responses is considered 
an antigen. Two main components of the immune system, the innate and the adaptive, are distinguished in 
vertebrates based on the type of antigens they recognize, recognition strategy and kinetics of response. 
 
3.1.1. The innate immune system 
The innate immune system consists of distinct subsystems that prevent the entrance and establishment of 
infectious agents. Its main property is fast activation of pre-existing defense mechanisms (Table 3.1), 
thereby is considered as the first line of defense against potential danger. The principal components of 
innate immunity are physical and chemical barriers (epithelia, anti-microbial substances), cells 
(phagocytes, natural killer cells), blood proteins (complement) and cytokines. The receptors of the innate 
system are germ-line coded molecules that recognize so called pathogen-associated molecular patterns 
(PAMPs), as well as molecules expressed by host cells upon infection or any kind of cellular stress, 
including malignant transformation. PAMPs are evolutionary conserved structures unique to pathogens 
and often shared by particular classes of microbes. In addition, they usually represent essential 
evolutionary preserved components necessary for pathogen survival. Typical examples are complex lipids 
and carbohydrates found in bacterial (LPS, peptidoglycan, lipoteichoic acid) and fungal (β-glycan) cell 
walls, some viral proteins (m157 from mouse CMV) or specific modifications of viral and bacterial nucleic 
acids (double-stranded RNA, unmethylated CpG DNA sequences). The best characterized 
pattern-recognition receptors (PRRs) are the Toll-like receptors (TLRs), which recognize a multitude of 
pathogen-derived molecules [1]. TLR triggering stimulates pathogen uptake by phagocytic cells 
(macrophages, dendritic cells, neutrophils), which results in their destruction and secretion of factors 
(proinflammatory cytokines and chemokines) that recruit and activate other immune effectors. Pathogen 
detection and uptake by dendritic cells (DC), which are termed professional antigen-presenting cells 
(APC), lead to their maturation and migration to the local lymph node, where they initiate the adaptive 
immune response. In general, many mechanisms employed by the innate immune system function to not 
only eliminate infectious agent but also to prime, enhance and polarize the proper adaptive immunity
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tailored according to the pathogen type. The effective response to the invading pathogen depends on the 
proper activation of both arms of the immune system. 
 
Innate subsystem  Principal function 
Barriers 
Epithelial layers  Prevent microbial entry 
Defensins  Microbial killing 
Intraepithelial lymphocytes  Microbial killing 
Circulating effector cells 
Neutrophils  Early phagocytosis and microbial killing 
Macrophages 
Efficient phagocytosis and microbial killing 
Secretion of cytokines that stimulate inflammation 
NK cells  Lysis of infected cells, activation of macrophages 
Dendritic cells 
Antigen uptake and processing 
Priming of adaptive immune system 
Circulating effector proteins 
Complement 
Microbial killing and opsonization 
Activation of leukocytes 
Mannose‐binding lectin (collectin)  Microbial opsonization, activation of complement 
C‐reactive protein (pentraxin)  Microbial opsonization, activation of complement 
Coagulation factors  Walling off infected tissues 
Cytokines 
TNF, IL‐1, chemokines  Inflammation 
Type I interferons  Resistance to viral infections 
IFNγ  Macrophage activation 
IL‐12  Induction of IFNγ production 
IL‐15  NK cell proliferation and survival 
IL‐10, TGFβ  Control of inflammation 
 
Table 3.1. Subsystems of the innate immune system. The principal components of the innate immunity are physical 
and chemical barriers that prevent pathogen entry and establishment of infection, and cells, blood proteins and 
cytokines that participate in the clearance of microbes from the organism. Representative components of innate 
subsystems are listed in the table. [2] 
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3.1.2. The adaptive immune system 
The hallmarks of adaptive immunity are delayed responses compared to the innate immune system upon 
the first encounter with pathogen, high diversity of receptors formed by the process of somatic 
recombination and the ability to develop immunological memory. Memory response is raised upon any 
subsequent recognition of the previously encountered antigen and it is faster and stronger in intensity, 
thereby more efficient. The diversity of the antigen receptors of adaptive immune cells is formed through 
the process of somatic recombination in which sets of germ-line coded DNA sequences are randomly 
brought together to form functional B cell (BCR) and T cell receptor (TCR) genes [3]. RAG-1 and RAG-2 
are the genes encoding the enzymes, which are the main components of the recombination machinery [4]. 
Since the expression of functional receptors is the prerequisite for B and T cell maturation, mice deficient 
in RAG coded enzymes lack B and T cells [5-6]. Every B and T cell expresses only one type of receptor 
with unique specificity, forming a clonally distributed repertoire. The receptors of adaptive immune system 
are not able to distinguish non-self from self. Rather, non-reactivity to self is achieved through the complex 
sequences of mechanisms called tolerance induction, which includes deletion or specific inactivation of 
self reactive clones, differentiation of regulatory cells and others [7-8].  
 
 
Figure 3.1. Differentiation of B cells into specialized effector subsets after antigen recognition. Activated B cells 
differentiate into antibody-secreting plasma cells or memory cells. In the germinal centers formed in the peripheral 
lymphoid organs activated B cells undergo a process of proliferation, isotype switch and affinity maturation that 
enables the differentiated plasma cells to secrete antibodies with high affinity for encountered antigen. Various 
isotypes of produced antibodies are specialized for different functions. Memory cells reside in bone marrow and are 
capable of fast differentiation into plasma cells upon subsequent recognition of the same antigen. [9]  
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The humoral and cellular effector arms are the two main systems operated by adaptive immunity. Humoral 
immunity is mediated by B cells and it is targeted against extracellular antigens. B cell receptors (BCR) are 
membrane bound immunoglobulins that can recognize diverse microbes and microbal toxins and activate 
B cells to differentiate into either antibody-secreting plasma cells or memory cells (Figure 3.1). In addition, 
activated B cells can accomplish the function of APCs and contribute to the development of cellular 
immunity. Antibodies represent isotype-switched soluble immunoglobulin molecules secreted by B cells. 
Different classes of antibodies mediate specific responses that include antigen neutralization, which 
prevents the host cell invasion, and opsonization of pathogens enabling their phagocytosis and/or 
destruction by the innate cellular effectors. In addition, antibodies activate the complement system, 
mediate mucosal immunity and stimulate mast cell degranulation. 
Intracellular pathogens that are not accessible to antibodies are attacked by cell mediated immunity 
operated through T cells. T cells, like B cells, originate in the bone marrow (BM), but unlike B cells, migrate 
to the thymus to complete their maturation. T lymphocytes recognize protein antigens via the T cell 
receptor complex only when displayed as peptides bound to self major histocompatibility complex (MHC) 
molecules and presented by APCs. Based on the expression of membrane glycoproteins, which are the 
essential parts of TCR complex, T cells are divided into CD4+ and CD8+ subsets. CD4+ T cells recognize 
MHC class II associated peptides, which are derived mainly from endocytosed proteins, while CD8+ T cells 
recognize MHC class I associated peptides, which are mainly derived from cytosolic, endogenously 
produced proteins. To become fully activated, in addition to TCR engagement, costimulatory signals 
provided by APCs are crucial to trigger the functional T cell responses. In addition to the quality of 
costimulation, cytokines produced by innate immune cells at the site of antigen recognition polarize T cell 
differentiation towards effector cells with specific functional properties (Figure 3.2).  
CD4+ T cells differentiate into one of three T helper cell (Th) lineages - Th1, Th2 and Th17, or to the 
induced regulatory T cells (iTreg) (Figure 3.2) [11]. IFNγ and IL-12 potentiate differentiation of Th1 cells, 
which produce IFNγ and activate macrophages, DCs, B cells and CD8+ T cells to perform their functions. 
IL-4 triggers the differentiation of the Th2 subset. They produce IL-4, IL-5 and IL-13 and control 
multicellular parasite infections through B cell, mast cell and basophil activation. Finally, transforming 
growth factor β (TGFβ) in the presence of proinflammatory cytokines, such as IL-6, IL-21 and IL-23, 
triggers the differentiation of Th17 cells. In the absence of inflammation, a high concentration of TGFβ 
favors the differentiation of regulatory T cells. Th17 cells produce IL-17 and IL-22 and play an important 
role in the clearance of extracellular bacteria and fungi, especially at mucosal surfaces. Regulatory T cells 
inhibit responses of other effector cells. They are involved in the control of ongoing immune responses, but 
also in the prevention of autoimmunity. 
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Figure 3.2. Differentiation of CD4+ T cells into specialized effector subsets after antigen recognition. Activated CD4+ T 
cells can differentiate into four functional subsets driven by cytokines present in the microenvironment. Th1 cells 
support cell-mediated immunity and develop under the influence of IL-12 and IFNγ. Th2 cells differentiate in the 
presence of IL-4 and support humoral immunity. TGFβ in the presence of IL-6 induces differentiation of Th17 cells, 
which stimulate the clearance of extracellular bacteria and fungi. In the absence of IL-6, regulatory T cells, which 
control the responses of multiple immune effector cells, are differentiated. [10]  
Naïve CD8+ T cells differentiate into cytolytic T lymphocytes (CTLs) upon antigen recognition and 
additional stimuli provided by Th1 cells. Their main effector functions are the elimination of target cells 
expressing the peptide-MHC I complexes against which response has been raised and production of IFNγ. 
Thus, specific effector functions of different components of the adaptive system are developed based on 
initial pathogen encounter by innate immune recognition mechanisms and mediators produced dependent 
on the pathogen type. One of the functions of specialized adaptive responses raised in such way is further 
enhancement of innate mechanisms necessary for pathogen clearance. 
 
 
3.2. NK cells 
Natural killer (NK) cells represent a lymphocytic population that provides the first line of defense against 
diverse pathogens through the direct elimination of infected cell and production of cytokines and 
chemokines. In addition, NK cells are recognized to be important for the control of graft rejection and 
pregnancy. They also play an important role in tumor growth control and prevention of metastatic 
dissemination [12-15].  
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NK cells are classified as innate immune effector cells based on the observations that they lack typical T 
and B cell surface markers, and, more importantly, do not depend on the process of somatic 
recombination. Therefore, they are present in mice and humans unable to rearrange their antigen receptor 
genes. Instead, NK cells express several classes of germ-line coded receptors, which are used for 
recognition of potential danger signals. Initially, NK cells were discovered as a spleen cell population of 
naïve mice and rats and peripheral blood cell subset of healthy human donors that mediate spontaneous 
cytotoxic activity against different tumor cell lines [16-19]. Although very often defined as killing effectors 
with the capacity to eliminate dangerous cells without prior sensitization, there is emerging evidence that 
NK cell activation is regulated by integrated signals provided by surface receptors recognizing both 
potential targets and sensing local microenvironment [20]. In response to activating signals, besides 
cytotoxicity, the production of multiple cytokines and chemokines is triggered. Through these effector 
responses NK cells can eliminate potentially dangerous target cells, but also impact on ongoing innate and 
emerging adaptive immune responses [21]. 
 
3.2.1. NK cell activation - recognition of target 
3.2.1.1. Inhibitory NK cell receptors 
Primary targets of NK cells are infected, transformed as well as cells experiencing any kind of stress, 
including heat shock or irradiation. To be able to perform their effector functions upon target encounter, 
it is essential for NK cells to distinguish potentially dangerous from normal cells. Kärre and colleagues 
formulated the “missing-self” hypothesis describing a strategy for recognition based on the observation 
that MHC class I deficient congenic tumor cells are very efficiently lysed by NK cells [22-24]. Cells that 
express MHC class I on the cell surface at sufficient density would be then protected due to the 
engagement of inhibitory receptors expressed by NK cells that specifically recognize self MHC class I 
(Figure 3.3A). C-type lectin Ly49 receptor family in mice, killer cell immunoglobulin-like (KIR) and 
leukocyte immunoglobulin-like (LIR) receptor family in humans and CD94/NKG2A complex in both species 
interact with self MHC class I ligands (Table 3.2). The principal mechanism of action of MHC I specific 
inhibitory NK receptors is based on the presence of immunoreceptor tyrosine-based inhibitory motif (ITIM) 
in their cytoplasmic tail, which recruits inhibitory signaling molecules and terminates putative activating 
signal transduction (Figure 3.3B). Most of NK cells express at least one MHC class I specific receptor. 
Inhibitory receptor repertoire formed over the individual cells allows the global NK cell pool to successfully 
monitor self and reacts when pathological conditions interfere with MHC class I expression [25-26].  
NK cells expressing no inhibitory receptors for autologous MHC I alleles have been identified in healthy 
individuals and mice. However, they are rendered hyporesponsive in order to prevent possible 
autoreactive responses [27-28]. Similarly, in humans with transporter-associated antigen processing (TAP) 
deficiency or in mice with no MHC I expression (β2m, TAP1, H2-K
b, H2-Db gene deficient mice), NK cell 
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effector responses are reduced [29-30]. The need of NK cell to recognize self MHC class I during 
maturation in order to develop full effector competence is referred to as “licensing” [31]. 
In addition to MHC I specific receptors, NK cells express several other inhibitory receptors that recognize 
ligands widely expressed on normal cells. Their level of expression is often modified upon infection or 
malignant transformation. For example, the KLRG1 inhibitory receptor that recognizes cadherins can be 
considered as receptor providing an alternative strategy of sensing “altered-self” [32-33]. 
 
Receptor  Species  Ligand 
NKG2A/CD94  Mouse, Human 
HLA‐E in human 
Qa‐1 in mouse 
KLRG1  Mouse, Human  Cadherins 
2B4  Mouse, Human  CD48 
NTB‐A  Mouse, Human  NTB‐A 
Ly49A  Mouse  H‐2d, k, p
Ly49C  Mouse  H‐2b,d,k,s 
Ly49I  Mouse  H‐2r, b, d, k, q, s, v
Other Ly49  Mouse  Various mouse MHC I alleles 
NKR‐P1B  Mouse  Clr‐b 
CD161  Human  LLT1 (Clec2D) 
Various KIR  Human  HLA‐A/‐B/‐C 
KIR2DL4  Human  HLA‐G 
LIR1  Human  HLA I, UL18 HCMV protein 
CAECAM1  Human  CAECAM1 
Siglec‐7/9  Human  Sialic acid 
 
Table 3.2. Inhibitory NK cell receptors and their ligands. [34-35] 
 
 
3.2.1.2. Activating NK cell receptors 
MHC class I deficiency is not sufficient to trigger full NK cell activation that requires in addition the 
engagement of activating receptors, including members of the Ly49 family in mice, KIR-S family in humans 
and natural cytotoxicity receptors (NCR), NKG2D, DNAM-1 and CD94/NKG2C complex in both species 
(Table 3.3). Those receptors recognize diverse ligands that can be derived from invading pathogens or 
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induced on infected, transformed and stressed cells. The necessity for the existence of a positive signal for 
NK cell activation in addition to the absence of inhibition represents the basis for the “induced-self” 
recognition strategy. A delicate balance of inhibiting and activating pathways that govern NK cell activation 
is further hard-wired with cytokine, chemokine and costimulatory signals, which together influence the final 
effector response defined both by the nature of the target and the local microenvironment. 
Receptors for MHC class I often exist in pairs of activating and inhibitory receptor with a highly 
homologous extracellular domain. The inhibitory receptors have a significantly higher ligand affinity 
compared to the activating counter receptors. In steady state conditions, inhibitory signals dominate over 
the interaction of NK cell and autologous target cell. This inhibition is based on the recruitment of SRC 
homology 2 (SH2)-domain-containing protein tyrosine phosphatases to the ITIM motifs of inhibitory 
receptors, such as SHP-1 and SHP-2. They dephosphorylate and inactivate signaling molecules, which 
mediate activation downstream of activating receptors (Figure 3.3B) [36-38].  
 
Figure 3.3. NK cell activation upon recognition of susceptible target cells.  A) Normal cells typically engage both the 
activating and the inhibitory NK receptors. Signals delivered through the inhibitory receptors dominate and prevent NK 
cell activation and the lysis of normal cell. Infected or transformed cells dowregulate expression of inhibitory ligands 
(missing self recognition) or/and upregulate ligands for activating NK cell receptors (induced-self recognition) allowing 
NK cell activation. B) Upon ligand engagement, activating NK cell receptors recruit signaling molecules, such as 
protein kinases Syk, ZAP70 and PI3K that mediate NK cell activation. The inhibition of NK cell triggering is based on 
the recruitment of tyrosine phosphatases, such as SHP-1, to the ITIM motifs of inhibitory receptors or associated 
adaptor molecules, which dephosphorylate and inactivate signaling molecules downstream of activating receptors. 
[34, 39] 
Several pathogen-encoded molecules are known to be directly recognized by NK cells and induce their 
activation. The MCMV derived m157 protein is detected via Ly49H, influenca A and Sendai virus derived 
haemagglutinins via NKp44 and NKp46, Staphylococcus aureus derived endotoxin B and ligands derived 
from Mycobacterium tuberculosis, Plasmodium falciparum and Leismania spp. via yet unidentified 
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receptors. However, the majority of pathogens are sensed by accessory cells, such as monocytes, 
macrophages and dendritic cells that upon encounter of pathogen transmit activation signals to NK cells 
via soluble mediators or in a contact-dependent manner [40].  
Stress induced ligands are molecules that are usually not expressed or are present at very low levels in 
healthy cells, but strongly induced upon infection or malignant transformation. As such, they can be 
recognized by NK cell activating receptors and trigger lytic activity and/or cytokine production. Some of 
them can be induced on activated immune effectors, e.g macrophages incubated with LPS, where they 
could have a potential role in the control of an immune response [41]. The most extensively defined family 
of stress induced ligands engage the activating receptor NKG2D (Rae1α-ε, H60, Mult1 in mice; MICA/B, 
ULBP1-4, RAET1G/L in human). Their expression is induced through various forms of cellular stress, such 
as heat shock, viral infection, wound healing, UV radiation or DNA damage [42]. Many tumor cell lines and 
analyzed tumor tissues have been reported to express NKG2D ligands indicating their potential role in 
tumor growth control by NK cells and other NKG2D expressing immune effectors [43]. Similarly, ectopic 
expression of mouse Rae1β and H60 causes rejection of subcutaneously implanted tumor cells in 
a NKG2D dependent manner [44-45]. 
 
Receptor  Species Ligand
CD16  Mouse, Human IgG
NKp46  Mouse, Human Viral haemagglutinin, ? 
CD94/NKG2C/E  Mouse, Human 
HLA‐E in human
Qa‐1 in mouse 
NKG2D  Mouse, Human 
MICA/B, ULBPs in human 
Rae1, H60, MULT1 in mice 
DMAM‐1  Mouse, Human CD112, CD155
2B4  Mouse, Human CD48
CRACC  Mouse, Human CRACC
NTB‐A  Mouse, Human NTB‐A
NKR‐P1C  Mouse ?
NKR‐P1F  Mouse Clr‐g
Ly49H  Mouse m157 MCMV protein
Ly49D  Mouse H‐2d,a, b, k, p, q, s
NKp30  Human B7‐H6, ?
NKp44  Human Viral haemagglutinin
NKp80  Human AICL
KIR2DS  Human HLA‐C
 
Table 3.3. Activating NK cell receptors and their ligands. [46-47] 
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Activating NK cell receptors mainly couple to three signaling pathways: DAP12/Syk/ZAP70, DAP10/PI3K 
and SAP/Fyn that further activate a signaling cascade via PLCγ and Vav family members. When such 
a cascade becomes fully activated in contact with sensitive targets, it typically leads to the delivery of 
cytotoxic granules to the synapse with target cell and/or cytokine and chemokine release. [48] [49].  
 
3.2.1.3. NK cell costimulation 
Several receptors and ligands expressed on target cells have been described to costimulate other NK 
receptors rather than mediating direct activation. The term costimulation has been adopted from the T cell 
system. Naïve T cells have an absolute requirement for TCR engagement to be activated. However, 
in addition they need triggering of costimulatory receptors, mainly CD28. Nevertheless, CD28 engagement 
alone cannot induce T cell activation [50]. In the mouse system, NKG2D coupled to DAP12 can directly 
trigger NK cells, while coupled to DAP10 adaptor molecules rather enhance the response initiated via 
other activation pathways. Indeed, DAP12 mediated signaling resembles TCR (Syk/ZAP70), while DAP10 
recruits similar signaling molecules as CD28 (Grb2, PI3K) [51]. Similar functional properties are attributed 
to the receptors that recognize CD40, CD70, B7-1 (CD80), B7-2 (CD86), ICOS-L, OX-40L and 4-1BBL, 
ligands previously described to costimulate T cell effector functions at the different stages of activation 
[52-53].  
CD40 on APCs engages T cell expressed CD40L, which is the interaction crucial for T cell priming and 
development of humoral responses [54-55]. Its ectopic expression on tumor cell lines triggers NK cell 
cytotoxic responses [56]. However, it is not clear which receptor on NK cells recognizes CD40, since 
CD40+ targets are lysed by CD40L deficient NK cells equally as by WT effectors. A relatively high 
proportion of human melanoma has been reported to express CD40 [57], thus its contribution to the NK 
cell activation might be relevant for anti-tumor responses. 
B7-1 and B7-2, similar to CD40, induce NK cell cytotoxicity and IFNγ production. B7-1 and B7-2 positive 
lymphoma enhances NK cell mediated cytotoxicity in vitro being potent enough to overcome inhibition by 
MHC I [56, 58]. T cells recognize the B7-1/2 ligands via receptors CD28 and CTLA-4 [59]. B7-1 recognition 
by both human and mouse NK cells has been controversial. NK cells have not been reported to express 
CTLA-4. In mice, CD28 expression has been only shown by some studies on IL-2 expanded NK cells [60]. 
Proliferation and IFNγ production induced by B7-1+ cell lines has been contributed to CD28 in studies of 
Kelly et al [61], while the lysis of B7-1 expressing tumor targets was shown to be CD28 and CTLA-4 
independent [58]. Similarly, recognition of B7-2 could not be contributed to CD28 and CTLA-4 [56]. Human 
NK cells seem to express different variants of CD28 that mediates activation by NK cell sensitive (MHC I-) 
but not NK cell resistant (MHC I+) tumor cell lines [62]. B7 costimulatory ligands are expressed at different 
levels by cell lines derived from patients with gastric, esophageal and colorectal cancer [63], as well as on 
AML and B cell precursor ALL blasts [64-65]. Therefore, NK cell costimulation by B7-1/2 can be relevant 
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for direct recognition of tumor cells. In addition, APCs express high levels of B7-1/2 costimulatory 
molecules upon activation, which might be involved in their cross-talk with NK cells [66]. 
CD70 is recognized by the tumor necrosis factor (TNF) family receptor, CD27, which is constitutively 
expressed on resting, naïve T, B and NK cells, and further up-regulated following activation [67]. 
The function of CD27 seems to be controlled via availability of its ligand, CD70, that shows restricted, 
transient and activation dependent expression on T, B and dendritic cells. CD70 is positively regulated via 
TLR triggering and pro-inflammatory cytokines, such as IL-1β, TNFα, IL-12 and GM-CSF, while IL-4 and 
IL-10 reduce its expression. CD27 engagement is not absolutely required for naïve T cell activation, but it 
strongly enhances differentiation and function (IL-2, IFNγ production) of effector cells through the positive 
effects on survival and proliferation. To prevent possible immunopathology, prolonged CD27 costimulation 
utilizes negative feedback mechanisms, which includes reduction of receptor expression, receptor 
shedding from the cell surface and induction of negative mediators, such as IL-10, Fas, FasL and 
inhibitory receptor PD-1 [67]. Both human and mouse NK cells subsets differentially express the CD27 
receptor. Its level of expression is widely used to define the functional and/or maturation status of NK cells 
(see 3.2.3). Functional analysis of CD27 revealed its role in the positive regulation of NK cell effector 
functions, mainly proliferation and IFNγ production, without direct impact on cytotoxicity [68].  
Ectopic expression of CD70 and CD80 on implanted tumor cells facilitates NK cell anti-tumor responses, 
leading to tumor rejection and generation of functional immunological memory. Those effects are 
dependent on NK cells and both perforin and IFNγ effector responses [61, 69]. A recent study of 
Chan et al. showed that activating NK cell receptor DNAM-1 is costimulated via CD70 and CD80 
mediating suppression of lung melanoma metastases after IL-2 application [70].  
ICOS-L (ICOS ligand) engages costimulatory receptor ICOS that is expressed on T cells upon activation 
and enhances T cell cytokine production and effector functions [71]. Similarly, ICOS is not expressed on 
resting NK cells, but it is induced by cytokine stimulation [72]. Its cross-linking promotes NK cell IFNγ 
production, while ectopic expression of ICOS-L induced efficient killing of tumor cells in vitro. ICOS-L 
expressing tumor cells are better controlled in vivo in a NK cell dependent manner. Among human tumors, 
leukemia cells express ICOS-L [73]. In addition, it is expressed on the surface of B cells, APCs and certain 
nonhematopoietic tissues. Thus, ICOS dependent costimulation of NK cells may play an important role in 
NK cell activation through the interaction with both target cells and other immune cell. 
OX40L and 4-1BBL are members of the TNF superfamily ligands primarily involved in the regulation of 
T cell responses and cross-talk between T cells and other cells [74]. Both the ligands and their receptors 
(OX40 and 4-1BB) show inducible expression following immune cell activation. The ligands are primarily 
expressed by professional APCs, but also by non-immune cells as smooth muscle and endothelial cells. 
NK cells were shown to express OX40 and 4-1BB receptors as well as their ligands, which enables their 
extensive cross-talk with other immune cells during ongoing response.  
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3.2.2. NK cell effector responses  
3.2.2.1. NK cell cytotoxic responses 
Upon proper NK cell triggering, susceptible targets can be eliminated through perforin/granzyme 
dependent or death receptor initiated apoptosis (Figure 3.4.) [75]. Perforin and granzymes are crucial 
cytotoxic effector proteins stored in specialized lytic granules with secretory lysosome characteristics. 
Both NK cells and cytotoxic T lymphocytes (CTL) exert their cytolytic functions through the delivery of 
granule content to the contact site with target cell. The fusion of secretory granules with the plasma 
membrane leading to the release of cytotoxic mediators or cytokines is termed “degranulation”. The 
process is used to measure NK cell activity at the single cell level upon triggering of specific activating 
pathways or encounter of target cells. It is based on the appearance of lysosomal membrane glycoproteins 
1 and 2 (CD107a and CD107b) on the cell surface due to degranulation [76-77]. CD107a/b are proteins 
found in the lysosomal membrane, but redistribute on the cell surface shortly after granules fuse with the 
cell membrane. This process is followed by fast internalization and CD107a/b removal from the surface. 
 
Figure 3.4. Cytotoxic mechanisms used by NK cells. NK cells use three distinct pathways to induce death of target 
cells. Granule exocytosis pathway mediates the release of the lytic granuli content including the membrane 
pore-forming protein perforin and serin-proteases granzymes that initiate target cell death. In antibody dependent 
cellular cytotoxicity (ADCC), NK cells recognize target cells opsonized with antibodies via Fc receptors that trigger 
NK cell activation and release of lytic granules. In death-receptor pathway, death inducing ligands (TNF, FasL, TRAIL) 
expressed by NK cells engage the cognate receptor on target cells inducing a series of events that lead to the 
activation of caspases and target cell apoptosis. [39, 78] 
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Perforin is a highly conserved membrane-disrupting protein vital for NK cell cytotoxicity [79]. Current 
models suggest that perforin polymerizes within the endosome- and/or plasma membrane and forms 
pores causing granzyme diffusion and necrosis of target cells. [80]. Perforin mediated cytotoxicity plays an 
important role in NK cell mediated tumor suppression [81-83]. Various anti-tumor therapies (e.g. IL-2 or 
IL-21 application) activate NK cells to destroy implanted tumors in a perforin dependent manner [84-85].  
Granzymes represent structurally related serine-proteases with various substrate specificities. Apoptotic 
cell death triggered by granzymes is mediated via activation of caspases, induction of mitochondrial 
damage, which leads to the release of pro-apoptotic factors, and/or DNA damage pathway [80]. Besides 
induction of cell death, it was shown that certain granzymes could exert distinct biological roles. As an 
example, granzyme A can activate IL-6, IL-8 and IL-1β through the direct or indirect cleavage of their 
pro-peptides, thereby having a pro-inflammatory effect [86]. 
Antibody-coated target cells trigger a strong NK cell cytotoxic response named antibody dependent 
cellular cytotoxicity (ADCC), which can be seen as an example of coordinated actions of adaptive and 
innate effector mechanisms. When an antibody binds to a cell antigen, its Fc portion (carboxy-terminal 
constant region of an Ig molecule) can be recognized by low-affinity receptor for IgG (FcεRIγ), expressed 
by NK cells. Cross-linking of Fc receptors triggers NK cell activation and target cell destruction in a perforin 
dependent manner (Figure 3.4). ADCC is the dominant component of anti-cancer activity of currently 
applied antibodies in clinical settings against non-Hodgkin’s lymphoma (αCD20, rituximab) and breast 
cancer (αHER2/neu receptor, trastuzumab) [87].  
NK cells express at least three TNF family ligands – Fas ligand (FasL), TNF and TNF-related apoptosis 
inducing ligand (TRAIL), which mediate death receptor induced apoptosis of target cells (Figure 3.4). The 
engagement of the ligands induces a conformational change of death receptor and recruitment of adaptor 
proteins that initiate a complex series of events leading to apoptosis. The event crucial for apoptosis 
induction is the activation of signaling cascades whose main components are proteolytic enzymes 
caspases [88-89]. The usage of the specific lytic pathway depends on the tumor type, receptor/ligand 
expression by both effector and target cells and the way that NK cells are pre-activated. As an example, 
NK cell mediated metastases clearance and control of chemically induced tumors was shown to involve 
TRAIL [90-91]. Anti-metastatic effects achieved by IL-18 administration, rely on the FasL pathway [92]. 
Similarly, IFNγ produced by NK cells can induce Fas expression on cancer cells, followed by NK cell 
mediated target elimination [93].  
 
3.2.2.2. NK cell cytokine production 
Numbers of different cytokines are reported to be secreted by NK cells including IFNγ, TNFα, GM-CSF, 
IL-5, IL-10 and IL-13. IFNγ is seen as the most important effector cytokine produced by NK cells due to its 
crucial role in the early anti-viral and anti-bacterial response and orchestration of both innate and adaptive 
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cell activation against cancer [94]. IFNγ can target both tumor and host cells (Figure 3.5). Tumor cell 
responsiveness to IFNγ facilitates rejection via multiple mechanisms. IFNγ inhibits cell proliferation, 
induces sensitivity to apoptosis through its impact on caspase, FasL and TRAIL expression and makes 
tumor cell sensitive to CTL lysis via induction of MHC I and tumor antigen presentation. Host dependent 
anti-tumor effects are based on its role in polarization of Th1 responses, CTL maturation, macrophage 
activation and inhibition of angiogenesis and regulatory T cells generation [95]. 
 
Figure 3.5. Central role of NK cell derived IFNγ in anti-tumor response. NK cell derived IFNγ inhibits angiogenesis and 
tumor cell proliferation and induces tumor cell sensitivity to apoptosis. IFNγ increases MHC I expression and activates 
CTLs and macrophages to destroy tumor cells. DC maturation and Th1 cell polarization is supported by IFNγ, while 
differentiation of regulatory T cells is inhibited. [96] 
Complex microenvironmental signals control the cytokine production by NK cells. Cross-linking of 
activating receptors such as NKG2D, NK1.1, and NKp46 can induce IFNγ release in vitro [97-98]. 
Viral pathogens induce type I IFNs, which are also potent inducers of IFNγ [94]. IL-12, produced by 
macrophages, DCs and neutrophils at the site of infection, participates in the positive feedback loop by 
promoting IFNγ secretion, which in turn further potentiates IL-12 production. TNFα, IL-1 and IL-18 were 
described to further increase the IL-12 mediated release of IFNγ. In contrast, IL-10 and TGFβ are shown 
to suppress its production. When the amount of IL-12 and/or IL-18 is limited, co-triggering of activating 
NK receptors leads to maximal IFNγ induction. IL-18, initially described as IFNγ-inducing factor (IGIF) [99], 
exerts the most potent synergy with IL-12 regulating INFγ production by both NK and T cells [100]. 
The underlying mechanism of the synergistic action includes the reciprocal induction of the corresponding 
cytokine receptors and recruitment of different sets of transcription factors to the IFNγ promoter. The main 
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producers of IL-18 are macrophages, DCs, Kupffer cells and keratinocytes upon encounter of pathogens. 
The innate responses to intracellular microbes and viruses are amplified by IL-18 through its facilitation of 
cytokine (IFNγ, GM-CSF, IL-1β, IL-6, TNFα) and chemokine (IL-8) expression, induction of adhesion 
molecules and effector cell activation. IL-18 enhances neutrophil and NK cell cytotoxicity, Th1 responses 
in combination with IL-12, Th2 responses with IL-2 and Th17 responses with IL-23. 
Due to the potent stimulating effects through both innate and adaptive immune effector arms, both IL-12 
and IL-18 were widely exploited in therapeutic settings in mouse tumor models. Systemic IL-18 application 
has been shown to mediate the regression of poorly immunogenic B7-1 expressing mouse melanoma in 
a NK dependent manner [101]. IL-12 treatment induced suppression of metastatic growth by the 
enhancement of perforin dependent cytotoxicity, while in the same settings, IL-18 required tumor 
sensitivity to FasL [102]. However, IL-18 can have opposite pro-tumoral effects [100]. IL-18 dependent 
tumor growth promotion is correlated to its ability to support tumor angiogenesis through the induction of 
VEGF and hamper immune response by inducing FasL expression on tumor cells. Degradation of 
extracellular matrix by MMP-9 and expression of adhesion molecules on vascular endothelia, both induced 
by IL-18, support metastatic dissemination. 
 
3.2.2.3. NK cell regulatory functions. Interaction with dendritic cells (DCs)  
When a certain tissue is affected by pathogen invasion or malignant transformation, multiple immune 
effectors are recruited in response to released inflammatory mediators. Innate immune cells, which are 
first to invade the affected tissue establish multiple interactions both within each other and with resident 
cells, that can have multiple impacts on the quality and strength of ongoing innate and adaptive response 
that follows. It was shown that NK cell interaction with dendritic cells can shape both NK and DC effector 
functions (Figure 3.6) [66, 103]. The initial activation of tissue resident NK and dendritic cells is achieved 
via signals derived from tumor or virus infected cells in the environment and then further amplified through 
the NK/DC cross-talk. It was shown in the human system that the engagement of NKp30 in interaction with 
DCs induces TNFα release by NK cells, which in turn mediates DCs maturation. Activated DCs secrete 
IL-12 and IL-18, cytokines known to induce potent IFNγ secretion by NK cells. Such a cross-activation of 
NK and DCs is proposed to take place in invaded tissues at early time points when NK/DC ratio is 
relatively low. In addition, it can be highly relevant in lymph nodes, where the early release of IFNγ by NK 
cells plays a crucial role in T cell priming [104]. In a mouse model of MCMV infection, conventional DCs 
enhance NK cell lytic potential in IFNα and NKG2D dependent manner and IFNγ production through IL-12 
and IL-18 production [105]. In tumor settings, adoptively transferred DCs promoted NK cell mediated 
control of MHC I deficient mesothelioma independently of IL-12 or type I IFNs [103].  
Another possible result of the NK/DC interaction is the elimination of immature DCs by activated NK cells. 
In the human system, a major role in lysis of iDCs is played by TGFβ and the activating receptors NKp30 
and DNAM-1 whose ligands are expressed by DCs. Since iDCs express MHC I molecules, killing is 
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mediated by CD94/NKG2Alow NK subset. Upon maturation, the increased density of MHC I protects mDC 
from NK cell mediated elimination. A proposed purpose of iDCs lysis is the elimination of DCs that might 
fail to mediate optimal T cell priming and might take place in the late phase of the response when NK/DC 
ratio is relatively high [106-108]. 
 
Figure 3.6. NK cell interaction with DC. DCs activated by the pathogen encounter increase NK cell cytotoxic response, 
IFNγ production, proliferation and survival through direct contact or via release of cytokines. In turn, activated NK cells 
support DC maturation or kill immature DCs providing optimal conditions for T cell priming. [109] 
 
3.2.3. NK cell development, subsets and tissue distribution 
The main pool of mouse peripheral NK cells develops from hematopoietic stem cells following a series of 
sequential stages of maturation, expansion and acquisition of specific NK receptors [110]. Every stage is 
defined by specific phenotypic and functional characteristics, although stimuli and limitations governing the 
progression through the stages are not completely understood. Committed NK cell precursors from bone 
marrow are lineage negative (Lin-, CD3-CD19-Gr1-) and express the IL-2/IL-15R common β subunit 
(CD122). Further NK cell development as well as survival in the periphery are completely dependent on 
IL-15. Committed Lin-CD122+ precursors at the next stage upregulate integrin αv subunit and NK1.1 and 
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NKG2/CD94 receptors (Figure 3.7). Expression of tyrosine kinase c-Kit and acquisition of different Ly49 
receptor family members are further events and precede the expansion stage in bone marrow. Fully 
mature NK cells are recognized by the expression of a variety of integrins like Mac-1 (αM subunit 
associated with β2, or CD11b) or DX5 (α2 subunit associated with β1 or CD49b), which are upregulated in 
the final maturation stage. In addition to integrins and in contrast to immature precursors, fully mature NK 
cells co-express CD43, known as leukosialin, low levels of c-Kit and no αv, which are both downregulated 
as differentiation proceeds. Finally, fully mature NK cells show a functional competence concerning 
cytotoxic responses and IFNγ production.  
 
Figure 3.7. Model of murine and human NK cell development. NK cells originate from hematopoietic stem cell (HSC) 
and mature in bone marrow. Committed NK cell precursors (NKP) are lineage negative (Lin-, CD3-CD19-Gr1-) and 
express IL-2/IL-15Rβ (CD122). NK cell development and survival in the periphery are completely dependent on IL-15. 
The differentiation of the fully matured NK cells is characterized by the sequential acquisition of expression of NK cell 
receptor and adhesion molecules. Several molecules are expressed transiently during differentiation and therefore are 
used as the phenotypical markers for immature NK cells (c-Kit, CD117). The final step of maturation includes 
acquisition of functional competence for cytotoxic responses and IFNγ production. [111] 
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Although defined by different marker molecules, there is evidence that human NK cells follow a similar 
differentiation pathway in vivo. The maturation of human NK cells is characterized by the gradual 
upregulation of CD56 and CD11b and sequential upregulation of NK receptors: CD161 and NCRs, 
followed by CD94 and, at the final stage, CD16 and KIRs [112]. Human NK cells are defined as 
CD3-CD56+ and comprise two functionally distinct subsets. CD56highCD16- NK cells express CCR7 and 
CD62L and thereby dominate in lymph nodes, where they can interact with DCs. They are very potent 
cytokine producers, while exerting poor cytotoxic responses against typical NK cell targets. On the other 
hand, they efficiently eliminate immature dendritic cells. The CD56dimCD16+ subset dominates in 
peripheral blood and inflamed tissue and shows high cytotoxic activity [113]. 
A.     B. 
 
Figure 3.8. CD11b/CD27 based definition of NK cell maturation stages. (A) Four different subpopulations representing 
sequential maturation stages of NK cells: DN → CD11blow → CD27high → CD27low. (B) Different phenotype and 
functional properties of mature CD27high and CD27low NK cell subsets. (C) Differential tissue distribution of various 
NK cell subsets; DN, double negative; BM. bone marrow; LN, lymph nodes 
It has been recently described that the fully matured CD11bhigh NK cell pool can be further divided into two 
functional subpopulations according to the expression of the TNF family member receptor CD27 
(Figure 3.8) [114]. CD27low NK cells represent the final maturation stage co-expressing inhibitory Ly49C/I 
receptors at high frequency, and KLRG1, inhibitory lectin-like receptor, but no early activation antigen 
CD69, c-Kit and CD127. This subpopulation dominates in non-lymphoid organs of adult mice, such as lung 
and peripheral blood, and has limited proliferation turnover. In contrast, CD27high subset still expresses low 
levels of CD69, c-Kit and CD127 markers indicating a less mature phenotype. Together with the immature 
C. 
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CD11blow subset, this subpopulation is dominant in bone marrow and lymph nodes, and represents the 
proliferating pool of NK cells. Surprisingly, the CD27high subset displays agreater capacity in migration 
towards certain chemokines, killing certain susceptible targets and producing IFNγ upon cytokine 
stimulation or co-culture with dendritic cells. It has been recently described that double negative 
CD11b-CD27- NK cells comprise precursors of CD11b and/or CD27 expressing subsets, suggesting 
a linear model of NK cell development (Figure 3.8A) [115].  
Among the total NK cell pool in the periphery, a population characterized by the expression of IL-7Rα 
(CD127) has been found to originate in thymus and strictly depend on the transcription factor GATA-3 and 
IL-7Rα [116]. Thymic NK cells are the most abundant in the thymus and lymph nodes. Compared to the 
mature bone marrow derived NK cells, they show a specific CD11blowCD16-CD69highLy49low phenotype, 
reduced cytotoxicity and enhanced cytokine production. Interestingly, a functionally similar human 
CD56bright NK subset, predominating in human lymph nodes, expresses CD127, while in blood and spleen 
a dominant CD56dim subset is highly cytotoxic and CD127 negative.  
NK cell development can take place at some additional anatomical places from different precursor cell 
pools. NK cells can potentially arise from bipotent T/NK precursors found in fetal liver, spleen and blood 
[117]. In addition, a subset of immature thymocytes on both a double negative CD4-CD8-CD44+CD25- and, 
to a lesser extent, double positive CD4+CD8+CD44+CD25+ maturation stage can differentiate toward 
NK cells [118]. A subpopulation of lymph node cells in mice resembling immature thymocytes is also found 
to differentiate into NK cells in vitro [119]. 
NK cells found in different organs can have different phenotype and exert different functional 
characteristics. However, it is still not clear whether mature NK cells modify their phenotypic and functional 
attributes in defined microenvironmental conditions or immature precursors mature in those conditions 
giving rise to divergent NK cell functional subsets. Based on the CD11b/CD27 subset definition, the spleen 
NK cell compartment is composed of all four subsets, immature NK cells dominate in bone marrow, while 
at peripheral sites such as blood and lungs, preferentially mature CD27low NK cells can be detected. 
Lymph nodes contain low percentages of NK cells that are mainly CD27high and express CD127. Since 
those cells have a high capacity of cytokine production, they could play a very important role during T cell 
activation by providing IFNγ for Th1 polarization [120].  
 
3.2.4. NK cells with specialized functions 
Liver NK cells 
Mouse liver preferentially contains NK cells of the immature CD11blowDX5low phenotype that express 
TRAIL, but no Ly49 receptors, perforin and granzymes. TRAIL+ NK cells are predominant in fetal and 
neonatal mice being distributed in spleen and other peripheral lymphoid organs. Their number decreases 
with age and they are retained only in the liver. On the one hand, the liver can represent the pool of 
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immature NK cells that can differentiate into fully mature effectors in a short time period. On the other 
hand, TRAIL expressing NK cells can have very well defined but still not fully discovered biological 
purposes, including elimination of potentially dangerous targets arising in liver, including metastasing 
tumor cells [121]. In addition, evidence exists that the total pool of NK cells residing in the liver could 
contain cells with memory properties [122].  
Uterine NK cells 
Uterine NK cells in human were shown to invade the decidua early in gestation at the time of implantation 
of the fetal trophoblast. They constitute of up to 70% of the immune cells present in the deciduas during 
the first trimester of pregnancy. Human decidual NK cells cosist of the predominately CD56brightCD16- 
phenotype with special functional properties. They promote the migration of trophoblast and 
vascularisation of placenta by the production of IL-8, CXCL10, VEGF and PDGF [123]. Mouse uterine 
NK cells have an unusual phenotype distinct from splenic NK cells [124]. Similar to the immature NK cell 
precursors, they do not express NK1.1 and DX5, while expressing low levels of CD11b and high levels of 
CD69 and c-Kit. However, unlike immature NK cells, uterine NK cells express Ly49 receptors with 
a repertoire qualitatively and quantitatively different compared to the NK cells found in the spleen. 
Gut NK cells 
Recent studies have shown that both human and mouse gut-associated lymphoid tissue harbor NK cells 
with unique phenotypical and functional properties, whose main characteristics are the production of IL-22. 
IL-22 is a member of the IL-10 cytokine family essential for host defense at the musical barriers. The IL-22 
receptor is expressed on epithelial cells and its triggering induces the production of multiple anti-microbial 
mediators [125-126]. In mucosal areas of human tonsils and Payer’s patches a specialized subset of 
NKp44+ NK cells expressing the chemokine receptor CCR6 is identified to produce IL-22 [127]. In mouse, 
the analysis of the lamina propria and the intraepithelial surfaces of small intestine revealed a minor 
subpopulation of mature classical NK cells, expressing Ly49 receptors, perforin and IFNγ, and an 
additional IL-22 producing NK cell subset that express CD127 (IL-7Rα), CD117 (c-Kit), but not Ly49 
receptors, perforin and IFNγ [128-130]. While conventional NK cells require IL-15 for their development 
and homeostasis, thereby are absent from IL-15-/- and IL-2γc-/- mice, IL-22 producing NK cells depend on 
the transcription factor RORγt and commensal flora and develop normally in the absence of IL-15 signal. 
Interferon-producing killer DC (IKDC) 
A number of recent publications have described a cell population with dual nature, combining the 
properties of both DCs (antigen presentation, IL-12 secretion) and NK cells (lytic capacity and IFNγ 
production) [131-132]. The phenotypical characterization indicated that those cells could be found within 
the CD11c+ (DC marker) NK1.1+ (NK cell marker) spleen subpopulation. However, it is still not clear if the 
dual NK/DC function can be performed by a single cell type within the CD11c+NK1.1+ population and 
whether it is exerted at the same time or sequentially acquired during ongoing response. Indeed, the study 
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of Ullrich et al. indicated that upon IL-15 trans-presentation those cells lose their DC potential and become 
typical NK effectors [133]. Commonly named natural killer DC (NKDC) or interferon-producing killer DC 
(IKDC), this population is further defined by the co-expression of B220 (CD45R) and DX5, while T cell 
(CD3), B cell (CD19) and granulocyte-monocyte (Gr1) markers are absent. More recent studies revealed 
their close relationship with NK cells, supported by the finding that IKDC express the typical NK cell 
marker NKp46, as well as Ly49 receptors, NKG2D and CD122 [134-135]. In addition, their dependence on 
IL-15 and the fact that NK cells upregulate CD11c and B220 upon stimulation, support the view of IKDCs 
being a subpopulation of activated NK cells. Upon target encounter and elimination, IKDCs upregulate 
MHC II and costimulatory molecules (B7-1/2, CD40, OX40L), a process shown to depend on IFNγ, and 
are able to activate CD4+ and CD8+ cells [136-137]. Similar phenotypical and functional properties can be 
attributed to the NK cells, activated through target cell recognition and lysis [138].  
In spleen of naive C57BL/6 mice, approximately 1% of all CD11c+, and about 10% of CD3-NK1.1+ NK cells 
phenotypically correspond to IKDCs [139]. More importantly, IKDCs were found to accumulate in tumor 
tissue and mediate potent anti-tumor activities. B16 melanoma progression in mice can be markedly 
inhibited by the adoptive transfer of CD11c+B220+, but not CD11c-B220- NK cells into Rag-/-IL-2Rγc-/- tumor 
bearing mice. A current hypothesis suggests that the dual function of IKDCs (or activated NK cells) can be 
beneficial during early responses to tumor and pathogens, due to their fast activation and potential to 
eliminate targets, uptake antigens, accumulate in lymph nodes and prime T cell responses. 
 
3.2.5. NK cells and cancer 
3.2.5.1. NK cells and cancer immunosurveillance 
Cancer immunosurveillance represents a concept, which predicts that the immune system recognizes and 
in most cases destroys precursors of cancer before it becomes clinically apparent [140]. There are 
numerous experimental data indicating that different components of immune response are implicated in 
cancer surveillance (Table 3.4), including both the adaptive and the innate immune system. 
The involvement of NKG2D, IFNγ, perforin and TRAIL mediated mechanisms in the process strongly 
suggests that NK cells could play a very important role in the control of tumor development. However, it is 
clear that the role of a single cell type and different mechanisms applied by a given cell, depends on the 
tumor type and the strategy that particular developing tumor uses to evade the response of the immune 
system. For example, MCA induced sarcomas show higher incidences in DNAM-1, but not in NKG2D 
deficient mice. On the other hand, NKG2D is implicated in the control of development of Eµ-Myc driven 
B cell lymphomas [42]. 
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Mouse strain 
Tumorigenesis promoting 
system 
Tumor type 
Defective immune 
component 
Spontaneous tumors 
129/Sv  ‐ Colon, Lung RAG2 
129/Sv  ‐ Colon, mammary RAG2 and STAT1
C57BL/6  ‐ B cell lymphoma β2m and perforin
C57BL/6  ‐ Lymphoma TRAIL 
C57BL/6  ‐ Lymphoma perforin
Transgenic and knockout tumor models
129/Sv  Tp53‐/‐ Lymphoid and other STAT1 
129/Sv  Tp53‐/‐ Lymphoid and other IFNγR 
C57BL/6  Tp53‐/‐ Lymphoid and other TRAIL 
C57BL/6  Tp53‐/‐ Lymphoid perforin
C57BL/6  Tp53‐/‐ Lymphoid and other TCRJα28 and CD1d
C57BL/6  TRAMP Prostate NKG2D 
C57BL/6  TRAMP Prostate TCRδ 
C57BL/6  Eµ‐Myc B cell lymphoma NKG2D 
C57BL/6  Eµ‐Myc B cell lymphoma TRAILR 
C57BL/6  Eµ‐Myc B cell lymphoma RAG1 
Carcinogen induced tumors 
129/Sv  MCA Fibrosarcoma RAG2 
129/Sv  MCA Fibrosarcoma IFNγ 
129/Sv  MCA Fibrosarcoma IFNγR 
129/Sv  MCA Fibrosarcoma STAT1 
129/Sv  MCA Fibrosarcoma RAG2 and STAT1
C57BL/6  MCA Fibrosarcoma IFNγ 
C57BL/6  MCA Fibrosarcoma perforin
C57BL/6  MCA Fibrosarcoma TRAIL 
C57BL/6  DEN Hepatocarcinoma TRAILR 
C57BL/6  MCA Fibrosarcoma TCRJα28
FVB  MCA Fibrosarcoma TCRβ 
FVB  MCA Fibrosarcoma TCRδ 
FVB  DMBA and TPA Cutaneous TCRδ 
C57BL/6  MCA Fibrosarcoma TCRδ 
 
Table 3.4. Immune deficiencies associated with greater tumor incidence or tumor severity in mice.  [42] MCA, 
methylcholanthrene; DMBA, 7,12-dimethylbenzanthracene; TPA, 12-O-tetradecanoylphorbol-13-acetate; DEN, diethylnitrosamine 
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The broader concept of immunoediting states that the complex interplay between the cancer and immune 
system eventually leads to progressive tumor outgrowth. It is proposed that cancer usually develops 
through the series of steps characterized by events that all together can alert the immune system 
(Figure 3.9). Elimination, equilibrium and escape are the three phases of immunoediting [95].  
Elimination. Activation of oncogenes or/and mutation affecting tumor-suppressor genes can induce DNA 
damage, heat-shock and other responses that result in cell cycle arrest, cell senescence and apoptosis. 
At the same time, those mechanisms have been shown to induce numerous ligands on the surface of 
affected cells (e.g. upregulation of NKG2D ligands upon DNA damage [141]) allowing the immune system 
to be alerted for potential danger and eliminate transformed cell.  
Equilibrium. If some tumor cells are not destroyed in the elimination phase, they can persist, being 
prevented to expand by the immune system, in the so called equilibrium phase.  
Escape. Under the selective pressure of immune response, further mutations in malignant cells, which 
affect the genes regulating metabolic processes, proliferation, survival and sensitivity to immune 
destruction, can help the evasion of protective mechanisms leading to the development of cancer. 
For example, tumor cells can downregulate MHC I, antigen-processing machinery, death receptors and 
other apoptosis mediators. The direct or indirect immune system inactivation involves the expansion and 
recruitment of suppressive cell populations and production of suppressive mediators, such as TGFβ, 
IL-10, IL-13, IDO, arginase-1 and others. In order to become invisible, tumor cells can differentially 
regulate the expression of ligands that can be recognized by the immune system. Expression of NKG2D 
ligands can be downregulated by shedding the proteins from the cell surface by metaloproteinases [142]. 
In other cases, high expression of NKG2D ligands can be exploited to downregulate the receptor on 
immune effector cells due to the chronic engagement, which can lead to the impairment of NKG2D as well 
as other activation pathways [142-147]. In patients with MICA positive tumors, soluble MICA ligands have 
been detected in serum, which correlated with the downregulation of NKG2D on effector cells and 
impairment in their responsiveness [143]. Similarly, AML patients show impaired NK cell activity correlated 
to low expression of natural killer cell triggering receptors (NCRs) [148]. 
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Figure 3.9.  Cancer immunoediting. [95] The process of malignant transformation leads to the upregulation of danger 
signals and the expression of various molecules that alert the immune system. Transformed cells are destroyed by 
immune effector cells in the phase of elimination. In the equilibrium phase, small numbers of cancer cells that were not 
eliminated persist, but do not proliferate due to the control established by the immune system. Genetic instability and 
immune selection result in the evasion of protective mechanisms leading to the development of cancer, which further 
inhibits immune responses through various mechanisms.  ECM, extracellular matrix; IDO. Indolamine 2,3-dioxygenase 
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3.2.5.2. NK cell based cancer immunotherapy 
NK cells are recognized as potent anti-tumor effectors in vitro and in mouse models in vivo. Multiple NK 
cell effector mechanisms can be exploited for anti-cancer therapy, both direct (destruction of tumor 
targets) and indirect (activation of adaptive responses via DCs). Up to date, various strategies have been 
designed to implement NK cells in anti-tumor therapeutic settings (Table 3.5). 
Treatment   
Clinical 
application 
Clinical effects  Effects on NK cells 
Recombinant cytokines 
IL‐2  i.v.  Melanoma 16% OR High toxicity 
IL‐2  i.v. or s.c.  RCC  15% OR  
IL‐2  + LAK  RCC  21% OR  
IL‐2  + IFNα  RCC  20.6% OR  
IL‐2  + BMT  BC, NHL  No improvement  ↑ IFNγ in serum, ↑ PBMC cytotoxicity 
IL‐2  s.c.  Advanced cancer  ‐  ↑ NK number, cytotoxicity, IFNγ, ADCC 
IFNα  i.v.  CML  60‐80% OR  ↑ NK cytotoxicity, IFNγ 
IL‐12  i.v.  Melanoma, RCC  1PR, 3SD (n=14)  ↑ IFNγ, IL‐15, IL‐18  in serum 
IL‐12  i.v.  Advanced cancer  ‐  ↑ NK cytotoxicity, LFA‐1 
IL‐12  i.v. + IL‐2  Melanoma, RCC  1 PR (n=28)  ↑ NK number, ↑ IFNγ, CXCL10 in serum 
IL‐18  i.v. 
RCC, melanoma, 
HD 
2 PR (n=28) 
↑ NK FasL 
↑ IFNγ, GM‐CSF, IL‐18BP  in serum 
IL‐21  i.v.  Melanoma  1 CR (n=29) 
↑ NK cytotoxicity 
↑ Prf, GzmB mRNA in PBMCs 
Flt3L  s.c. + BMT  HD, BC  ‐  ↑ circulating iDCs 
Vaccines 
Hsp96  s.c.  Colorectal cancer 
33% DFS 
79% 24‐months OS 
↑ NK cytotoxicity, IFNγ, NKG2D, NKp46, 
CD69, CD25 
↑ CD40, CD83, IL‐12 by PBMCs 
Hsp96 
+ IFNα 
+ GM‐CSF 
Melanoma  11 SD (n=38)  ↑ NK IFNγ, ↑ T cell activity 
CpG  i.v.  NHL  2 PR (n=23)  ↑ NK cytotoxicity 
MD‐DC+CEA   
Metastatic CEA+
cancer 
5 SD (n=9)  ↑ NK number, cytotoxicity 
DEX  s.c.  Melanoma 
1 PR, 2 MR, 2 SD 
(n=15) 
↑ NK number, cytotoxicity, ↑ NKG2D 
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Antibody therapeutics 
Rituximab  + IL‐2 s.c.  B cell NHL  53% OR  ↑ NK number, ADCC 
Rituximab  + IL‐2 s.c.  Indolent NHL  8.8% OR  ↑ NK number, ADCC 
Rituximab 
+ IL‐2 i.v. 
+ LAK 
B cell NHL  1 PR, 4 SD (n=10)  ↑ NK number, ADCC 
Trastuzimab  + IL‐12 i.v.  BC  1 CR, 2 SD (n=15)  ↑ NK IFNγ, ADCC 
αCD16/CD30 
bispec Ab 
i.v.  HD  25% OR  ↑ NK cytotoxicity 
αCD16/CD30 
bispec sAb 
+ IL‐12 
+ GM‐CSF 
HD  29% OR  ↑ NK number, ADCC 
Daclizumab    Uveitis    ↑ NK number, IL‐10 
Daclizumab  + IFNβ  MS 
70% CNS lesion 
reduction 
↑ NK number, cytotoxicity against 
activated T cells 
 
Table 3.5. Clinical trials using strategies to modulate NK cell function. [87] i.v., intraveneous; s.c., subcutaneous; LAK, 
lymphokine activated killer cells; BMT, bone marrow transplantation; RCC, renal cell carcinoma, BC, breast cancer; NHL, 
non-Hodgkin’s lymphoma; CML, chronic myeloid leukemia; HD, Hodgkin’s lymphoma; MS, multiple sclerosis; OR, overall response; 
PR, partial response; SD, stable disease; CR, complete response; DFS, disease-free survival; OS, overall survival; CNS, central 
nervous system; Prf, perforin; GzmB, granzyme B 
 
Use of autologous NK cells 
The systemic or local application of multiple factors previously known to enhance NK cell functions has 
been shown to be beneficial in mouse tumor models. IL-2 suppresses many experimental tumors by NK 
cell dependent mechanisms that require perforin and/or IFNγ [90, 102]. Positive effects are reported for 
IL-12 [84], IL-15 [149-150], IL-18 [102] and IL-21 [151-152]. 
In humans, Rosenberg and colleagues performed pioneering studies in advanced renal cancer and 
melanoma patients applying the adoptive transfer of ex vivo expanded autologous NK cells together with 
IL-2, however with no benefits compared to IL-2 alone [153]. In addition, high dose of IL-2 used for the 
activation of both endogenous NK and T cells, although beneficial, has been shown to have toxic side 
effects and can exert additional negative action through T regulatory cells expansion or induction of 
activation-induced cell death (AICD) of NK cells [154-155]. Moreover, toxicities have precluded the use of 
IL-12, although striking effects have been achieved in mouse models [156]. In contrast, IL-21 was shown 
to be effective with no adverse effects [157-158]. Therefore, it has a good potential to be implemented in 
the future therapy designs.  
NK cell proliferation, expression of activating receptors as well as lytic and secretory potential can be 
enhanced by other cytokines, such as IL-15, IL-18 and type I IFNs, which are shown to be efficient when 
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used in combination therapies with other agents, e.g. IL-15 together with haploidentical NK cell transfer in 
patients with poor-prognosis AML. Essentially, any treatment that harness the ability of DCs to mediate NK 
cell activation (e.g. TLR agonists such as CpG) is potentially mediated by IL-12, IL-15 and IL-18, produced 
by DCs and macrophages [159].  
Many drugs used in current anti-cancer clinical protocols are proven to work at least in part via NK cells. 
Examples include Mycobacterium bovis bacillus Calmette-Guerin (BCG) treatment of bladder cancer 
[160-161] or tyrosine kinase inhibitor imatinib mesylate (Gleevec), used for patient with gastrointestineal 
stromal tumors [162]. The efficiency of antibody based therapeutics is to a large extent contributed by 
NK cell mediated ADCC [163-164]. 
Use of allogenic NK cells 
The best example of the use of allogenic NK cell is provided in the haploidentical stem cell transplantation 
in patients with AML that greatly improves disease free survival and reduces relapse rates [165]. Unlike 
T cells, donor-derived NK cells in these settings do not mediate GVHD, but exert a strong GVL effect. 
Together with NK cells developed from donor hematopoietic stem cells, they do not only eliminate residual 
tumor cells, but also recipient’s APCs, preventing antigen presentation and activation of alloreactive 
T cells. A prerequisite for the successful treatment is the KIR-ligand mismatch or in other words, 
the recipient should lack one or more HLA I ligands that engage donor inhibitory KIRs. A similar approach, 
called NK cell based donor lymphocyte infusion, is used in high risk leukemia patients after relapse. It is 
based on the infusion of highly purified haploidentical NK cells that can mediate potent anti-tumor effects 
[166-167]. 
Haploidentical NK cell infusions together with IL-2 were given by Miller and colleagues in 
non-transplantation settings to renal cell carcinoma, Hodkin’s disease and AML patients. When high doses 
of IL-2 were applied, donor NK cell proliferation has been observed. A long term survival in this study has 
been correlated with KIR mismatch [168]. 
Trials with adoptive transfer of the NK cell line NK-92 have also been performed and found to be safe. The 
advantages of the NK-92 line could be seen in easy production, no expression of inhibitory KIR molecules 
and the possibility of in vitro manipulation and adjustments. The efficacy of the treatment is to be analyzed 
in future studies [169]. 
Crucial issues for NK cell based anti-cancer therapy 
Although the knowledge about NK cell anti-tumor effects is increasing, the clinical efficacy in human trials 
using NK cell effector responses in different ways has been modest. A possible reason can be that most of 
the studies have been performed in patients with heavy tumor burdens for whom conventional therapeutic 
approaches were ineffective. It is known from the studies in mice that NK cells have a very limited capacity 
to impact on established malignancies. The most effective use of NK cells is considered to be in situations 
when tumor burdens are relatively low, e.g. in patients with minimal residual disease, post surgery, 
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through other treatments or following relapse. In addition, approaches used so far are to be further 
improved via the manipulation of NK cell numbers, activation state and activating and inhibitory receptor 
repertoire, choosing subpopulations with desired functional capacities and enhancing trafficking to the 
tumor site. NK cell based therapies against large solid tumors still remain a challenge, until sufficient 
knowledge is acquired about their homing to the tumor site, migration through tumor tissue, interactions 
with both tumor cell and other immune effectors, including inhibitory populations, and all other forces that 
can impede or improve NK cell anti-tumor actions. 
 
3.3 B7 family 
Naive T cells require two signals for activation [170]. The first signal is delivered by the engagement of the 
T cell receptor (TCR) by proper MHC-peptide complex. Naïve T cells provided solely by a TCR signal 
(if this signal is quantitatively not very strong) are rendered anergic and become inactivated. The second 
signal required for activation is delivered through costimulatory receptors, primarily CD28, and cytokines 
provided by the microenvironment. CD28 belongs to the B7 receptor-ligand family, which is mainly 
implicated in the regulation of T cell activation and effector function [171]. While positive regulators of the 
family support T cell activation, negative regulators are important for the prevention of inappropriately 
directed responses, e.g. to self-antigens, and for limiting the size and duration of an immune response, 
thereby preventing  immune mediated tissue and organ damage. 
 
Figure 3.10. Structural characteristics, binding partners and the functional consequences of B7 family activation [172]. 
The prototypic B7 family receptors CD28, CTLA-4 and PD-1 engage B7-1/2 and B7-H1/PD-L2 ligands and deliver 
activating (CD28) or inhibitory (CTLA-4, PD-1) signals. However, reverse signaling of the ligands has been also 
reported. Some B7 members interact with non-B7 molecules, such as HVEM (TNF family), NKp30 (IgG family) and 
TREML2.  
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The members of the CD28/B7 family do not function independently but rather modify primary signals 
delivered by the TCR. The receptors of the B7 family are type I transmembrane proteins with a conserved 
IgV domain, while ligands are type I transmembrane molecules with both IgV and IgC domains 
(Figure 3.10) [173]. Within the family a single receptor can bind to multiple ligands and a single ligand can 
engage more than one receptor. In addition, bidirectional signaling has been reported for several 
interaction partners [52]. The final outcome of regulation through B7 family members will then depend on 
the established interaction type and the integration of the signals delivered from different family members 
with TCR derived signals. In addition, tight spatial and temporal regulation of the expression of different 
receptor-ligand pairs contributes by adding a new level to the diversity of B7 driven regulation. 
 
3.3.1. Costimulation through B7 family members 
3.3.1.1. CD28 
CD28 is constitutively expressed by both resting and activated mouse T cells [171]. In the absence of TCR 
signaling its engagement does not play a significant role. When the TCR is triggered simultaneously, 
CD28 decreases the threshold for T cell activation and promotes T cell survival, expansion and 
proliferation. The main effects of CD28 co-engagement are increased transcription and stabilization of IL-2 
mRNA that supports proliferation [174] and up-regulation of anti-apoptotic protein Bcl-XL that supports 
survival [175]. CD40L, ICOS, OX40 and CD137 (4-1BB) are also induced by CD28 and further contribute 
to T cell activation providing the costimulatory signals of different quality. In addition, the increased 
expression of a glucose transporter and glycolytic enzyme activity as a consequence of CD28 triggering 
provides metabolic requirements for the cell division and effector function [171]. Recruitment and 
activation of phosphoinositide 3-kinase (PI3K) appears to be essential for CD28 mediated costimulation. 
The function of inhibitory B7 family receptors PD-1 and CTLA-4 is partially based on the counteraction of 
CD28 effects by targeting proximal signaling molecules in its pathway. PD-1 targets PI3K, while CTLA-4 
inhibits more downstream Akt activation via the phosphatase PP2A [176]. CD28 deficient mice exhibit 
impaired T cell responses [177] and reduced disease severity in murine models of arthritis, EAE and 
musosal lung inflammation [178-180]. 
CD28 engages two ligands, B7-1 and B7-2, that have different spatial and temporal regulation of 
expression, and are also recognized by the B7 inhibitory receptor CTLA-4. B7-2 is expressed constitutively 
at low levels on B cells, DCs and macrophages, but it is rapidly up-regulated following activation and plays 
an important role in the initiation of immune responses. B7-1 expression is induced in the span of several 
days upon activation, which makes it more important for the regulation of sustained T cell activation in the 
later phases of effector responses [181]. Although binding to the same receptors, due to the different 
binding affinities and expression patterns, B7-1/2 ligands induce different functional outcomes. 
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For example, while B7-1 engagement preferentially favors Th1 responses, B7-2 engagement augments 
IL-4 production and Th2 differentiation [182].  
There is evidence that both B7-1 and B7-2 can deliver reverse signals that differentially affect DCs. 
CD28 engagement by B7-1/2 expressed on DCs leads to IL-6 production and subsequent T cell 
immunostimulation [183]. On the other hand, binding of CTLA-4 induces IFNγ, which acts in an autocrine 
manner and induces indolamine 2,3-dioxigenase (IDO) synthesis by DCs [184]. Released in the 
microenvironment, IDO degrades tryptophan to kynurenines, which inhibit T cell proliferation and induce 
apoptosis [185]. Its induction is one of the mechanisms used by Treg to repress T cell function, owning to 
their constitutive expression of CTLA-4 [186].  
 
3.3.1.2. ICOS 
ICOS is a costimulatory receptor expressed as a homodimer on activated and memory T cells [187]. 
The expression of ICOS is positively regulated, although not absolutely dependent, upon TCR and CD28 
engagement. It typically functions distally to the CD28 delivered costimulation. While the CD28 
costimulation is critical in the priming phase and necessary for IL-2 production and T cell expansion, ICOS 
provides the signal for the sustained regulation of previously activated T cells. Its engagement leads to the 
enhancement of cytokine (IFNγ, TNFα, GM-CSF, IL-10, IL-4, IL-5 and IL-13, but not IL-2) production and 
effector T cell function [71]. Although upregulated on both Th1 and Th2 cells, ICOS is found to costimulate 
Th2 responses more effectively. In addition, ICOS plays a very important role in antibody responses and 
germinal center formation. The engagement of ICOS by ICOS-L expressed on B cells could be a critical 
event for the activation of the CD40:CD40L pathway, necessary for the development of humoral immune 
responses [188]. Its ligand is constitutively expressed by B cells, macrophages and dendritic cells and can 
be further modulated by inflammatory stimuli such as IFNγ, TNFα, GM-CSF or LPS. Interestingly, ICOS-L 
is highly expressed on immature DCs and B cells and its expression is reduced in the presence of 
bacterial stimuli and BCR triggering, respectively [59].  
 
3.3.2. Inhibition through B7 family members 
3.3.2.1. CTLA-4 
In both mouse and human, the ctla-4 gene is mapped to the same chromosomal region as cd28 and 
considered to arise by duplication of an ancestral costimulatory gene. On protein levels these two 
molecules share 30% identity. Interestingly, the cytoplasmic tail of the CTLA-4 protein is 100% conserved 
among mammalian species [189]. CTLA-4 is encoded by 4 exon gene encoding leader peptide, 
ligand-binding site, transmembrane region and cytoplasmic tail, respectively. In human and mouse the 
CTLA-4 transcript undergoes alternative splicing giving rise to full-length CTLA-4 (flCTLA-4), soluble 
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CTLA-4 (sCTLA-4), a transcript coding only exon 1 and 4, and, in mouse only, ligand-independent CTLA-4 
(liCTLA-4) [190]. Upon TCR engagement, CTLA-4 mRNA is detected within 1h peaking at 24-36h 
post-stimulation. The stability of the transcript increases in the presence of CD28 costimulation. CTLA-4 
protein can be detected on T cell surface after 24-48 h [191]. However, most of the protein is retained 
intracellularly and only about 10% is exposed on the cell surface [192]. The trans-Golgi network (TGN) as 
well as endosomal and lysosomal compartments were identified to comprise CTLA-4 intracellular pools 
(Figure 3.11). Intracellular trafficking of CTLA-4 is tightly regulated by association with adapter proteins. 
At the Golgi site, CTLA-4 cytoplasmic tail interacts with TRIM, which mediates its transport to the surface, 
or AP-1, which targets it to lysosomes. Surface exposed CTLA-4 has a very short half-life, since it is 
internalized upon binding of AP-2, and targeted to endosomes and lysosomes for degradation. Upon T cell 
activation, the CTLA-4 cytoplasmic tail is phosphorylated, which prevents AP-2 binding and stabilizes 
CTLA-4 surface expression. In addition, the level of surface expression can be further enhanced by the 
activation induced secretion of CTLA-4 enriched lysosomes [192-194].  
A.                   B. 
 
Figure 3.11. Intracellular trafficking of CTLA-4. [195] (A) Newly synthesized CTLA-4 binds to the transmembrane 
adapter TRIM in the TGN promoting the formation of CTLA-4-containing vesicles and their transport to the cell 
surface. On the cell surface, CTLA-4 and TRIM no longer associate allowing TRIM to interact with other receptors, 
possibly the TCR complex. Shuttling to the lysosomal compartment from the TGN occurs due to adapter AP-1 binding 
to CTLA-4. On the surface, CTLA-4 becomes phosphorylated by kinases Lck, Fyn, and Rlk leading to the association 
of PI3K and possibly other proteins. Phosphorylation retards internalization. Dephosphorylation allows binding to the 
clathrin adapter AP-2 and rapid internalization to endosomes and lysosomes. Upon T-cell activation, CTLA-4 enriched 
lysosomes and endosomes are recycled to the cell surface. (B) Pattern of intracellular CTLA-4 staining in WT T cells. 
Cells were labeled with anti-Syntaxin (TGN marker, green) and anti-CTLA-4 (red). TRIM, T-cell receptor-interacting 
molecule; TGN, trans-Golgi network; PI3K, phosphoinositide 3-kinase 
 
Ana Stojanovic    Introduction 
‐ 42 ‐ 
 
CTLA-4 is a high affinity receptor for B7-1 and B7-2, ligands shared with the activating counter-receptor 
CD28. The avidity of the CTLA-4 binding to shared ligands is around 20 times higher when compared to 
CD28. As a consequence, in situations when ligand expression is limited, CTLA-4 might out-compete 
CD28 for binding, which results in overall inhibition. Structural analysis revealed that pairing of CTLA-4 
with B7-1/2 results in the formation of extended organized periodic network at the interface of a T cell and 
APC (Figure 3.12). Such a structure might prevent diffusion of receptors and/or ligands from the contact 
site and favor recruitment of signaling molecules at a high concentration, but can also interfere with signals 
established by the initial interaction between two cells. All these mechanisms might underline possible 
CTLA-4 dependent inhibitory actions. 
 
Figure 3.12. Extended periodic array formed by the CTLA-4:B7-1/2 complexes. [173] A lattice-like network is created 
by the interaction of  a single CTLA-4 receptor with two different B7-1 or B7-2 dimmers.  
The two main effects of CTLA-4 engagement are decreased IL-2 production and cell cycle arrest that 
finally results in the termination of T cell responses represented by cytokine production and/or cytotoxicity. 
There are several proposed mechanisms of CTLA-4 mediated inhibition of T cell effector functions 
(Figure 3.13) [196]. First one assumes that due to the much higher avidity for the ligands, CTLA-4 simply 
sequesters B7-1/2 molecules, reducing the CD28 engagement and thereby CD28 derived costimulation. 
This mechanism does not require an intact function of the cytoplasmic domain. However, it was shown 
that the cytoplasmic tail was necessary for the CTLA-4 recruitment to the site of immunological synapse 
[197]. In addition, CTLA-4 is able to inhibit the T cell function in the absence of CD28. Mice that express 
tail-less CTLA-4 develop lymphoproliferative disorder similar to CTLA-4 deficient animals [198]. A less 
aggressive appearance of the disease still indicates that ligand competition is a mechanism that plays 
a role in CTLA-4 dependent T cell inhibition and might be of crucial importance when amounts of ligands 
are limited. In addition to ligand sequestering, CTLA-4 excludes CD28 from the immunological synapse 
and blocks the formation of microclusters containing adapters and kinases needed for the effective signal 
transmission downstream of the TCR. The third mechanism implicates a direct inhibitory signal delivered 
by CTLA-4 expressed on the cell surface. Indeed, simultaneous cross-linking of CTLA-4 and TCR in the 
presence of CD28 costimulation is sufficient to inhibit IL-2 production and induce cell cycle arrest [199]. 
CTLA-4 lacks an intrinsic enzymatic activity and a classical immunoreceptor tyrosine-based inhibitory motif 
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(ITIM) frequently found in other inhibitory receptors. Despite this, SH2-containing thyrosine phosphatase-2 
(SHP-2) and serine–threonine phosphatase protein phosphase 2A (PP2A) have been reported to associate 
with the cytoplamic tail of CTLA-4 (Figure 3.14A). However, their binding is not absolutely required for the 
inhibitory function. In addition, SHP-2 is rather implicated in positive signal transduction that leads to cell 
activation [195]. Both phosphatases associate with CD28 as well and differential recruitment to CTLA-4 
during an ongoing immune response, which is regulated by phosphorylation, could be crucial for the final 
outcome of regulation (reviewed in [200]). 
 
Figure 3.13. Mechanisms of CTLA-4 mediated inhibition of T cell function. [196] CTLA-4 inhibitory function is achieved 
by the combined action of several mechanisms: the direct competition for ligands with the activating receptor CD28, 
recruitment of inhibitory signaling components and prevention of lipid rafts and signaling microcluster formation. Under 
different conditions defined by the TCR signal strength, B7-1/2 ligand concentration, recruited signaling molecules etc, 
different mechanisms can play a dominant role in mediating inhibition.  
Furthermore, CTLA-4 has been reported to induce positive signaling events in T cells (Figure 3.14B) [195]. 
CTLA-4 binds to PI3K with the same avidity as CD28 and activates JNK, while inhibiting extracellular 
signal-regulated kinases (ERKs). The inhibition of ERKs could account for negative signaling, while the 
activation of JNK could contribute to the positive effects on Th1 differentiation. Through the PI3K/Vav1 
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pathway CTLA-4 enhances LFA-1 integrin clustering and adhesion, which might stabilize the contact with 
interacting cells. In addition, CTLA-4 binding to PI3K leads to the activation of the PKB⁄Akt pathway, 
similar as CD28. CTLA-4 co-ligation in such circumstances acts to increase cell survival, while at the same 
time inhibits effector responses and/or induces state of non-responsiveness.  
 
A.             B. 
 
 
Figure 3.14. Functional consequences of CTLA-4 signaling. (A) CTLA-4 recruits two phosphatases that might be 
involved in direct dephosphorylation of TCR and/or CD28 proximal signaling molecules leading to the repression of 
T cell responses [201]. (B) Recruitment of PI3K leads to the activation of pro-survival pathways [195]. 
CTLA-4 deficient mice are born healthy. However, 5-6 days after birth, a large proportion of T cells 
becomes activated, causing splenomegaly, lymphoadenopathy and tissue destruction due to the infiltration 
of peripheral organs. The increased activation of B cells results in elevated levels of immunoglobulins 
in the serum. This pathology results in death at 3-4 weeks of age. T cells in CTLA-4 deficient mice show 
an activated CD69+CD25+CD44high phenotype, increased proliferation rate and cytokine production 
compared to WT counterparts. Both CD4+ and CD8+ T cells of broad specificity mediate the disorder 
[202-203]. Antigen-specific stimulation and costimulation via CD28:B7-1/2 pathway is required for the 
activation of CTLA-4 deficient T cells. The lymphoproliferative disorder due to the CTLA-4 deficiency is not 
cell autonomous. In the presence of WT counterparts, CTLA-4 deficient T cells do not cause the disease 
and undergo normal activation and expansion upon infection challenge [204-205]. In humans, several 
polymorphisms in the ctla-4 gene have been connected to different autoimmune disorders, such are 
Graves’ disease, multiple sclerosis, Addison’s disease, type I diabetes, systemic lupus erythematosus 
(SLE) and rheumatoid arthritis, indicating its important role in the maintenance of peripheral tolerance and 
restriction of responses to self-antigens [206]. 
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3.3.2.2. PD-1 
PD-1 has been initially described as a receptor induced on a T cell line undergoing activation-induced cell 
death [207]. However, the expression of PD-1 is not a consequence of induction of cell death per se, but 
rather triggered by T cell activation [208]. In addition to activated T cells, PD-1 is expressed on activated 
B and NKT cells, monocytes and DCs, as well as on maturing thymocytes, playing a role in central 
tolerance induction [209-210]. Particularly high PD-1 expression is a characteristic of functionally 
exhausted effector CD8+ T cells found in multiple persistent viral infections in both mouse and human 
[211-212]. The blockade of PD-1 or its ligand, B7-H1, leads to restored T cell proliferation and cytokine 
production. Regulatory T cells (Treg) show specific pattern of PD-1 protein expression: constitutively 
synthesized protein is stored intracellularly and transported to the cell surface upon stimulation [213]. 
B7-H1 (PD-L1, CD274) and PD-L2 (B7-DC, CD273) are two described ligands of PD-1 (PD-Ls). PD-1 
engagement by its ligands leads to T and B cell inhibition [214-216]. However, it was reported that PD-Ls 
can also costimulate T cell responses, by increasing proliferation, IL-10, IFNγ and GM-CSF, but not IL-2 
and IL-4 production [217-218]. Since costimulation by PD-Ls was observed in PD-1 deficient T cells, 
the existence of a second receptor has been postulated. The pattern of PD-Ls expression is significantly 
broader as compared to other B7 family ligands [219-220]. B7-H1 is broadly expressed on both 
hematopoietic (resting T and B cells, macrophages, DCs, NK cells) and non-hematopoietic (endothelium, 
epithelium, muscle cells, hepatocytes, pancreatic islets, placenta, eye) cells. It is further up-regulated by 
typical proinflammatory stimuli as type I IFNs, IFNγ or LPS. In contrast, PD-L2 is restricted to the 
hematopoietic lineage, more specifically to activated DCs, macrophages and resting peritoneal B1 B cells. 
It can be induced on monocytes and macrophages by GM-CSF, IL-4, IL-13 and IFNγ stimulation 
[221-222]. Due to the their distinct expression pattern and functions, PD-L2 might play a major role in the 
enhancement of T cell responses during the priming phase, while B7-H1 may act at the periphery by 
promoting Th2 cytokine production and down-regulating effector functions. The stimulatory role of PD-L2 
is further supported by the increased immunogenicity of tumor cells that ectopically express this molecule 
[223]. In addition, its cross-linking on DCs leads to their activation and increased ability to stimulate T cells 
[224].  
PD-1 attenuates T cell responses by mechanisms distinct from activation-induced cell death [176]. 
The delivered inhibition depends on the strength of the TCR signal with greater inhibition exerted at low 
levels of TCR stimulation. The cytoplasmic tail of PD-1 contains two tyrosines belonging to an ITIM 
(Immunoreceptor Tyrosine-based Inhibition Motif) and an ITSM (Immunoreceptor Tyrosine-based Switch 
Motif), respectively. Cross-linking of PD-1 alone does not transduce the signal. Simultaneous engagement 
of both TCR and PD-1 results in tyrosine phosphorylation of PD-1 ITIM and ITSM and in the recruitment of 
tyrosine phosphatase SHP-2, which mediates dephosphorylation of proximal TCR signaling components. 
Although both tyrosines are phosphorylated, only the ITSM motif was shown to be crucial for SHP-2 
recruitment. ITSM is reported to transduce both positive and negative signals, which might indicate 
possible dual function of PD-1 receptor. 
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The functional consequences of PD-1 activation include decreased cytokine production and cell cycle 
arrest, mainly through the inhibition of IL-2 secretion, Bcl-XL expression and repression of transcription 
factors associated with T cell effector function (GATA-3, Tbet and Eomes) [225]. Exogenous IL-2 or CD28 
costimulation can rescue PD-1 mediated inhibition [214, 226]. Due to the broad expression of B7-H1 at the 
periphery, PD-1 is seen as a key regulator of peripheral tolerance and attenuator of self reactive T cells. 
In addition, the vigorous response to pathogens that can lead to immune mediated tissue damage is 
controlled by the PD-1 mediated inhibitory function [227].  
PD-1 deficiency, consistent with its negative regulatory function, results in a late onset, chronic, 
progressive lupus-like glomerulonephritis and arthritis on C57BL/6 background [228]. On the other hand, 
Balb/c PD-1 deficient mice develop very rapidly autoimmune-dilated cardiomyophaty that leads to heart 
failure and premature death. B and T cells are required for the pathology to develop, since no disease is 
observed in Balb/c PD-1-/-RAG-/- mice [229]. On an autoimmune-prone background, PD-1 deficiency 
negatively influences disease progression. Onset and severity of insulitis in NOD mice and EAE in 
a mouse model of MS are accelerated when PD-1/PD-Ls interaction is disrupted [230-231]. Similarly, 
in humans, several polymorphisms within the PD-1 encoding gene have been associated with 
autoimmune diseases, including SLE, type I diabetes, RA, MS and Grave’s disease [232]. 
Various tumor cell lines [233-234] and established tumors [235-240] express PD-Ls, which are used by 
tumors to escape immunosurveillance by attenuation of effector cell responses via PD-1 engagement. 
This notion is supported by the observation that B7-H1 expression by tumor cells correlates with poor 
prognosis. In addition, tumor infiltrated lymphocytes upregulate PD-1, which correlates with decreased 
responses [241-242]. Apart from tumor cells, B7-H1 is expressed by vascular endothelial cells and myeloid 
cells, including DCs, in the tumor tissue, which can impair both T cell extravasation and activation at the 
tumor site. In mouse tumor models, treatment with αPD-1 or αB7-H1 blocking mAb as well as tumor 
implantation in PD-1 deficient hosts, augments anti-tumor responses [234, 243-245].  
 
3.3.3. Other B7 family members 
B7-H3 is a distant B7 family ligand initially found to costimulate IFNγ production and T cell cytotoxic 
response. It can be induced on dendritic cells by IFNγ and on monocytes by GM-CSF. Its receptor, 
expressed on T cell upon activation [246], has been recently identified as the triggering receptor 
expressed on myeloid cells (TREM)-like transcript 2 (TREML2) [247]. Alternatively, the inhibition of T cell 
function by B7-H3 has also been reported [248], but the receptor mediating inhibition is not known. It is 
also possible that in different conditions provided by the microenvironment the same receptor can have 
a dual functional role. Moreover, discrepancies were reported when mouse tumor models were compared 
with human malignances. While ectopic B7-H3 expression leads to the tumor regression in mice, its high 
expression in human tumors associates with higher dissemination of metastases and poor prognosis 
[249]. 
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B7-H4, another distant B7 ligand member, has been detected on activated T and B cells, DCs, 
macrophages and monocytes and described as negative regulator of T cell responses [250-252]. Myeloid 
cells stimulated with IL-6 or IL-10 upregulate B7-H4, while DC differentiating cytokines GM-CSF and IL-4 
decrease its expression. It was reported for different human cancers that B7-H4 was highly expressed by 
tumor cells and infiltrated macrophages, which correlated with poor prognosis [219]. 
B7-H6 has been recently identified as B7 family member that specifically binds and activates NK cell 
cytotoxicity via the receptor NKp30 [253]. Interestingly, B7-H6 was neither detected in normal tissues nor 
could be induced under various conditions of cellular stress. However, several tumor cell lines and primary 
tumor cells obtained from patients with hematological malignancies were found to express B7-H6, 
indicating that it can be upregulated by cell transformation. 
BTLA (B and T lymphocyte attenuator) is a transmembrane B7 family receptor structurally similar to PD-1 
and CTLA-4. It is expressed on most hematopoietic cells and increased upon stimulation [254]. Grb2 and 
PI3K binding sites were found in its cytoplasmic tail [255], as well as two ITIM motifs [256]. An inhibitory 
function of BTLA was supported by in vitro data [257] and the phenotype of the knock-out mice that 
develop a spontaneous autoimmune hepatitis-like disease at a late age. BTLA binds to the TNF-R 
superfamily member HVEM that is widely expressed through the lymphoid compartment. HVEM is also 
known for its ability to engage several TNF ligands, such as lymphotoxin α and LIGHT, acting as a positive 
regulator [258-259]. In addition, human T cells are shown to be inhibited through the HVEM interaction 
with CD160, another Ig superfamily inhibitory receptor mainly expressed on cytotoxic lymphocytes, 
including NK cells [260-261]. 
BTNL2 (butyrophilin-like 2) belongs to the family of butyrophilins, which are structurally closely related to 
B7 molecules [262]. Mouse BTNL2 is a type I transmembrane protein with two pairs of IgV-IgC domains, 
which are found in B7 receptors in one copy. Its mRNA is highly expressed in the lymphoid tissues as well 
as in the intestine. It recognizes a putative receptor whose expression on B and T cells is significantly 
enhanced after activation. BTNL2 engagement inhibits T cell proliferation and TCR activation of NFAT, 
NF-kappaB, and AP-1 signaling pathways.  
 
3.3.4 B7 family members as therapeutic targets 
Two main classes of disorders, malignancies and autoimmune diseases, are considered as the best 
therapeutic targets using approaches that modulate the activity of costimulatory and/or coinhibitory B7 
family members. Autoimmunity, accompanied with deregulated inhibition towards self antigens, is usually 
treated in the way that blocks unleashed stimulation. On the other hand, multiple approaches are 
considered for the treatment of tumors. The self-nature of tumor antigens requires breaking of self 
tolerance by mechanisms which will dissociate therapy induced activation from possible adverse effects. 
In addition, proper costimulation should be achieved in order to prevent anergy induction. At the same 
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time, exhaustion and thereby inhibition of immune effectors due to the chronic stimulation should be 
avoided. Thus, the proper combination of therapeutic agents applied at the correct time points in the 
course of effector cell activation, within a window that will ensure a beneficial effect without detrimental 
side effects, should be designed to combat outgrowing tumors. 
Providing costimulation 
In several mouse models the introduction of B7-1 on tumor cells was sufficient to induce T cell mediated 
tumor rejection as well as subsequent memory responses. However, this strategy was not efficient for 
non-immunogenic tumors [263]. The mmunization with B7-1 irradiated transfectants can protect 
vaccinated mice from the subsequent challenge, but does not induce the rejection of established tumors. 
In general, B7-1 expression by tumor cells is thought to augment the effector phase of anti-tumor 
response, while efficient T cell priming rely on the cross-presentation and the proper expression of 
costimulatory molecules by APCs. B7-1 integrated in several vaccination strategies in phase I and II 
clinical trials confirmed the induction of specific responses with clinical benefits for some of the patients 
[263]. However, despite the induction of systemic immune response, the benefits were limited, since 
multiple layers of negative regulation are operating to hamper efficient responses within the tumor 
microenvironment. 
Removing inhibition 
So far, two B7 mediated inhibitory pathways were widely analyzed for their ability to suppress tumor 
immunity. Removing CTLA-4:B7-1/2 or/and PD-1:B7-H1 mediated inhibition was shown to be beneficial in 
enhancing T cell anti-tumor responses. 
CTLA-4:B7-1/2 
Mice challenged with colon carcinoma or fibrosarcoma cell lines treated with CTLA-4 blocking Ab 
demonstrated improved tumor rejection and the generation of protective T cell memory [264]. The effect 
was seen in both prophylactic and therapeutic settings with a relatively small tumor burden. Although 
similar results were obtained in lymphoma, prostate and renal carcinoma models [249], CTLA-4 
neutralization was inefficient when applied at high tumor loads or with poorly immunogenic tumors. 
Improved rejection has been achieved in models of mammary cancer and melanoma by 
combining CTLA-4 blockade with immunization with an irradiated GM-CSF producing tumor vaccine 
(GVAX) [265-266]. This treatment was efficient only when applied at very early stages of tumor 
progression. Recently, a Flt3L producing tumor cell vaccine (FVAX) was also shown to be effective in 
controlling B16 melanoma and prostate cancer progression when combined with CTLA-4 neutralization 
[267]. Two fully human αCTLA-4 mAbs have been investigated in clinical trials with end-stage, 
treatment-resistant melanoma and renal cell carcinoma patients showing overall response rates around 
10% with significant duration [268]. Anti-CTLA-4 monotherapy is thought to enhance pre-existing as well 
as to induce de novo anti-tumor responses. Evidence of immunological activity has also been 
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demonstrated in cases of prostatic, ovarian, breast and colon carcinoma, although objective response 
criteria have not been met. However, promising results were obtained from trials that combined CTLA-4 
blocking with specific peptide vaccine, high dose IL-2 and GM-CSF producing tumor vaccine indicating 
that multimodal approach might be a better choice for the efficient treatment. However, patients that 
benefit from the treatment with αCTLA-4 mAb usually develop severe autoimmune side effects indicating 
the need for the improvement of therapeutic designs to reduce unfavorable responses and enrich 
responding patient population at the same time [268]. 
PD-1: B7-H1 
Even when low or no expression is observed on tumor cell lines, most of human and mouse cancers 
express high levels of B7-H1. In addition, tumor associated immune cells are observed to upregulate 
surface B7-H1 expression [269]. B7-H1 exploits many different modes of action in order to suppress 
immune mediated tumor destruction including the induction of apoptosis, anergy and/or exhaustion of 
T cells, IL-10 production by DCs, promotion of Treg mediated immune suppression and formation of 
a “molecular shield” that protects tumor cells from direct lysis. Reverse signaling of B7-H1 into the tumor 
cells has been shown to induce resistance to apoptosis by multiple pathways [270]. Ectopic expression of 
B7-H1 into highly immunogenic P815 mastocytoma tumor cell line leads to progressive growth when 
injected in syngenic mice [233-234, 243]. However, B7-H1 expression by poorly immunogenic tumors, 
as B16 melanoma, does not influence tumor control [234]. Application of B7-H1 or PD-1 blocking 
antibodies can cause tumor regression in several mouse tumor models and treatment settings [244-245, 
271-272]. Two humanized αPD-1 mAb have been developed and are to be further tested for their efficacy. 
So far, phase I trials documented clinical benefits for patients with hematological malignancies, but not for 
the cases with advanced solid tumors [263]. 
Crucial issues for B7 based anti-cancer therapy 
The current knowledge reveals a very complex regulation of expression and function of B7 molecules. 
Dissection of the proper therapeutic targeting is proven to be difficult due to the multitude of possible 
interactions that can be established within the family and reverse signaling observed for most of them. 
In addition, in many cases both immune effector cells and tumor cells express the potential targets and 
can be affected in an opposed way by the given therapeutic agents. Although most of the studies dissect 
the clinical application with T cells as the main players in an anti-tumor immune response that is to be 
raised, it should be considered that other immune cells can potentially express targeted molecules and 
could respond to the therapy in different ways. In addition to adding and/or removing one or several 
B7 mediated interactions, from current studies it is clear that additional stimuli have to be provided to 
achieve efficient responses. Those stimuli are to enhance different modalities of global anti-tumor activities 
including cell priming, homing to the tumor site, extravasation, migration through tumor tissue, 
proliferation, cytokine production, cytotoxicity or other events that might synergize with B7 related 
therapeutics. 
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4. Aim of the Study 
NK cells are recognized as potent anti-tumor effectors. They are particularly efficient in the recognition of 
tumor cells that lose the expression of MHC I molecules, which inhibit NK cell activation [23]. In cancer 
patients, many tumors downregulate MHC I in order to escape direct recognition by cytotoxic T cells, 
which are MHC I restricted [273]. At the same time, these tumors become susceptible to attack by 
NK cells. NK cells can efficiently eradicate disseminating cancer cells [39]. However, solid tumors usually 
grow progressively, despite the MHC I deficiency detected for majority of cases. Infiltration of the tumor 
tissue by NK cells represents a good prognostic factor [274-275]. Despite this, in cancer patients NK cells 
are found to be impaired in performing their effector functions [276].  
In this regard, the aim of our study was to analyze NK cells responses against the MHC I deficient 
lymphoma, RMA-S. To better understand the nature and mechanisms that influence NK cell responses to 
progressively growing lymphoma in vivo, comprehensive analysis of NK cell phenotype in tumor bearing 
mice including the expression of surface markers used to define their maturation stage, subset 
composition, activation status and functional competence was performed. We took advantage of a global 
gene expression profiling of blood and tumor infiltrating NK cells. We aimed at the characterization of 
possible systemic changes in peripheral blood NK cells that could occur due to the tumor outgrowth and 
can be used as potential clinical biomarkers of tumor presence. In addition, we analyzed features of 
NK cells infiltrating the tumor to investigate possible mechanisms that operate within tumor tissue to inhibit 
NK cells anti-tumor responses. Our work describes some of the mechanisms involved in the complex 
control of NK cell responses, which should be considered for design of novel NK cell based anti-cancer 
therapies.  
 
 
 
 
 
 
 
 
 ‐ 51 ‐ 
 
5. Materials and Methods 
 
5.1. Materials 
5.1.1. Laboratory equipment 
Product  Company 
Analytical scales, AE163  Mettler Toledo 
Analytical scales, AG285  Mettler Toledo 
Anesthesia machine, Vapor 19.1  Drägerwerk AG 
Cell culture incubator, Heraeus BBD 6220 (CO2)  Kendro 
Centrifuge 5415 R (table)  Eppendorf 
Centrifuge 5417 R (table)  Eppendorf 
Centrifuge, Heraeus Biofufe Pico  Kendro 
Centrifuge, Heraeus Multifuge 4 K‐R/3 S‐R  Kendro 
Centrifuge, Sorvall Evolution RC  Kendro 
DNA Engine PTC‐200  MJ Research 
ELISA microplate reader, GENios  TECAN 
EPS 3501XL Electrophoresis Power Supply  GE Healthcare 
FACS™ sorter, FACS™Diva  BD 
FACS™ sorter, FACS™Vantage SE  BD 
Flow cytometer, FACS™Calibur  BD 
Flow hood, Heraeus Hera Safe BBD 6220  Kendro 
Flow hood, LabGuard NU‐437‐600E  IBS Integra 
Freezer ‐20°C, Premium/Comfort/Profi line  Liebherr 
Freezer ‐86°C, VIP series  Sanyo 
Fridge, Premium/Profiline  Liebherr 
Gel Documentation System 2000  Bio‐Rad 
Heatblock  VWR/Scientific Industries 
Ice machine  Hoshizaki 
Magnetic stirrer, MR3001 K  Heidolph 
Microscop, WIIovert 30  Hund Wetzler 
N2 tank, CryoSystem 6000  MVE 
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Product  Company 
PerfectBlueTM Horizontal Mini Electrophoresis Systems, Mini S and L  peQLab 
pH meter  WTW 
Photometer, Ultraspec 3100  Amersham Biosciences 
Pump, Econo Pump  Bio‐Rad 
Scales, PB602‐S  Mettler Toledo 
Thermomixer, Compact/Comfort  Eppendorf 
Vortex, VortexGenie2  VWR/Scientific Industries 
Waterbath, Heraeus Julabo TW20  Kendro 
Waterbath, SWB 20  Medingen 
Gamma‐counter, Cobra auto‐gamma Packard, PerkinElmer 
Gamma cell 1000  Atomic Energy of Canada Ltd 
 
5.1.2. Cell culture products 
Product  Company  Catalog no.
Standard tissue culture flasks/filter screw caps – 25 cm2 TPP 90026
Standard tissue culture flasks/filter screw caps – 75 cm2 TPP 90076
Standard tissue culture flasks/filter screw caps – 150 cm2 TPP 90151
Tissue culture flasks/filter screw caps – 182 cm2  Greiner  660175 
96‐well U‐bottom with lid – Standard TC BD 353077
96‐well flat‐bottom with lid – Standard TC BD 353072
48‐well flat‐bottom with lid – Standard TC BD 353078
24‐well flat‐bottom with lid – Standard TC BD 353047
12‐well flat‐bottom with lid – Standard TC  BD  353043 
6‐well flat‐bottom with lid – Standard TC BD 353046
6‐well flat‐bottom with lid – non‐treated TC BD 351146
24‐well flat‐bottom with lid – non‐treated TC BD 351147
50 ml conical tubes Falcon™ BD 352070
15 ml conical tubes Greiner  188271
5 ml round‐bottom polypropylene test tube BD 352008
5 ml round‐bottom polystyrene test tube w/ cell strainer BD 352235
Serological pipettes, 5, 10, 25, and 50 ml, sterile Costar  ‐
70 μm cell strainer Falcon™ BD 352350
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Product  Company  Catalog no.
40 μm cell strainer Falcon™ BD 352340
Cryovial®, 2ml sterile Roth E309.1
NalgeneTM Freezing Container, “Mr. Frosty” Nunc 5100‐0001
0.5, 1.5 and 2 ml safe‐lock tubes Eppendorf  ‐
10, 20, 100, 200, 300 and 1000 µl filter tips Biozym  ‐
50 ml Reagent reservoirs, sterile  Corning  4870 
0.5, 1.5 and 2ml safe‐lock tibes Eppendorf  ‐
50 ml conical tubes with 0.22 µm filter top (Sterilflip) Milipore  SCG00525
Syringe driven filter units, low protein binding, 0.22 and 0.45 µm Milipore  ‐
1, 5, 10, 20 ml syringes BD ‐
 
5.1.3. Cell culture media and solutions 
Product  Company  Catalog no. 
RPMI 1640 (1x) w/o L‐Glutamine  GIBCO‐Invitrogen  31870 
D‐MEM (1x) (High Glucose) with L‐Glutamine, 4500
mg/L D‐Glucose, w/o sodium pyruvate 
GIBCO‐Invitrogen  41965 
IMDM with L‐Glutamine, 25mM HEPES and sodium pyruvate  GIBCO‐Invitrogen  21980 
D‐PBS (1x) w/o Ca, Mg, sodium bicarbonate  GIBCO‐Invitrogen  14190 
RPMI 1640 (1x) w/o L‐Glutamine with sodium bicarbonate  Sigma  R0883 
D‐MEM (1x) with L‐Glutamine, 4500
mg/L D‐Glucose, with sodium pyruvate and sodium bicarbonate 
Sigma  D6429 
IMDM with 25 mM HEPES, w/o L‐glutamine  Sigma  51472C 
D‐PBS (1x) w/o Ca, Mg, sodium bicarbonate  Sigma  D837 
Fetal Bovine Serum, Origin: EU Approved  GIBCO‐Invitrogen  10270 
Penicillin/Streptomycin‐Solution
10000 U/ml penicillin, 10000 μg/ml streptomycin 
GIBCO‐Invitrogen  15140 
L‐Glutamine 200 mM (100x), 29.2 mg/ml  GIBCO‐Invitrogen  25030 
Non‐essential amino acids (100x)  GIBCO‐Invitrogen  11140035 
Sodium pyruvate MEM 100mM  GIBCO‐Invitrogen  11360088 
β‐mercaptoethanol 50mM  GIBCO‐Invitrogen  31350010 
Trypsin‐EDTA (1x) HBSS w/o Ca2+/Mg2+ w/ EDTA  GIBCO‐Invitrogen  25300 
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Product  Company  Catalog no. 
Dimethylsulphoxide Hybri Max® (DMSO)  Sigma‐Aldrich  D2650 
Cell Dissociation Solution Non‐enzymatic (1x)  Sigma‐Aldrich  C5914 
 
5.1.4. Solutions 
Solution  Indigrents
ACK lysis buffer 
0.15 M NH4Cl
10 mM KHCO3 
0.1 mM EDTA 
pH 7.2‐7.4 
FACS™ buffer 
1X PBS
0.02 % NaN3 (v/v) 
1 % FCS 
2 mM EDTA 
Freezing medium 
1X FCS
10 % DMSO (v/v) 
MACS® buffer 
1X PBS
0.5 % FCS 
2 mM EDTA 
Primary cell culture medium (PCM) 
1X RPMI
10 % FCS 
2 mM L‐glutamine 
100 U/ml penicillin 
100 mg/ml streptomycin 
1 mM sodium pyruvate 
1X non‐essential amino acids 
0.25 mM β‐mercaptoethanol 
10X PBS 
1.37 M NaCl
27 mM KCl 
100 mM Na2HPO4 (anhydrous) 
20 mM KH2PO4 
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5.1.5. Chemicals and biological reagents 
Product  Company  Catalog no. 
7‐AAD  BD  559925 
Carboxyfluorescein succinimidyl ester (CFSE)  Sigma‐Fluka  21888 
Chromium‐51  PerkinElmer  NEZ030005MC 
Collagenase, type IV from Clostridium histolyticum  Cell Systems  LS004188 
CpG oligonucleotide ODN 1668  InvivoGen  tlrl‐modnb 
DNA mass ladder (high)  Invitrogen  10068‐013 
DNA mass ladder (low)  Invitrogen  10496‐016 
Dnase I  Sigma‐Aldrich  DN25 
dNTP Mix  Promega  U1511 
FACS™ lysing solution (10x)  BD  349202 
Golgi Stop  BD  554724 
Heparin‐Sodium B  Braun  1708.00.00 
Hyaluronidase type V  Sigma‐Aldrich  H6‐254 
Isofluran B  Braun  6724123.00.00 
Lipopolysaccharide (LPS)  Sigma‐Fluka  L4391 
Lympholite® M  Cedarline  CL5035 
Pellet Paint co‐precipitant  Novagen  69‐049‐3 
PMSF  Applichem  A0999 
Polyinoside‐polycytidylic acid (pI:C)  InvivoGen  tlrl‐pic 
Recombinant human IL‐2  Chiron  50‐4413 RN 
Recombinant human IL‐2  Hoffmann‐La Roche  1104‐0890 
Recombinant mouse IFN‐g  Peprotech  315‐05 
Recombinant mouse IL‐12  Peprotech  210‐12 
Recombinant mouse IL‐15  Peprotech  210‐15 
Recombinant mouse IL‐18  MBL  B002‐5 
RNA Storage Solution  Ambion  AM7000 
Rnasin® Plus Rnase Inhibitor  Promega  N2615 
Triton X‐100  Sigma‐Fluka  T9284 
Two‐Cycle Target Labeling and Control Reagents  Affymetrix  900494 
UltraPure™ DEPC‐Treated Water  Invitrogen  750024 
Nuclease‐Free Water (not DEPC treated)  Ambion  AM9937 
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5.1.6. Antibodies 
5.1.6.1. Fluorochrome-conjugated antibodies for flow cytometry 
Specificity  Fluorochrome  Clone  Isotype  Company  Catalog no. 
2B4  FITC  eBio 244F4  Rat IgG2a  eBioscience  11‐2441 
B7‐1  PE  16‐10A1  Hamster IgG  Biolegend  104708 
B7‐1  FITC  16‐10A1  Hamster IgG  Biolegend  104706 
B7‐2  PE  GL‐1  Rat IgG2a  Biolegend  105008 
CD107a  FITC  1D4B  Rat IgG2a  BD  553793 
CD107b  FITC  ABL‐93  Rat IgG2a  BD  558758 
CD11b  FITC  M1/70  Rat IgG2b  BD  553033 
CD11b  APC  M1/70  Rat IgG2b  BD  553312 
CD11b  FITC  M1/70  Rat IgG2b  Biolegend  101206 
CD11c  FITC  HL3  Hamster IgG1  BD  557400 
CD11c  FITC  N418  Hamster IgG  Biolegend  117306 
CD127  FITC  A7R34  Rat IgG2a  eBioscience  11‐1271 
CD19  APC  1D3  Rat IgG2a  BD  550992 
CD27  PE  LG.3A10  Hamster IgG1  BD  558754 
CD27  PE  LG.3A10  Hamster IgG1  Biolegend  124210 
CD27  FITC  LG.3A10  Hamster IgG1  Biolegend  124208 
CD28  PE‐Cy5  37.51  Hamster IgG  Biolegend  102108 
CD3ε  FITC  145‐2C11  Hamster IgG1  BD  553062 
CD3ε  PerCP‐Cy5.5  145‐2C11  Hamster IgG1  BD  551163 
CD3ε  APC  145‐2C11  Hamster IgG1  BD  533066 
CD3ε  FITC  145‐2C11  Hamster IgG1  Biolegend  100306 
CD3ε  PerCP‐Cy5.5  145‐2C11  Hamster IgG1  Biolegend  100328 
CD3ε  APC  145‐2C11  Hamster IgG1  Biolegend  100312 
CD4  APC  RM4‐5  Rat IgG2a  BD  553051 
CD43  FITC  S7  Rat IgG2a  BD  553270 
CD45.1  APC  A20  Mouse IgG2a  eBioscience  17‐0453 
CD45.1  FITC  A20  Mouse IgG2a  BD  553775 
CD45.1  PE  A20  Mouse IgG2a  BD  553776 
CD45.2  PerCP Cy5.5  104  Mouse IgG2a  Biolegend  109828 
CD45.2  FITC  104  Mouse IgG2a  BD  553772 
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Specificity  Fluorochrome  Clone  Isotype  Company  Catalog no. 
CD48  PE  HM48‐1  Hamster IgG  eBioscience  12‐0481 
CD69  FITC  H1.2F3  Hamster IgG  BD  557392 
CD8  PE  53‐6.7  Rat IgG2a  BD  553033 
c‐Kit  FITC  2B8  Rat IgG2b  BD  553354 
CTLA‐4  PE  UC10‐4B9  Hamster IgG  Biolegend  106306 
CTLA‐4  PE  UC10‐4F10‐11  Hamster IgG  BD  553720 
F4/80  Alexa 488  BM8  Rat IgG2a  Caltag  MF48020 
Granzyme B  PE  16G6  Rat IgG2b  eBioscience  12‐8822 
I‐A/I‐E  PE  M5/114.15.2  Rat IgG2b  BD  557000 
I‐A/I‐E  Alexa 647  M5/114.15.2  Rat IgG2b  Biolegend  107618 
ICOS  PE  7E.17G9  Rat IgG2b  BD  552146 
ICOS‐L  PE  HK5.3  Rat IgG2a  Biolegend  107406 
IFN‐γ  FITC  XMG1.2  Rat IgG1  BD  554411 
IFN‐γ  FITC  XMG1.2  Rat IgG1  eBioscience  11‐7311 
KLRG1  FITC  F1  Hamster IgG  Southern Biotec  1807‐02 
Ly49C/I/G/H  PE  14B11  Hamster IgG  Biolegend  108208 
Ly49D  APC  eBio 4E5  Rat IgG2a  eBioscience  51‐5782 
Ly49A  PE  YE1/48.10.6  Rat IgG2a  Biolegend  116808 
Ly49G2  FITC  eBio 4D11  Rat IgG2a  eBioscience  11‐5781 
NK1.1  APC  PK136  Mouse IgG2a  BD  557391 
NK1.1  FITC  PK136  Mouse IgG2a  BD  553164 
NK1.1  PE  PK136  Mouse IgG2a  BD  557391 
NK1.1  PerCP‐Cy5.5  PK136  Mouse IgG2a  Biolegend  108728 
NK1.1  Alexa 647  PK136  Mouse IgG2a  Biolegend  108720 
NK1.1  APC  PK136  Mouse IgG2a  Biolegend  108710 
NKG2D  APC  CX5  Rat IgG1  eBioscience  17‐5882 
NKp46  PE  29A1.4  Rat IgG2a  eBioscience  12‐3351 
NKp46  Alexa 647  29A1.4  Rat IgG2a  eBioscience  51‐3351 
PD‐1  PE  J43  Hamster IgG  BD  551892 
PD‐1  PE  RMP1‐30  Rat IgG2b  Biolegend  109104 
PD‐L1  PE  MIH5  Rat IgG2a  BD  558091 
PD‐L2  PE  Ty25  Rat IgG2a  BD  557796 
Perforin  PE  eBio OMAK‐D  Rat IgG2a  eBioscience  12‐9392 
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Specificity  Fluorochrome  Clone  Isotype  Company  Catalog no. 
B220  FITC  RA3‐6B2  Rat IgG2a  BD  553092 
B220  APC  RA3‐6B2  Rat IgG2a  BD  553087 
CD3ζ  biotin  H146‐968  Hamster IgG  Cedarlane  CL 7230 B 
F4/80  Alexa 488  BM8  Rat IgG2a  Caltag  MF 48020 
ICAM‐1  PE  3E2  Hamster IgG  BD  553253 
 
5.1.6.2. Affinity purified antibodies for functional assays 
Specificity  Clone  Isotype Company  Catalog no.
CD28  37.51  Hamster IgG Biolegend  102112
2B4  eBio 244F4 Rat IgG2a eBioscience  14‐2441
Ly49D  4E5  Rat IgG2a BD 555312
NKG2D  CX5  Rat IgG1 eBioscience  14‐5882
NKG2D  A10  Rat IgG1 Biolegend  115602
NKp46  polyclonal Goat IgG R&D AF2225
NKp46  29A1.4  Rat IgG2a eBioscience  16‐3351
NK1.1  PK136  Mause IgG2a Biolegend  108712
CTLA‐4  UC10‐4B9 Hamster IgG Biolegend  106308
B7‐1  16‐10A1 Hamster IgG Biolegend  104710
TGFβ  1D11  Mouse IgG R&D MAB1835
CD16/CD32  93  Rat IgG2a  Biolegend  101310 
 
5.1.6.3. Affinity purified fusion proteins for functional assays 
Recombinant protein  Linker C‐terminus Company  Catalog no.
Recombinant mouse B7‐1/Fc Chimera  DIEGRMD Human IgG1 R&D  740‐B1‐100
Recombinant mouse CTLA‐4/Fc Chimera IEGRMD Human IgG1 R&D  434‐CT‐200
Recombinant mouse EphA4/Fc Chimera IEGRMD Human IgG1 R&D  641‐A4‐200
 
5.1.6.4. Antibodies for in vivo application 
Specificity Clone Isotype Company Catalog no.
CTLA-4 UC10-4F10-11 Hamster IgG BioXCell BE0032 
PD-1 J43 Hamster IgG BioXCell BE0033-2 
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5.1.6.5. Isotype controls and secondary reagents for flow cytometry 
Isotype  Fluorochrome Clone Company  Catalog no.
Rat IgG2a, k  FITC R35‐95 BD 553929
Rat IgG2a, k  PE R35‐95 BD 554689
Rat IgG2a, k  APC ‐ eBioscience  17‐4321
Rat IgG2a, k  Alexa 647 R35‐95 BD 557690
Rat IgG2b, k  FITC A95‐1 BD 553988
Rat IgG2b, k  PE eB149/10H5 eBioscience  12‐4031
Rat IgG2b, k  APC eB149/10H5 eBioscience  17‐4031
Rat IgG2b, k  Alexa 647 RTK4530 Biolegend  400626
Rat IgG1  FITC eBRG1 eBioscience  11‐4301
Hamster IgG  FITC HTK888 Biolegend  400906
Hamster IgG  PE HTK888 Biolegend  400908
Hamster IgG  PE‐Cy5 SHG‐1 Biolegend  402010
Hamster IgG  biotin HTK888 Biolegend  400904
Goat anti‐Human IgG F(ab)2  PE ‐ Jackson Immuno Res.  109‐116‐098 
Streptavidin  FITC ‐ BD 554060
Streptavidin  PE ‐ BD 554061
Streptavidin  PerCP‐Cy5.5 ‐ Biolegend  405214
Streptavidin  APC ‐ BD 554067
 
5.1.6.6. Isotype controls and secondary reagents for functional assays 
Isotype  Clone Company Catalog no.
Rat IgG2a, k  RTK 2758 Biolegend 400516
Mouse IgG2a, k  MOPC‐173 Biolegend 400224
Hamster IgG  HTK888 Biolegend 400916
Goat IgG  polyclonal R&D AB‐108‐C
Goat anti‐Hamster IgG  polyclonal Jackson Immuno Res 127‐005‐160
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5.1.7. Reagents for magnetic cell sorting 
Product  Company Catalog no. 
anti‐APC Beads 
Miltenyi Biotec 
130‐090‐855 
anti‐DX5 Beads  130‐052‐501 
Streptavidin Beads  130‐048‐101 
Pan‐T‐cell Isolation Kit  130‐090‐861 
Anti‐CD62L beads  130‐049‐701 
LS columns  130‐042‐401 
MS columns  130‐042‐201 
 
5.1.8. Kits 
Product  Company Catalog no.
BCA Protein Assay kit  Pierce 23227
FITC BrdU Flow Kit  BD 557891
GeneChip Mouse Genome 430A 2.0 Array Affymetrix  900499 
Mouse IFN‐g OptEIATM Set BD 555138
OptEIATM Reagent Set B  BD 550534
Foxp3 Staining Buffer Set  eBioscience 00‐5523
RNeasy® Mini Kit  Qiagen 74124
TURBO DNA‐free™  Ambion AM1907
Two‐Cycle Target Labeling and Control Reagents Affymetrix 900494
 
5.1.9. Cell lines 
Name  Description Medium*
RMA  Mouse T cell lymphoma RPMI 1640
RMA‐S  TAP2‐deficient variant of RMA RPMI 1640
RMA‐S.B7‐1  TAP2‐deficient variant of RMA transduced to express B7‐1 IMDM
B16  Mouse melanoma DMEM
B16.B7‐1  Mouse melanoma transduced to express B7‐1 DMEM
B16.Rae1ε  Mouse melanoma transduced to express Rae1ε DMEM
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Name  Description Medium*
B16.Rae1ε.B7‐1  Mouse melanoma transduced to express Rae1ε and B7‐1 DMEM
YAC‐1   Mouse lymphoma RPMI 1640
LL2  Mouse Lewis lung carcinoma DMEM
2.4G2  anti‐CD16/CD32 hybridoma DMEM
X6310‐GMCSF  GM‐CSF producing cell line DMEM
 
* All cell culture media were supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin with the exception of medium for the 2.4G2 hybridoma,  which was supplemented with 
5% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate and 
0.25 mM β-mercaptoethanol. 
 
5.1.10. Mice 
C57BL/6 (WT) mice were purchased from Charles River Laboratories (Sulzfeld, Germany and 
Erembodegem, Belgium). CD28-/- and B7-1-/- mice were purchased from Jackson Laboratory 
(Bar Harbor, Maine, USA). Congenic C57BL/6-Ly5.1+ mice were purchased from Charles River 
Laboratories or bred in our animal facility. CTLA-4 -/- OT-I transgenic mice were kindly provided by 
Prof. M. Brunner-Weinzierl (Experimentelle Pädiatrie, Universitätskinderklinik, Otto-von-Guericke 
Universität, Magdeburg, Germany). B7-H1-/- mice were kindly provided by Prof. L. Chen (Institute for Cell 
Engineering, Johns Hopkins University School of Medicine, Baltimore, USA). RAG2-/- mice were bred in 
our animal facility. Mice were housed under specific pathogen-free conditions and used in experiments at 
8-16 weeks of age. All experiments were performed according to local animal experimental ethics 
committee guidelines and permission. 
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5.2. Methods 
5.2.1. Cell culture methods 
Thawing cells 
Frozen cryovials were submerged in a 37°C water bath until ∼ 10% of the cell suspension remained 
frozen. The cell suspension was immediately diluted into 10 ml of appropriate medium and centrifuged 
(1200 rpm, 5 min, RT). Cells were resuspended in the appropriate medium and cultured at 37°C, 5% CO2. 
Splitting of suspension cells 
Cells in suspension reaching an optimal density were split in desired ratios by adding the appropriate 
volume of the required medium. 
Splitting of adherent cells 
Cell culture medium was removed from the flasks and cells were washed once with PBS. Pre-warmed 
0.05% Trypsin-EDTA or non-enzymatic Cell Dissociation Solution was added in sufficient amounts to 
cover the cell layer. Cells were incubated at 37°C until a complete detachment from the flask was 
observed under the microscope. Cells were then resuspended in pre-warmed medium, collected in 
Falcon™ tubes and centrifuged (1200 rpm, 5 min, RT). Cells were subsequently diluted at appropriate 
ratios and distributed to new flasks. 
Determination of cell numbers 
Appropriate dilution of cell suspension was mixed in a 1:1 ratio with a 0.05 % trypan blue solution (w/v) to 
distinguish dead from live cells. Cells were counted using a Neubauer counting chamber (0.1 mm depth). 
The number of live cells per ml of cell suspension was calculated as: the average cell number per 
chamber square (0.1 mm3) x dilution factor x 104. 
Freezing cells 
For cell freezing, cell suspensions were centrifuged (1200 rpm, 5 min, RT) and the pellet was resuspended 
in freezing medium (90% FCS / 10% DMSO) at a concentration of 2.8 x 106 cells/ml. 1.8 ml (5 x 106 cells 
total) was aliquoted in cryovials and placed in freezing containers. After initial 24 h storage at -80°C, frozen 
vials were transferred to liquid nitrogen for long term storage. 
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5.2.2. Organ dissection and preparation of single cell suspensions 
Blood 
Animals were sacrificed by asphyxiation with CO2 and blood was obtained by heart puncture. Typically, 
0.8-1 ml of the collected blood was mixed with 50 µl of heparin until treated with 25 ml of buffered 
ammonium chloride potassium phosphate solution (ACK-buffer) to obtain red blood cell lysis. Cells were 
further washed with PBS (1600 rpm, 10 min, 4°C) and resuspended in appropriate buffer. 
Spleen 
Animals were sacrificed by dislocation of the neck; the spleen was excised using sterile forceps and kept 
in ice-cold PBS. A single cell suspension was obtained by mincing the spleen through a 70 µm-pore cell 
strainer followed by washing with PBS (1400 rpm, 10 min, 4°C). To lyse erythrocytes, splenocytes were 
treated with buffered ammonium chloride potassium phosphate solution (ACK-buffer), washed with PBS 
(1400 rpm, 10 min, 4°C) and then resuspended in an appropriate buffer. 
Lymph nodes 
Animals were sacrificed by dislocation of the neck; the lymph nodes were excised using sterile forceps and 
kept in ice-cold PBS. A single cell suspension was obtained by mincing the tissue through a 70 µm-pore 
cell strainer followed by washing with PBS (1400 rpm, 10 min, 4°C).  
Lung 
Animals were sacrificed by dislocation of the neck and the the thoracic cavity opened using sterile forceps 
and scissors. The lungs were perfused with PBS by slow application of solution through the right chamber 
of the heart. Perfused lungs were dissected, cut into small pieces (∼ 1-2 mm) and treated 30 min at 37°C 
with 10 ml digestion buffer per lung (1 mg/ml collagenase type I, 0.5 mg/ml DNase I). Single cell 
suspensions were obtained by mincing the digested lung through a 70 µm-pore cell strainer followed by 
washing with PBS (1400 rpm, 10 min, 4°C). Cells were subsequently resuspended in the appropriate 
buffer. 
Tumor 
Tumor bearing animals were sacrificed by dislocation of the neck. Tumor was excised using sterile 
forceps. Tumors were then cut into small pieces (∼ 1 - 2 mm) and treated 30 min at 37 °C with 10 ml 
digestion buffer per tumor (0.5 mg/ml hyaluronidase type V, 0.5 mg/ml DNase I). Single cell suspensions 
were obtained by mincing the digested tumors through a 70 µm-pore cell strainer followed by washing with 
PBS (1500 rpm, 10 min, 4°C). Cells were subsequently resuspended in 7 ml of PBS and filtered through 
40 µm-pore cell strainer. Live cells were obtained by centrifugation (1500 g, 20 min, RT) of cell suspension 
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loaded on Lympholite® M and subsequent collection of the middle cell layer. Cell were intensively washed 
with PBS (1500 rpm, 10 min, 4°C) before resuspension in the appropriate buffer. 
Bone marrow (BM) 
Animals were sacrificed by dislocation of the neck and the hind legs were dissected using sterile forceps 
and scissors. Under the sterile conditions bones were freed from all sinews and muscle tissue. The femur 
and tibiae were separated by breaking the knee and the heel, washed briefly in 80 % ethanol and placed in 
ice-cold DMEM. To rinse out the BM, the ends of the bones were cut and 5-10 ml of ice-cold PBS was 
forced through the bone cavity using 27G needle. The isolated BM was filtered through a 70 µm-pore cell 
strainer followed by washing with DMEM (1400 rpm, 10 min, 4°C). Cells are subsequently treated with 
buffered ammonium chloride potassium phosphate solution (ACK-buffer) to remove red blood cells, 
washed with DMEM (1400 rpm, 10 min, 4°C) and than resuspended in the appropriate buffer. 
 
5.2.3 Cell separation 
5.2.3.1 Magnetic cell sorting (MACS®) 
NK cells 
Single cell suspensions prepared from spleen were washed with MACS® Buffer (PBS 2mM EDTA 
0.5% FCS) and resuspended at 1x108 cells/ml. Splenocytes were first treated with 10% 2.4G2 supernatant 
for 15 min at 4°C to block Fc receptors and further incubated with APC conjugated αCD3 mAb. CD3+ cells 
were then depleted using αAPC Beads according to the manufacturer’s instructions. CD3 depleted 
splenocytes were then positively selected for DX5+ cells using DX5 magnetic beads.  
Naive T cells 
Single cell suspensions prepared from spleen and lymph nodes were pooled, washed with MACS® Buffer 
(PBS 2mM EDTA) and resuspended at 1x108 cells/ml. Cells were treated with 10% 2.4G2 supernatant for 
15 min at 4°C to block Fc receptors. T cells were isolated via negative selection with pan T cell kit 
according to the manufacturer’s instructions. Naïve T cells were then positively selected using CD62L 
magnetic beads. 
 
5.2.3.2 Fluorescence activated cell sorting (FACS™) 
Blood NK cells 
Single cell suspensions prepared from blood were resuspended in PBS at concentration 5x106 cells/ml 
and treated with 10 µg/ml αCD16/CD32 mAb to block Fc receptors. Cells were subsequently stained with 
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fluorochrome labeled αCD3 and αNK1.1 mAb for 30 min at 4°C. After washing (1500 rpm, 10 min, 4°C), 
cells are resuspended in PBS at a concentration 5x107 cells/ml and filtered through a 30 µm cell mesh.     
7-AAD solution was added to the cell suspension 10 min prior to sorting to label dead cells. 
7-AAD-CD3-NK1.1+ single cells were sorted using FACSDiva® or FACSVantage® cell sorter instruments. 
Tumor infiltrating NK cells 
Single cell suspensions prepared from tumors of C57BL/6-Ly5.1 mice were resuspended in PBS at 
concentration 1x107 cells/ml and treated with 10 µg/ml αCD16/CD32 mAb to block Fc receptors. Cells 
were subsequently stained with APC labeled αLy5.1 mAb. Ly5.1+ cells, representing tumor infiltrating 
hematopoietic cells, were positively selected using αAPC Beads according to the manufacturer’s 
instructions. Ly5.1+ cells  were further labeled with flurochrome conjugated αCD3 and αNK1.1 mAb for 
30 min at 4°C. After washing (1500 rpm, 10 min, 4°C), cells are resuspended in PBS at concentration 
5x107 cells/ml and filtered through 30 µm cell mesh. 7-AAD solution is added to cells 10 min prior to 
sorting to label dead cells. 7-AAD-Ly5.1+CD3-NK1.1+ cells were sorted using FACSDiva® or 
FACSVantage® cell sorter instruments. 
 
5.2.4 Primary cell culture 
NK cells 
Single cell suspension was prepared under sterile conditions from spleens of Rag2 -/- mice as described 
before (section 5.2.2). Cell were resuspended in the primary cell medium (25 ml per spleen) and incubated 
in 175 mm2 cell culture flasks for 2h (37°C, 5% CO2) to deplete adherent cells. A non-adherent fraction 
was harvested, washed with primary cell medium (1500 rpm, 10 min, 4°C) and resuspended at 
a concentration of 1x106 cells/ml in primary cell medium containing 1700 U/ml rhIL-2. Suspension was 
distributed over round-bottomed 96-well plate (200 µl/well) and cultured for up to 12 days (37°C, 5% CO2). 
Cell were routinely split 1:2 every second day with primary medium containing 1700 U/ml rh IL-2. 
When NK cells were obtained from WT mice, single cell suspensions prepared from spleens were first 
depleted of CD3+ cells by magnetic cell sorting through two-step procedure – cell labeling with 
CD3-APC mAb followed by αAPC magnetic Beads and subsequent separation. The CD3- fraction was 
then positively selected for DX5+ cells using DX5 magnetic beads according to the manufacturer’s 
instructions. CD3-DX5+ cells were cultured in primary cell medium with 1700 U/ml of rhIL-2 as described 
before. Day 7 cell culture routinely gave rise to ∼99% pure CD3-NK1.1+ NK cells. 
Bone marrow derived dendritic cells (BMDC) 
Single cell suspension was prepared from BM under sterile conditions as described before (section 5.2.2). 
Cells were resuspended in primary DMEM (30 ml per mouse) containing 10% supernatant of GM-CSF 
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producing cell line X6310-GMCSF (DMEM-G). Cell suspension was incubated 24h (37°C, 5% CO2) to 
deplete adherent cells. Non-adherent fraction was harvested, washed (1500 rpm, 10 min, 4°C) and 
resuspended at the concentration of 1x106 cells/ml in DMEM-G. Suspension was distributed over cell 
culture non-treated polystyrene flat-bottomed 6-well plates (2.5 ml/well) and cultured at 37°C, 5% CO2. 
Cells were split when full confluence was observed. Non-enzymatic cell dissociation buffer was used for 
cell detachment. 
 
5.2.5 Cell staining 
Surface staining  
105-106 cells collected from the culture or single cell suspensions generated from organs or blood were 
first washed and than resuspended in 100 µl of FACS™ buffer. Fc receptors were blocked by incubation 
with 10% 2.4G2 supernatant for 15 min at 4°C. Appropriate fluorochrome labeled antibodies were added 
and cells were further incubated for 30 min at 4°C in the dark. When biotinylated antibodies were used 
cells were washed with FACS™ buffer and incubated with fluorochrome conjugated streptavidin for an 
additional 30 min at 4°C. At the end of the staining procedure, all samples were washed with FACS™ 
buffer to remove unbound antibodies. For discrimination of dead cells, 7-AAD was added to the samples 
10 min prior to analysis. FACSCalibur® flow cytometer and CellQuest software were used for sample 
acquisition and data analysis, respectively. 
Intracellular staining 
105-106 cells collected from the culture or single cell suspensions generated from organs or blood were 
stained for surface markers as described above. At the end of the staining procedure, all samples were 
washed with FACS™ buffer and fixed using Fixation/Permeabilization Buffer (eBioscience, San Diego, CA, 
USA) according to manufacturer’s instructions. Cells were further permeabilized with Permeabilization 
Buffer (eBioscience, San Diego, CA, USA) and incubated with 20% 2.4G2 supernatant for 30 min at 4°C in 
100 µl total volume of Permeabilization Buffer. Intracellular targets were then stained with the appropriate 
mAb for 45 min at 4°C. Samples were washed with Permeabilization Buffer to remove unbound antibodies 
and resuspended in FACS™ buffer for analysis. 
Prolonged surface staining of CTLA-4 
A prolonged surface staining procedure was used to determine the surface expression of target proteins 
with a high rate of internalization. 6h before the cell collection from the culture 10% 2.4G2 supernatant was 
added to the culture and cells were incubated for 2h at 37°C. Appropriate mAb or isotype control Ab was 
then added and cells incubated for additional 4h at 37°C. Upon collection, cells were washed with FACS™ 
buffer and surface makers were stained as described before. 
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5.2.6 Functional assays 
51Cr release cytotoxicity assay  
Target cells were labeled with 100μCi 51Cr for 1.5h and washed three times with primary cell medium. 
A total of 1x103 51Cr labeled target cells per well were distributed over the U-bottomed 96-well plate. NK 
cells were added at different effector to target (E:T) ratios to the final volume of 200 μl. The plates were 
centrifuged at 400 rpm for 3 min to obtain an optimal cell contact and then incubated for 4h at 37oC, 
5% CO2. At the end of the incubation, 100 μl of supernatant was collected from each well and the 
radioactivity was counted in a beta counter. The percentage of specific release was calculated as: 
100 x [mean measured release – minimum (spontaneous) mean release] / [maximum (total) mean release – 
minimum (spontaneous) mean release], 
Minimum (spontaneous) release corresponds to the amount of radioactivity released by tumor cells 
cultured in the absence of NK cells. Maximum release relates to the amount of radioactivity released by 
tumor cells cultured in the presence of 10% Triton X-100. 
CD107 degranulation assay 
100 µl NK cell suspension in primary cell medium at the concentration of 1x106 cells/ml were distributed 
over the U-bottomed 96-well plate. Target cells were added at different effector to target (E:T) ratios to the 
final volume of 200 μl. 1 µl of GolgiStop with 1 µg of CD107a and CD107b mAb each or equal amount of 
Rat IgG2a, k isotype control was added to each well. The plates were centrifuged at 400 rpm for 3 min to 
obtain an optimal cell contact and incubated for 3 h at 37°C, 5% CO2. Upon the end of incubation, cells 
were harvested, stained for surface markers and analyzed by flow cytometry. 
NK in vivo kill assay 
Single cell suspensions were obtained from spleens and lymph nodes of WT and tapasin-/- mice. After 
pooling spleen and lymph node fraction WT and tapasin-/- cells were labeled with 1.5 (high) and 0.1 µM 
(low) CFSE, respectively. Shortly, cells were resuspended in PBS at the concentration of 1x107 cells/ml 
and incubated with CSFE for 15 min at RT in dark with constant slow shaking. Labeled cells were washed 
3 times with PBS and resuspended at the concentration of 1x108 cells/ml. WT and tapasin-/- cells were 
then mixed in 1:1 ratio and 200 µl of mix was injected in recipient mice (2x107 cells/mouse, 
1x107 cells/target) through the tail vain. As a control 200 µl of mix were incubated in 10 ml of primary 
medium at 37°C, 5% CO2. Mice were sacrificed after 6h and single cell suspensions were made from 
desired organs. Differentially labeled CFSE+ cells were quantified by flow cytometry and NK cell cytotoxic 
activity in given organ in vivo was calculated as:  
% specific kill = 100-[(100 x ratio treated) / ratio untreated]/ ratio treated 
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ratio treated corresponds to the ratio of CFSEhigh and CFSElow labeled cells obtained from recipient mice. 
ratio untreated corresponds to the ratio of CFSEhigh and CFSElow labeled cells cultured in vitro.  
Plate bound Ab stimulation assay 
Flat-bottomed 96-well plates were coated for 18h at 4°C with 50 µl per well of appropriate mAb (10 µg/ml) 
or IgG fusion protein (2 µg/ml) dilution in PBS. Control wells were incubated with PBS only. At the end of 
incubation, wells were washed 3 times with 300 µl PBS. NK cells were first resuspended in PBS at the 
concentration of 5x106 cells/ml and treated with 10 µg/ml αCD16/CD32 mAb for 30 min at 4°C. Upon 
washing, cells were further resuspended in primary cell medium at the concentration of 1x106 cells/ml, 
seeded over coated wells and incubated for 8-12h at 37°C, 5% CO2. 
BrdU proliferation assay 
Cells were stimulated as indicated. To analyze the frequency of the cells that actively enter cell cycle, 
BrdU was added to the cells 45 min before the end of stimulation at the final concentration of 10 µM. After 
harvesting, cells were stained for surface markers as described before followed by BrdU staining 
according to the manufacturer’s instructions. Cell samples were analyzed by flow cytometry. 
CFSE proliferation assay 
Before stimulation cells were labeled with 1 µM CFSE. Briefly, cells were resuspended in PBS at the 
concentration of 1x107 cells/ml. Appropriate amount of CFSE was added while vortexing the cell solution. 
After 10 min of incubation at 37°C, 5% CO2, cells were washed 3 times with PBS and resuspended in 
primary medium at 1x106 cells/ml. Upon stimulation, the frequency of proliferating cells and number of 
division were analyzed by flow cytometry.  
 
5.2.7. Cytokine production determination 
Quantification of cytokines 
The amount of released cytokine over a given time period was determined by enzyme-linked 
immunosorbent assay (ELISA). At the end of incubation, cell free supernatants were collected and stored 
at -20°C until analysis. Cytokine concentration was measured using sandwich ELISA according to the 
manufacturer’s instruction. 
Quantification of cytokine producing cells 
The frequency of cytokine producing cells was determined by intracellular staining. Prior to the collection 
from culture, cells were incubated 4-6h with Golgi Stop in order to prevent protein secretion. 
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5.2.8. Genetic expression profile analysis 
Experimental setup 
Groups of 20 mice were injected subcutaneously with PBS (naïve controls) or 106 RMA-S cells 
resuspended in 100 µl of PBS. Mice were used at 9 weeks of age. Naïve mice were sacrificed on day 3 
post-injection. Groups of 20 tumor bearing mice were sacrificed on day 3, 10 and 17 post-injection. Single 
cell suspensions were prepared from blood and tumor as indicated in section 5.2.2. Blood and tumor 
infiltrating NK cells were isolated from the pooled blood and tumor samples as described in section 
5.2.3.2. Typically, 5-10x105 NK cells were obtained from blood and 1-2x105 NK cells were obtained from 
tumor samples with a purity of ≥99% and ≥98% for blood and tumor, respectively. Biological triplicates with 
indicated purity of sorted NK cells were collected for every treatment (naïve/tumor bearing), every time 
point (day 3/10/17) and every organ (blood/tumor).   
RNA isolation 
RNA was isolated from NK cells sorted out of tumor or blood using RNeasy® Mini Kit with minor changes 
of the recommended protocol. Typically, cells were lysed in RLT buffer according to manufacturer’s 
instructions and lysates stored at -80°C until continuing isolation. Obtained RNA was treated with DNase 
using TURBO DNA-free® kit in order to remove any possible genomic DNA contamination. 
RNA precipitation 
2 µl of Pellet Paint (Novagen), 0.1 v/v 3M NaAc pH 5.2 and 2 v/v 100% EtOH were added to the isolated 
and DNase treated RNA and incubated for 2 min at RT. RNA was pelleted (16000xg, 5 min, 4°C) and 
washed two additional times with 70% and 100% EtOH, respectively. The pellet was dried to remove any 
remaining EtOH and resuspended in RNA Storage Solution. Quantity and quality of obtained RNA was 
analysed using RNA Pico Assay performed on the Bioanalyzer 2100 Lab-on-a-Chip system. High quality 
RNA samples (RNA integrity number≥9) were chosen for microarray experiment.  
RNA amplification 
Identical starting amounts of RNA (35 pg) were amplified using Two-Cycle Target Labeling and Control 
Reagent kit according to the recommendations of the manufacturer. Two-cycle linear RNA amplification 
was performed. 
Microarray experiment  
Gene expression was detected using mouse genome 430 2.0 array from Affymetrix (Santa Clara, CA, 
USA). Five experimental groups were examined, with triplicates for each group. cDNA and cRNA 
synthesis, and hybridization to arrays were performed according to the recommendations of the 
manufacturer.  
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Microarray data analysis 
Microarray data was analyzed based on ANOVA using a commercial software package JMP Genomics, 
version 4.0 from SAS (SAS Institute, Cary, NC, USA). Briefly, values of perfect-matches were log 
transformed, quantile normalized and fitted with log-linear mixed models, with probe_ID and sample group 
considered to be constant and sample_ID random. Hierarchical clustering of differentially expressed 
genes was performed using a build-in program.  
Microarray pathway analysis 
To identify pathways that are likely to be affected by differential expression, an ORA approach using 
Fisher's exact test as described by Manoli et al. was performed [277]. Analyzed pathways were collected 
from the KEGG database (Kyoto Encyclopedia of Genes and Genomes), or manually generated. 
 
5.2.9 Mouse tumor models 
Subcutaneous tumor cell inoculation 
Tumor cells were harvested in the exponential growth phase after 5 days of culture and washed three 
times with PBS (1200 rpm, 10 min, 4°C). Cells were resuspended in PBS at the concentration of 
1x107 cells/ml (RMA-S, B16, B16.B7-1, LL2) or 1x106 cells/ml (RMA). Mice were injected subcutaneously 
in the left flank with 100 μl of tumor cell suspension. Tumor growth was assessed every second day with 
a caliper measuring along the perpendicular axes of the tumors and expressed as the product of the three 
diameters. If not used for an experiment at a particular time point of tumor growth, mice were killed when 
the tumor surface exceeded 4 cm2 or when became moribund.  
Metastases model 
For metastasis models 100 µl of tumor cell suspension in PBS were injected through tail vein. Mice were 
sacrificed two weeks post-injection. For the analysis of PD-1 and CTLA-4 expression in the lung of injected 
mice total of 105 RMA, RMA-S, RMA-S.B7-1, B16 or B17.B7-1 tumor cells were injected through tail vein. 
For the analysis of the IL-2 treatment effect on metastases formation (data not shown) total of 7.5x105 
B16.B7-1 tumor cells were injected through tail vein.  
Intraperitoneal tumor cell inoculation 
For short term experiments, mice were inoculated with 100 µl of 1x108 cell/ml RMA-S or RMA-S.B7-1 
tumor cell suspension in PBS and sacrificed 24h post-injection. For long term experiments total of 1x105 
tumor cells per mouse in 100 µl PBS was injected. The weight of individual mice was measured every two 
days. Mice were sacrificed 10-15 days upon tumor cell inoculation. 
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5.2.10. mAb application in vivo 
αCTLA-4 and αPD-1 
100 µl of 2.5 mg/ml αCTLA-4 or 3 mg/ml αPD-1 in PBS was injected i.p. in tumor bearing animals every 
three days starting one day before tumor cell inoculation. Control animals were injected with equal volume 
of PBS. 
 
5.2.11. Cytokine application in vivo 
IL-2 
For subcutaneous tumor models 100 µl of 106 U/ml IL-2 was injected i.p. in tumor bearing animals for five 
consecutive days staring from the day of tumor cell inoculation. Control animals were injected with equal 
volume of PBS. In some experiments IL-2 application was combined with αCTLA-4 or/and αPD-1 
treatments. In the case of metastases model 100 µl of 106 U/ml IL-2 was injected i.p. one day before tumor 
cell inoculation. 
IL-18 
100 µl of 20 µg/ml IL-18 was injected i.p., in tumor bearing animals for five consecutive days staring from 
day 8 after tumor cell inoculation. Control animals were injected with equal volume of PBS. 
 
5.2.12. TLR ligand application in vivo 
pI:C 
Polyinoside-polycytidylic acid (pI:C) was applied i.p. resuspended in 100 µl PBS. For short-term 
experiments 200 µg of pI:C per mouse were injected and animals were sacrificed after 18-24h. For 
long-term experiments 50 µg of pI:C per mouse were injected every three days. 
CpG 
Mice were injected peritumoral with 100 µl of water solution of CpG at concentration 200 µg/ml. Typically, 
2-3 spots around palpable tumor were chosen to apply the full volume of the resuspended reagent. 
Injections were repeated every three days. 
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6. Results 
 
6.1. Phenotype of tumor infiltrating NK cells 
6.1.1. Tumor infiltrating NK cells show an immature phenotype 
Four subsets of NK cells can be distinguished in the periphery according to the expression of the 
TNF family receptor CD27 and the integrin αm subunit CD11b [114]. Differential expression of 
the CD11b/CD27 marker combination characterizes maturation and the functional status, with 
CD11bhighCD27low being the most mature and CD11bhighCD27high being the most potent effector subset of 
NK cells. Peripheral organs are differentially populated with given NK cell populations. Solid tumors are 
complex tissues with their own blood and lymphatic system, composed of various cells including 
hematopoietic cells that can both support or hamper tumor progression [278]. We analyzed the expression 
of CD11b and CD27 in blood and tumor tissue of mice injected subcutaneously with tumor cells of different 
origin: B16 melanoma, RMA-S lymphoma and LL2 carcinoma cells (Figure 6.1A). The subset distribution 
in blood was not different between naïve and tumor bearing animals, with the most mature 
CD11bhighCD27low cells comprising the majority of gated CD3-NK1.1+ cells. In contrast, in all tumors 
CD27high NK cells were the dominant subset. To investigate if the distribution is changed during tumor 
progression, we analyzed the subset distribution in subcutaneous B16 melanomas of different tumor size. 
As shown in Figure 6.1B, even at early stages of tumor growth most of the cells in the tumor belonged to 
the CD27high subset. It is, however, still possible that, independently of the maturation state, CD27 is 
upregulated within the tumor tissue, owing to its potent costimulatory role for NK cell activity. Therefore, 
we analyzed the expression of several other markers that correlate with CD27 and characterize the less 
mature state of NK cells (Figure 6.1C). High expression of CD27 in the tumor was positively correlated 
with the expression of c-Kit and CD69 that are shown to be expressed by immature NK cells [109]. KLRG1 
and CD43 that characterize mature NK cells showed reduced expression on tumor infiltrating CD27high NK 
cells. Thus, our data indicate that solid tumors of different origin are preferentially infiltrated by the less 
mature CD27high NK cell subset.  
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Figure 6.1. Tumor infiltrating NK cells show an immature phenotype. Mice were inoculated subcutaneously with  PBS 
only (naive controls) or 106 tumor cells in 100 µl PBS. When tumor size exceeded 1 cm2 (A and C), mice were 
sacrificed and single cell suspensions were prepared from blood and tumor. In B, mice were sacrificed when tumors 
reached the indicated size. Phenotype of blood and tumor infiltrating NK cells, defined as CD3-NK1.1+, was analyzed 
by flow cytometry. % of cells in the depicted quadrants are shown in the dot-plots. 
 
6.1.2. Subset of tumor infiltrating NK cells show IKDC-like phenotype 
Besides CD11b and CD27, which are mainly used to indicate the maturation stage, several other markers 
define NK cells with special functional features. Recently defined IKDCs (Interferon Producing Killer 
Dendritic Cells) were described as a cell population with the properties of both NK and DCs [139]. Due to 
their high potency of IFNγ production and cytotoxicity, as well as antigen presentation potential and 
release of IL-12, IKDCs have been shown to be very efficient anti-tumor effectors. Their main phenotypic 
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characteristics are expression of NK1.1, high levels of CD11c and B220, as well as MHC class II. 
To further characterize NK cells found within the tumor tissue, we analyzed the expression of IKDC 
markers on NK cells in blood and tumor of tumor bearing hosts.  
In RMA-S injected mice, all NK cells, defined as CD3-NK1.1+, from both blood and tumor expressed 
CD11c and B220. Of note, expression of B220 was increased on subset on NK cells in tumor 
(Figure 6.2A). We did not observe MHC II+ NK cells in blood. In contrast, tumor infiltrating NK cells 
increased MHC II expression with tumor progression. A similar phenotype has been observed in both B16 
and LL2 tumor bearing mice (Figure 6.2B). These data indicate that subset of NK cells found in the tumor 
phenotypically resemble IKDCs. Functional analysis must be performed to confirm their potential ability to 
produce high amounts of IFNγ and/or IL-12. Importantly, NK cells within tumor tissue express MHC II, 
unlike their counterparts from blood, which indicates that they indeed might be able to present tumor 
antigens and activate adaptive immune responses. 
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Figure 6.2. Tumor-infiltrating NK cells show IKDC-like phenotype. Mice were inoculated with 106 tumor cells in 100 µl 
PBS. When tumor size exceeded 1 cm2, mice were sacrificed and single cell suspensions were prepared from blood 
and tumor. Phenotype of blood and tumor infiltrating NK  cells, defined as CD3-NK1.1+, was analyzed by flow 
cytometry. Representative stainings and quantification of CD11c, B220 and MHC II expression on NK cells from blood 
and tumor of RMA-S lymphoma (A), B16 melanoma and LL2 carcinoma (B) tumor bearing mice are shown. Graphs 
indicate mean±SD of experimental group of 3 treated animals from one out of two experiments performed. *, p<0.05 
by t-test 
 
6.1.3. Tumor infiltrating NK cells express elevated amounts of granzyme B 
Many transplanted tumors were shown to be controlled by NK cells in a perforin dependent manner 
indicating that direct cytotoxicity plays the central role in the NK cell anti-tumor response [81-82, 102]. 
However, when tumors efficiently evade immune surveillance mechanisms and progressive growth is 
established, NK cell functions might be altered. We compared NK cell cytotoxic response of blood and 
spleen NK cells derived from naïve or RMA-S tumor bearing animals. Ex vivo response was correlated to 
the level of NK cell degranulation, measured by CD107a/b expression, after the encounter with target cells 
in vitro. In vivo response was correlated to the clearance of tapasin deficient splenocytes that express 
reduced levels of MHC I, from the spleen of naïve and tumor bearing mice. Both ex vivo and in vivo NK 
Ana Stojanovic    Results 
‐ 76 ‐ 
 
cells efficiently responded to target cells (Figure 6.3). Of importance, ex vivo response was measured 
against NKG2D sensitive target cells, YAC-1, while in vivo killing was directed against MHC Ilow 
splenocytes. These data indicate that no systemic impairment of NK cell cytotoxic response involving 
different recognition pathways can be detected in tumor bearing animals.  
 
Figure 6.3. NK cells from tumor bearing animals exert normal cytotoxic responses. (A) Whole splenocytes from naïve 
or RMA-S inoculated animals (solid tumor, day 10 post-injection) were co-cultured with YAC-1 target cells in a 1:1 ratio 
in the presence of fluorochrome labeled CD107a/b mAbs or isotype control. Degranulation of NK  cells in response to 
target was analysed by flow cytometry and expressed as % of CD107a/b+ cells among gated CD3-NK1.1+7-AAD- cells. 
Graphs indicate mean±SD of triplicate culture from one out of two experiments performed. n.s., not significant by 
t-test. (B) WT or tapasin deficient splenocytes, labelled with different concentration of CFSE, were injected in naïve or 
RMA-S inoculated animals (solid tumor, day 17 post-injection) in a 1:1 ratio. After 6h, mice were sacrificed and % of 
differentially labelled CFSE+ cells from spleen was measured by flow cytometry. NK cell cytotoxic response in vivo 
was expressed as % of specific lysis of tapasin deficient (MHC class Ilow) compared to WT splenocytes. Graphs 
indicate mean±SD of experimental group of 3 treated animals from one out of two experiments performed.  
We could not compare cytotoxicity of tumor infiltrating NK cells with those derived from blood or spleen 
due to the low cell numbers that were obtained from the tumor tissue. We, however, observed that NK 
cells from the tumor expressed perforin and granzyme B (Figure 6.4). Perforin levels were slightly elevated 
in TINs compared to spleen NK cells, although the differences were not always significant. In addition, 
tumor infiltrating NK cells were positive for granzyme B, which was not detected in spleen NK cells. 
Presence of perforin and granzyme B indicates that NK cells in the tumor are armed to perform cytotoxic 
responses. 
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Figure 6.4. NK cells from tumor express perforin and granzyme B. Mice were inoculated with 106 RMA-S tumor cells in 
100 µl PBS. 10 days post-injection, mice were sacrificed and single cell suspensions were prepared from spleen and 
tumor. Expression of perforin and granzyme B of spleen and tumor infiltrating NK  cells, defined as CD3-NK1.1+, was 
analyzed by flow cytometry.  
 
6.2. Gene expression profile of tumor infiltrating NK cells 
Our previous data showed that tumor infiltrating NK cells might have special properties and exert functions 
different from NK cells found in the peripheral blood. Those properties could be the consequence of the 
natural response to the tumor targets and/or the microenvironment formed by the solid tumor. For the 
analysis of NK cells in tumor bearing animals we mainly used subcutaneous RMA-S lymphoma model. 
Owing to the low expression of MHC I by RMA-S tumor cells, when injected at low cell numbers, tumor 
formation is prevented in a NK cell dependent manner. When the initial tumor cell load is sufficient to drive 
tumor progression, we observed that tumor growth followed defined kinetics. Three phases of tumor 
growth can be recognized (Figure 6.5A). The first phase is represented by the slow kinetics of tumor 
progression and is followed by the intermediate phase in which tumor size does not change significantly 
for several days. While in the first phase innate immunity might play a dominant role in the anti-tumor 
response, in the second phase tumor growth might be efficiently controlled by combined actions of both 
the innate and the adaptive arm of the immune system. However, despite the fact that an initial control was 
established, all animals progress to the third phase characterized by tumor outgrowth that leads to death. 
When NK cells are removed from the system by application of αNK1.1 mAb, that depletes NK and NKT 
cells, the initial tumor control is lost and animals progress through the third phase-like tumor outgrowth 
(Figure 6.5B).  
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Figure 6.5. RMA-S tumor growth is controlled by NK cells. (A) Mice were injected with 106 RMA-S tumor cells 
subcutaneously and tumor growth was measured in regular time intervals. (B) Group of RMA-S inoculated mice was 
treated with αNK1.1 mAb on day -2, +2, +9 and +16 relative to the tumor cell inoculation, leading to efficient depletion 
of NK1.1+ cells, which was sustained during experiment (data not shown). Every line represents tumor growth kinetics 
of an individual mouse.  
We aimed to better understand the role of NK cells in tumor growth control during different phases of 
tumor progression. Therefore we performed global gene expression profile analysis of blood and tumor 
infiltrating NK cells from RMA-S tumor bearing animals at different time points of tumor progression. First, 
the experimental design (Figure 6.6) allowed us to compare blood NK cells from naïve and tumor bearing 
animals in order to characterize possible systemic changes that could occur due to the tumor outgrowth. 
If such changes were detectable from the early time points, they could be used as potential clinical 
biomarkers of tumor presence. Second, a comparison can be made between blood and tumor infiltrating 
NK cells in tumor bearing animals, allowing the analysis of potential special features of NK cells from the 
tumor tissue. Finally, the comparison between blood and tumor NK cell pools over time indicates how the 
NK cell effector functions and their potential to control the growth of MHC I deficient tumor changes while 
tumor progresses through the described phases (Figure 6.5). As shown in Figure 6.6A, we isolated NK 
cells from blood of naïve (day 0) and tumor bearing animals on day 3, 10 and 17 after tumor cell 
inoculation. NK cells from the tumor were obtained on day 10 and day 17 after tumor cell injection. Cells 
were sorted for high purity (≥99% from blood and ≥98% from tumor). RNA isolated from sorted NK cells 
was subjected to the quality test. High quality RNA was amplified, labelled and hybridized with mouse 
whole genome microarrays.  Every experimental group and time point was represented as biological 
triplicate in microarray experiment. 
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Figure 6.6. Experimental design of gene expression analysis of blood and tumor infiltrating NK cells. (A) Groups of 30 
mice were injected subcutaneosly with PBS (naïve controls) or 106 RMA-S lymphoma cells (day 0). NK cells were 
isolated from blood and tumor tissue at indicated time points after tumor cell inoculation. Biological triplicates were 
provided for every treatment, every organ and every time point of tumor growth. (B) Highly purified NK cells were 
obtained by flow cytometry sorting from blood and tumor of naive and tumor bearing mice. One representative 
analysis of purity of sorted NK cells is shown (left). Blood NK cells samples with purity ≥99% and tumor NK cell 
samples with purity ≥98% were selected for RNA isolation. Total RNA isolated from sorted cells was analysed for 
quality using RNA 6000 Pico Assay performed on the Bioanalyzer 2100 Lab-on-a-Chip system (right). Similar starting 
amounts of high quality RNA were subsequently amplified, labelled and hybridized with Affymetrix® mouse whole 
genome microarrays. (C) Comparisons of gene expression profiles were performed between different treatments 
(naïve vs tumor bearing), different organs (blood vs tumor) or between same organ at different time point of tumor 
growth.   
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6.2.1. Tumor infiltrating NK cells show strikingly different transcription profile compared to blood 
NK cells 
Nine different comparisons were performed over the transcription profiles of naïve blood, tumor bearing 
animal blood and tumor infiltrating NK cells isolated at different time points after tumor cell inoculation 
(Figure 6.7A). In total, 1387 transcripts were found to be differentially regulated between the various 
groups that have been compared. The heat map from Figure 6.7B shows clustering of top 50 genes 
differentially expressed in at least one of the comparisons, selected according to p-value. A similar pattern 
was observed when all changed genes were clustered together. The clustering pattern indicates that 
tumor infiltrating NK cells have strikingly different transcription profile when compared with NK cells 
isolated from blood of both naïve and tumor bearing animals. Less pronounced changes, reflected in the 
lower number of differentially regulated genes, were detected when the expression profile of NK cells from 
the blood of naïve mice was compared with the profile of blood NK cells of tumor bearing animals. Similar 
observation was made when expression profiles of different time points of tumor growth were compared 
for both blood and tumor infiltrating NK cells. 
 
Figure 6.7. Tumor infiltrating NK cells show strikingly different transcription profile compared to blood NK cells. 
(A) Expression profiles were obtained in triplicates for every sample shown and compared according to the given 
scheme. Blue arrows indicate the comparisons of NK cells from the same organ, thereby measuring temporal 
changes, while red arrows show the comparisons of NK cell profiles derived from different organs at the same time 
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point of tumor growth. (B) Unsupervised hierarchical clustering algorithm for genes that showed significant change in 
the expression level in at least one comparison performed, was applied accross all samples. The length and branching 
pattern in the resulting dendogram reflects the similarity/difference in gene expression profiles between each of the NK 
cell samples. Top 50 differentially expressed genes, sorted according to p-value, are shown.  
Functional classification revealed that differentially expressed genes between blood and TINs of tumor 
bearing mice were involved in the control of the function that might be highly relevant for anti-tumor 
responses (Table 6.1). Among the most significantly affected pathways are the BCR and TCR signaling 
pathway that utilize basically the same signaling components found downstream of NK receptors, such as 
Lck, Itk, Vav, PI3K, PLCγ, Cbl, MAP3Ks and NF-kB, all of which showed changed transcript levels in 
tumor infiltrating NK cells. This finding indicates that functionality of NK receptors might be differentially 
regulated within the tumor compared to blood. Effector functions triggered upon target recognition and NK 
receptor signaling include cytotoxicity and cytokine and chemokine production, all of which rely on vesicle 
trafficking and release of their components into extracellular space. Indeed, several genes regulating 
vesicle transport are positively regulated in TINs (pathway: SNARE interactions in vesicular transport), 
as well as some of the genes encoding cytotoxic vesicle components, such as cathepsins and several 
types of granzymes.  
 
Pathway  Hits  Total  Hit percent  Significance 
TCR signaling pathway  25  75  33.3333  0.00000  *** 
Cell cycle  23  84  27.3810  0.00000  *** 
NK cell mediated cytotoxicity  18  65  27.6923  0.00002  *** 
Chronic myeloid leukemia  16  57  28.0702  0.00004  *** 
Cytokine‐cytokine receptor interaction  29  155  18.7097  0.00020  *** 
MAPK signaling pathway  35  203  17.2414  0.00024  *** 
Streptomycin biosynthesis  5  8  62.5000  0.00030  *** 
Jak/STAT signaling pathway  20  95  21.0526  0.00039  *** 
BCR signaling pathway  12  45  26.6667  0.00062  *** 
Glycolysis and gluconeogenesis  10  35  28.5714  0.00122  ** 
Apoptosis  14  62  22.5806  0.00137  ** 
VEGF signaling pathway  13  57  22.8070  0.00182  ** 
Inositol phosphate metabolism  10  42  23.8095  0.00530  ** 
Hematopoietic cell lineage  13  64  20.3125  0.00533  ** 
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Pentose phosphate pathway  6  19  31.5789  0.00690  ** 
Carbon fixation  5  15  33.3333  0.00933  ** 
Adipocytokine signaling pathway  12  61  19.6721  0.00944  ** 
FcεRI signaling pathway  12  61  19.6721  0.00944  ** 
Pancreatic cancer  12  61  19.6721  0.00944  ** 
Glyoxylate and dicarboxylate metabolism  4  10  40.0000  0.00986  ** 
Thyroid cancer  6  21  28.5714  0.01017  * 
Purine metabolism  18  108  16.6667  0.01037  * 
Colorectal cancer  12  66  18.1818  0.01739  * 
Glycan structures biosynthesis  7  30  23.3333  0.01780  * 
Galactose metabolism  6  24  25.0000  0.01985  * 
Ethylbenzene degradation  3  7  42.8571  0.02104  * 
Phenylalanine tyrosine and tryptophan  3  7  42.8571  0.02278  * 
SNARE interactions in vesicular transport  6  25  24.0000  0.02412  * 
Fructose and mannose metabolism  7  32  21.8750  0.02503  * 
TLR signaling pathway  11  62  17.7419  0.02628  * 
ABC transporters  7  34  20.5882  0.03404  * 
Leukocyte transendothelial migration  13  82  15.8537  0.03855  * 
 
Table 6.1. Signaling pathways affected by differential gene expression in tumor infiltrating NK cells. To identify 
pathways that are likely to be affected by differential gene expression between blood and tumor infiltrating NK cells, 
an ORA approach using Fisher's exact test was performed [277]. Analyzed pathways were collected from the KEGG 
database (Kyoto Encyclopedia of Genes and Genomes), or manually generated. Number (Hits) and percentage 
(Hit percent) of differentially expressed signaling molecules of total molecules (Total) comprising the given pathways 
are shown.  
Apart from the direct cytotoxicity, NK cells can exert anti-tumor functions through the production of 
cytokines and chemokines, which can act directly on tumor cells or can modulate the responses of other 
immune effectors. Transcripts of several chemokines were found to be elevated in TINs, such as CCL1, 
CXCL2 and CXCL9, as well as chemokine receptors CCR2, CCR7 and CXCR4, while CX3CR1 
expression was reduced. Through the chemokine network established at the tumor site NK cells can 
attract other immune cells such as neutrophils, macrophages, DCs or T cells. In addition, those cells, 
including NK cells themselves, can further potentiate NK cell recruitment. Indeed, some of the given 
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chemokine-chemokine receptor interactions (CXCR3:CXCL9/10, CX3CR1:CX3CL1) have been previously 
shown to facilitate NK cell trafficking to the tumor [279-280].  
Gene name  Gene symbol 
day 10  day 17 
p‐value  Fold change  p‐value  Fold change 
chemokine (C‐C motif) ligand 1  Ccl1  17.55  2.65  14.88  2.40 
chemokine (C‐X‐C motif) ligand 2  Cxcl2  11.71  6.44  11.11  6.07 
chemokine (C‐X‐C motif) ligand 9  Cxcl9  9.56  3.04  5.51  2.25 
chemokine (C‐C motif) receptor 2  Ccr2  13.91  1.87  15.75  1.97 
chemokine (C‐C motif) receptor 7  Ccr7  9.66  3.24  7.25  2.68 
chemokine (C‐X‐C motif) receptor 4  Cxcr4  12.24  3.47  8.82  2.77 
chemokine (C‐X3‐C) receptor 1  Cx3cr1  39.34  ‐2.60  40.89  ‐2.66 
 
Table 6.2. Differential expression of chemokines and chemokine receptor by NK cells infiltrating the tumor tissue. 
Chemokine and chemokine receptors found to be differentially regulated on transcript level between blood and tumor 
infiltrating NK cells of tumor bearing animals are depicted. Fold change indicates the difference of tumor versus blood 
signal and is considered significant when p-value is ≥ 7. 
Genes whose products are known to influence cell adhesion and motility, functions important for migration 
across the endothelium and tissue infiltration, were differentially regulated by TINs. For example, integrin 
α2 (DX5) and α6, CD9, cadherin 22, CD151, MCAM are some of the molecules that mediate binding to 
endothelium and different components of extracellular matrix (ECM), thereby might promote NK cell 
migration through the tumor tissue. However, they were found to be negatively regulated by NK cells 
isolated from the tumor (Figure 6.8A). On the other hand, enzymes that modulate ECM by cleaving its 
components (Adam8, Adam9, Plaur) showed elevated transcript levels. These modulations can have 
multiple consequences including the release of active cytokines and chemokines bound to the cell surface 
or matrix components, but also support of tumor cell invasion and metastasis formation. We confirmed 
reduced expression of DX5 by tumor infiltrating NK cells at the protein level (Figure 6.8B). 
A. 
Gene name 
Gene 
symbol 
day 10  day 17 
p‐value  Fold change  p‐value  Fold change 
integrin alpha 2  Itga2  2.50  ‐1.24  8.79  ‐1.59 
integrin alpha 6  Itga6  5.91  ‐1.97  9.19  ‐2.43 
CD9 antigen  Cd9  8.94  ‐2.04  11.42  ‐2.38 
CD151 antigen  Cd151  2.22  ‐1.26  6.76  ‐1.55 
cadherin 22  Cdh22  6.66  ‐1.82  7.75  ‐1.93 
melanoma cell adhesion molecule  Mcam  15.55  ‐1.80  17.83  ‐1.90 
a disintegrin and metalloprotease domain 8  Adam8  33.29  3.25  42.72  4.23 
a disintegrin and metalloproteinase domain 9  Adam9  11.59  1.63  5.28  1.35 
urokinase plasminogen activator receptor  Plaur  7.17  1.72  4.73  1.53 
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Figure 6.8. Differential regulation of several adhesion molecules and ECM 
modifying enzymes was detected in tumor infiltrating NK cells. (A) Adhesion 
molecules and enzymes specific for extracellular matrix (ECM) components found 
to be differentially regulated on the transcript level between blood and tumor 
infiltrating NK cells of tumor bearing mice are depicted. Fold change indicates the 
difference of tumor versus blood signal and is considered significant when p-value 
is ≥ 7. (B) Mice were inoculated subcutaneously with 106 RMA-S cells in 100 µl 
PBS. When tumor size exceeded 1 cm2, mice were sacrificed and single cell 
suspensions were prepared from blood and tumor. Expression of integrin α2 
(DX5) on blood and tumor infiltrating NK cells, defined as CD3-NK1.1+7AAD-, was 
analyzed by flow cytometry. Graph indicates mean±SD of the experimental group 
of three animals from one out of two experiments performed. *, p<0.05 by t-test 
NK cells infiltrating the tumor showed increased transcript levels of cytokines, cytokine receptors and 
signaling molecules downstream of cytokine receptors (Table 6.1, Cytokine-cytokine receptor interaction 
and Jak/STAT signaling pathway). Lymphotoxin α and β, GM-CSF, TGFβ1, PDGFα and VEGFA 
transcripts were elevated in TINs when compared to blood NK cells (Figure 6.9A). Lymphotoxins and 
GM-CSF might support DC recruitment and activation [281-283], TGFβ can both suppress and promote 
tumor growth [284], while PDGFα and VEGFA promote angiogenesis [285]. Of note, NK cells showed 
elevated expression of many other molecules that facilitate angiogenesis (angiopoietin, arginase), 
indicating that they might play an active role in this process at the tumor site (Table 6.1, VEGF signaling 
pathway). IL-1R2, IL-2Rα, IL-4Rα, IL-7Rα, IL-15Rα, IFNγR1 and TGFβR2 are examples of increased 
regulation of cytokine receptors by TINs (Figure 6.9A). IL-7, IL-2 and IL-15 are shown to promote NK cell 
maturation, survival and activation [286]. Elevated expression of TGFβ receptor might render NK cell 
sesitive to TGFβ, which is known to suppress their ability to produce IFNγ [287]. As shown in Figure 6.9B, 
surface expression of IL-2Rα and IL-7Rα was increased on tumor infiltrating NK cells when compared to 
blood, indicating a positive correlation between transcript and protein level regulation. Protein levels of  
IL-4Rα and IFNγR1 were, however, unchanged.  
Multiple genes regulating the cell cycle were upregulated by NK cells found in tumor tissue. Most of them 
(cyclin E, A, B, cyclin-dependent kinases 2, 25B and others) indicate that NK cells actively progress 
through the cell division. However, at the same time, elevated expression of GADD45B (growth arrest and 
DNA-damage-inducible 45 beta) suggests that cell division might be arrested due to the cellular stress 
[288]. Indeed, the tumor tissue is characterized by unfavorable conditions such as low oxygen levels, 
acidosis and high intestinal fluid pressure. Changes involving metabolic pathways support the adaptation 
to such biochemical environment [289-290]. For example, under hypoxia, cells cannot efficiently utilize 
oxidative phosphorylation and switch their energy production preferentially towards glycolysis. In tumor 
infiltrating NK cells, we have observed high upregulation of the transcription factor HIF1α, the main 
regulator of gene expression under low oxygen concentrations. In addition, enzymes that facilitate glucose 
uptake, phosphorylation and finally mediate its breakdown, which are also under the control of HIF1α, are 
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found to be positively regulated by NK cells in the tumor. Finally, pro-angiogenic function of NK cells can 
be also a consequence of hypoxia and HIF1α activation. 
A. 
Gene name 
Gene 
symbol 
day 10  day 17 
p‐value  Fold change  p‐value  Fold change 
interleukin 2 receptor, alpha chain  Il2ra  30.35  2.73  30.46  2.74 
interleukin 7 receptor  Il7r  7.98  2.42  7.28  2.31 
interleukin 1 receptor, type II  Il1r2  10.84  2.03  13.28  2.23 
interleukin 4 receptor, alpha  Il4ra  13.67  1.37  20.24  1.49 
interleukin 15 receptor, alpha chain  Il15ra  13.19  1.21  9.02  1.16 
interferon gamma receptor 1  Ifngr1  10.09  1.81  6.37  1.57 
transforming growth factor, beta 1  Tgfb1  7.70  1.33  4.05  1.21 
transforming growth factor, beta receptor II  Tgfbr2  15.19  1.34  5.39  1.17 
vascular endothelial growth factor A  Vegfa  30.22  2.48  14.91  1.81 
platelet derived growth factor, alpha  Pdgfa  10.37  1.63  12.99  1.75 
granulocyte‐macrophage colony stimulating factor 2  Csf2  9.14  2.82  11.20  3.23 
 
B. 
 
Figure 6.9. Multiple cytokines and cytokine receptors are differentially regulated between blood and tumor infiltrating 
NK cells. (A) Cytokines and cytokine receptors found to be differentially regulated on the transcript level between 
blood and tumor infiltrating NK cells of tumor bearing mice are depicted. Fold change indicates the difference of tumor 
versus blood signal and is considered significant when p-value is ≥ 7. (B) Mice were inoculated subcutaneously with 
106 RMA-S cells in 100 µl PBS. When tumor size exceeded 1 cm2, mice were sacrificed and single cell suspensions 
were prepared from blood and tumor. Expression of depicted cytokine receptors on blood and tumor infiltrating NK 
cells, defined as CD3-NK1.1+, was analyzed by flow cytometry. Graphs indicate mean±SD of experimental group of 
three animals. *, p<0.05; **, p<0.01 by t-test 
In summary, our data reveal that tumor infiltrating NK cells showed strikingly different transcription profile 
compared to blood NK cells of tumor bearing animals. Differentially expressed genes are involved in 
multiple functions relevant for anti-tumor responses including target recognition and triggering through 
Ana Stojanovic    Results 
‐ 86 ‐ 
 
activating NK receptors, vesicle trafficking and cytotoxicity, production and response to cytokines and 
chemokines, migration, angiogenesis and regulation of proliferation, survival and metabolic functions in 
response to hypoxia. We evaluated protein levels of selected differentially regulated genes and confirmed 
that changes on transcript levels in most of the cases correlated with protein expression. Detailed analysis 
of detected changes will provide a better understanding of NK cell effector response within the complex 
microenvironment of solid tumors and might allow for proper manipulation to achieve better immune 
control of tumor development and progression. 
 
6.2.2. Tumor infiltrating NK cells downregulate expression of activating NK cell receptors 
Around 570 genes were found to be negatively regulated on the transcript level when blood and tumor 
infiltrating NK cells are compared on both day 10 and day 17 of tumor growth. Among those genes, 
several NK cell activating receptors were detected (Table 6.2).  
Gene name  Gene symbol 
day 10  day 17 
p‐value  Fold change  p‐value  Fold change 
natural cytotoxicity triggering receptor 1  Ncr1/NKp46  6.03  ‐1.61  7.85  ‐1.75 
killer cell lectin‐like receptor subfamily B 
member 1C 
Klrb1c/NKR‐
P1C/NK1.1 
9.24  ‐1.55  7.18  ‐1.46 
CD244 natural killer cell receptor 2B4  CD244/2B4  7.27  ‐1.49  4.03  ‐1.33 
CD48 antigen  CD48  12.61  ‐1.47  16.41  ‐1.57 
killer cell lectin‐like receptor, subfamily A, 
member 1 
Klra1/Ly49A  8.79  ‐1.23  3.07  ‐1.12 
killer cell lectin‐like receptor family E member 1  Klre1/NKG2I  12.15  ‐1.39  12.7  ‐1.4 
 
Table 6.2. Transcriptional regulation of activating receptors by tumor infiltrating NK cells. NK cell receptors found to be 
differentially regulated on the transcript level between blood and tumor infiltrating NK cells of tumor bearing mice are 
depicted. Fold change indicates the difference of tumor versus blood signal and is considered significant when 
p-value is ≥ 7. 
NKp46 belongs to the group of natural cytotoxicity receptors (NCRs). It was shown to recognize viral 
hemaglutinins as well as unknown ligand(s) on several tumor cell lines including RMA-S [291]. In addition, 
killing of different tumor cell lines can be partially or completely abrogated by blocking of NCRs [292-293]. 
NKp46 deficiency in mice was shown to hamper the control of lymphoma, however, the effect was 
dependent on the mouse strain and tumor cell line used [294]. NK1.1 belongs to the NKR-P1 family of 
receptors shown to recognize the Clr (Clec2, Ocil) family of ligands, both of which are C-type lectin-like 
molecules encoded within the same locus in the mouse genome [295-296]. Both stimulating and inhibitory 
isoforms of NKR-P1 receptors have been characterized and several ligands have been identified, which 
are either widely expressed or restricted to the certain cell types as macrophages, DCs or osteoclasts. 
The ligand for NKR-P1C, activating receptor recognized by PK136 (αNK1.1) mAb in BL6 mouse strain, 
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is still unknown. Both NKp46 and NKR-P1C (NK1.1) are coupled to the adaptor molecules CD3ζ and 
FcεRIγ, indicating that they could engage a similar signaling pathway leading to the similar outcome in 
response to different ligands. 2B4 is a receptor expressed on all NK cells, γδ T and CD8+ memory T cells. 
It can mediate both activation and inhibition and mode of its action depends on the level of surface 
expression, degree of ligand engagement and nature of adaptor molecules it associates with [297]. 
Its ligand, CD48, is expressed on all hematopoiteic cells and it was proposed to deliver a signal upon 
binding to 2B4, probably through recruited adaptor proteins. A bidirectional 2B4-CD48 interaction has 
been shown to be important for the proliferation and generation of NK cell effector functions through the 
homotypic NK-NK interaction [298] as well as for NK cell mediated stimulation of T cell responses [299]. 
Microarray data analysis revealed that NKp46, NKR-P1C (NK1.1), 2B4 and CD48 transcript levels were 
reduced in TINs when compared to blood in tumor bearing animals (Table 6.2). We analyzed the surface 
expression of NKp46, 2B4 and CD48 receptors in TINs and confirmed that the negative regulation at 
mRNA levels correlated with decreased protein levels detected on the cell surface (Figure 6.10). In all 
performed experiments, NK cells were defined as CD3-NK1.1+ cells. We have observed a slight 
downregulation of NK1.1 expression on gated NK cells within the tumor, which was not always significant. 
In parallel, we confirmed that the surface expression of the activating NK cell receptor NKG2D, which was 
not regulated at the mRNA level, was unchanged in the tumor compared to blood.  
 
Figure 6.10. Tumor infiltrating NK cells downregulate expression of activating receptors NKp46, 2B4 and CD48. Mice 
were inoculated subcutaneously with 106 RMA-S cells in 100 µl PBS. When tumor size exceeded 1 cm2, mice were 
sacrificed and single cell suspensions were prepared from blood and tumor. Expression of depicted receptors on 
blood and tumor infiltrating NK cells, defined as CD3-NK1.1+, was analyzed by flow cytometry. Graphs indicate 
mean±SD of experimental group of three animals and are representative of one out of two experiments performed. 
n.s., not significant; *, p<0.05 by t-test 
Beside the depicted activating receptors, expression of the inhibitory receptor Ly49A was also negatively 
regulated at the transcript level in TINs compared to blood in tumor bearing animals (Table 6.2). Our 
attempts to compare expression of Ly49 receptors on blood and tumor infiltrating NK cells were 
unsuccessful due to their differential sensitivity to digestion enzymes that must be used for tumor tissue 
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dissociation. While Ly49G2 and Ly49C/I/F/H were completely sheded from the blood derived NK cells by 
collagenase or hyaluronidase treatment, their expression could still be detected on TINs at the levels 
comparable to the untreated blood (Figure 6.11). The inhibitory receptor Ly49A, which was negatively 
regulated at the transcript level, showed high surface expression on TINs, elevated compared to blood NK 
cells treated in an identical way as tumor tissue (Figure 6.11). However, it is not possible to say if tumor 
infiltrating NK cells increased the expression of Ly49A due to the fact that the receptor on blood NK cells 
was partially affected by the treatment. Since most of Ly49 receptors bind MHC I molecules and mediate 
NK cell inhibition, we compared the levels of their expression in RMA-S, MHC I deficient, and RMA, MHC I 
sufficient, tumors. NK cells found within RMA tumors showed a similar pattern of Ly49 receptor expression 
(data not shown) indicating that their regulation is not influenced by MHC I expression levels on tumor 
cells.  
 
Figure 6.11. Differential regulation of Ly49 receptors by tumor infiltrating NK cells. Mice were inoculated 
subcutaneously with 106 RMA-S cells in 100 µl PBS. When tumor size exceeded 1 cm2, mice were sacrificed and 
single cell suspensions were prepared from blood and tumor. Tumor tissue was digested with hyaluronidase as 
indicated in Materials and Methods section. Blood cells were treated with hyaluronidase or left untreated. Expression 
of depicted Ly49 receptors was analyzed by flow cytometry. Representative stainings show the expression of depicted 
Ly49 receptors on gated CD3-NK1.1+ cells. 
In summary, our data showed that within tumor tissue NK cells negatively regulated expression of 
activating receptors NKp46, 2B4 and CD48 at both mRNA and protein level. Although NK1.1 was 
negatively regulated at the mRNA level, the surface protein was not found decreased in every experiment 
performed. However, this tendency was always observed. Expression of Ly49 receptors was rather 
regulated at the post-transcription and/or post-translation level in the manner that does not depend on the 
MHC I expression by tumor cells. Our data indicated that the surface expression of inhibitory Ly49 
receptors might be stabilized within tumor tissue by unknown mechanisms. 
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6.2.3. Tumor infiltrating NK cells upregulate expression of B7 family members 
Out of 1387 differentially expressed genes between NK cells from blood and tumor of tumor bearing mice, 
around 820 belong to the group of positively regulated transcripts. The subgroup of significantly 
upregulated genes was identified to belong to the B7 family of costimulatory molecules (Figure 6.12).  
Gene name 
Gene symbol/ 
Other name 
day 10  day 17 
p‐value  Fold change  p‐value  Fold change 
cytotoxic T‐lymphocyte‐associated protein 4  Ctla4  33.79  6.84  45.3  11.57 
programmed cell death 1 ligand 2 
Pdcd1lg2/PD‐
L2/B7‐DC 
45.29  2.99  40.74  2.72 
inducible T‐cell co‐stimulator  Icos  56.33  2.8  43.82  2.41 
programmed cell death 1 ligand 1 
Pdcd1lg1/PD‐
L1/B7‐H1 
33.81  2.5  26.55  2.15 
programmed cell death 1  Pdcd1/PD‐1  30.38  1.87  40.48  2.19 
CD86 antigen  Cd86/B7‐1  7.66  1.63  3.22  1.34 
icos ligand  Icosl/ICOS‐L  4.84  1.23  7.67  1.31 
 
 
Figure 6.12. Positive regulation of B7 family members by tumor infiltrating NK cells. B7 family members found to be 
differentially regulated at the transcript level between blood and tumor infiltrating NK cells in tumor bearing mice are 
depicted in the table. Fold change indicates the difference of tumor versus blood signal and is considered significant 
when p-value is ≥ 7. Lower panel indicates the so far known interactions established between the members found in 
the table and their functional outcomes [300]. 
We analyzed the protein expression of B7 family members on NK cells from blood and tumor of RMA-S 
tumor bearing mice. As shown in Figure 6.13, B7 family receptors CD28, CTLA-4, PD-1 and ICOS were 
not detectable in blood of either naïve (data not shown) or tumor bearing animals. However, tumor 
infiltrating NK cells upregulated CD28, CTLA-4 and PD-1, while the expression of the activating receptor 
ICOS remained low/negative and unchanged at the protein level. These data indicate that PD-1 and 
CTLA-4 regulation at the transcript level correlates with the protein level expression, while CD28 
expression is most probably regulated post-transcriptionally. Both CD28 and PD-1 expression levels were 
increased with tumor progression (data not shown) showing the highest expression at the high tumor load. 
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Interestingly, we did not detect CD28, CTLA-4 and/or PD-1 positive NK cells within the first 10 days of 
tumor progression. Typically, observed phenotypical changes were only detected in tumors bigger than 
1 cm2. In contrast to PD-1 and CD28, we did not measure substantial amounts of CTLA-4 on the cell 
surface of tumor infiltrating NK cells. Similarly to the expression pattern previously shown in T cells, 
CTLA-4 protein was stored intracellularly. However, we cannot exclude the possibility that small, yet 
undetectable amounts of the protein are transported to the cell surface and can have a functional effect. 
Indeed, short exposure on the cell surface followed by fast internalization has already been shown to take 
place in T cells and can have functional consequences due to the very high affinity of CTLA-4 for its 
ligands [190]. 
 
Figure 6.13. Expression of B7 family members on tumor infiltrating NK cells. Mice were inoculated subcutaneously 
with 106 RMA-S cells in 100 µl PBS. When tumor size exceeded 1 cm2, mice were sacrificed and single cell 
suspensions were prepared from blood and tumor. Expression of depicted molecules on blood and tumor infiltrating 
NK cells, defined as CD3-NK1.1+, was analyzed by flow cytometry. Surface expression is depicted for all molecules 
except CTLA-4 whose expression is measured by intracellular staining of the protein. Representative stainings from 
one out of three experiments performed are shown. 
Similar to the above mentioned receptors, PD-L2, the ligand of PD-1, was not expressed in blood, but 
induced on tumor infiltrating NK cells. ICOS-L already showed low expression in the blood and was slightly 
elevated in the tumor. In contrast to PD-L2, B7-H1, another PD-1 ligand, as well as binding partner of 
B7-1, is highly expressed on blood NK cells. We observed its elevated expression in the tumor, however, 
differences were not always significant. Expression of B7-1 and B7-2, shared ligands of CD28 and 
CTLA-4, was variable between experiments, which might be a consequence of their tight temporal 
regulation that can in addition be influenced by the tumor size. In general, the expression of B7-1 was low, 
while B7-2 was constitutively expressed by NK cells. 
In summary, RMA-S infiltrating NK cells showed elevated expression of multiple B7 family members at 
both mRNA and protein level. For most of the analyzed molecules, a correlation between changes at 
transcript and protein level was observed. The main phenotypic features of tumor infiltrating NK cells were 
induced expression of CD28, CTLA-4, PD-1 and PD-L2  when compared to their blood counterparts. 
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6.2.3.1. Expression of B7 family members in NK cell depends on the tumor type 
So far, we showed that NK cells that infiltrate different types of subcutaneous tumors had a very similar 
phenotype, as shown in Figure 6.1 and 6.2. We observed the induced expression of several B7 family 
members on NK cells that infiltrate RMA-S lymphomas, some of which were not reported to be expressed 
by NK cells before. Therefore, we analyzed the profile of several B7 family members on NK cells derived 
from the tumors of different origin. As shown in Figure 6.14, surface levels of the analyzed molecules are 
strongly dependent on the tumor type. While lymphomas (RMA, RMA-S) showed a tendency to highly 
upregulate PD-1 and CD28, melanoma (B16) and carcinoma (LL2) preferentially upregulated B7-H1. 
CD28 and PD-1 were expressed at very low levels in TINs of B16 and LL2 tumor bearing mice. However, 
in all tumor models analyzed, we observed expression of CTLA-4 (Figure 6.14), which seems to be 
a stable feature of NK cells infiltrating solid tumors. 
 
Figure 6.14. B7 family member expression in NK cells infiltrating tumors of different origin. Mice were inoculated 
subcutaneously with PBS (naïve controls) or 106 tumor cells in 100 µl PBS. When tumor size exceeded 1 cm2, mice 
Ana Stojanovic    Results 
‐ 92 ‐ 
 
were sacrificed and single cell suspensions were prepared from blood and tumor. Expression of depicted molecules 
on blood and tumor infiltrating NK cells, defined as CD3-NK1.1+, was analyzed by flow cytometry. Graphs indicate 
mean±SD of experimental group of 3 treated animals and are representative of one out of minimum two experiments 
performed. 
 
6.2.3.2. Expression of B7 family members on tumor infiltrating T cells and macrophages  
Several B7 family members were upregulated by NK cells found within the tumor tissue. It is possible that 
certain factors, both biological (e.g. cytokines) and chemical (pH, hypoxia) within the microenvironment 
were able to induce their expression. We analyzed if these molecules were similarly regulated on other 
immune cells found in RMA-S tumors. Figure 6.15 shows that both cells of the adaptive (T cells) and the 
innate (macrophages) immune system highly upregulated PD-1 in the tumor. In addition, T cells, both 
CD4+ and CD8+, showed elevated expression of B7-H1 and PD-L2, as well as high levels of CTLA-4 
assesed by intracellular staining. CTLA-4+ cells among the CD4+ subset might, however, be composed of 
both activated T effector cells and T regulatory cells that constitutively express CTLA-4 [213] and were 
shown to accumulate in tumor [301]. 
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Figure 6.14. Expression of B7 family members by tumor infiltrating T cells and macrophages. Mice were inoculated 
subcutaneously with 106 RMA-S tumor cells in 100 µl PBS. When the tumor size exceeded 1 cm2, mice were 
sacrificed and single cell suspensions were prepared from blood and tumor. Expression of the depicted molecules on 
blood and tumor infiltrating T cells (CD3+CD4+ and CD3+CD8+) and macrophages (CD11b+F4/80+) was analyzed by 
flow cytometry. Graphs indicate mean±SD of experimental groups of 3 treated animals. 
Thus, expression of certain B7 family members, such as PD-1, might be induced by the conditions in the 
tumor microenvironment (hypoxia, cytokine/s present in high concentrations). Regulation of the expression 
of other molecules might in addition require more defined cell/cell intreractions and/or the presence of 
certain factors acting on the specific cell types. 
 
6.2.3.3. Expression od PD-1 and CTLA-4 in RAG2 deficient mice 
Expression of PD-1 and CTLA-4 on tumor infiltrating NK cells was typically observed in the tumors that 
exceeded the size of 1 cm2 . This size corresponds to the phase of tumor progression, which is 
characterized by the established control of tumor growth and is followed by the final phase of progression 
that leads to animal death (Figure 6.4). The phase of control correlated to the time when the adaptive 
immune system is expected to be fully activated. To investigate if a factor/s derived from adaptive immune 
cells at that time might be responsible for PD-1 and CTLA-4 induction on NK cells in the tumor, we 
analyzed NK cells derived from RMA-S tumors established in RAG2 deficient mice. Tumors in RAG2 
deficient mice grew with the similar kinetics within the first 7-10 days upon tumor cell inoculation, but 
progressed more aggressively in the late phase due to the absence of the adaptive immune response to 
tumor (data not shown). In the tumors dissected when the  size of 1 cm2 was reached in both WT and 
RAG2 deficient mice, we observed a similar expression of PD-1 (Figure 6.15). However, CTLA-4 
expression was not induced in RAG2 deficient mice. These observations indicate that either a direct 
contact or/and factor/s derived from cells of adaptive immune system are necessary for the induction of 
CTLA-4 in NK cells. This putative interaction and/or the production of the factor/s is expected to take place 
only in the tumor since no CTLA-4 expression was observed in blood. 
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Figure 6.15. Induction of CTLA-4, but not PD-1, depends on the presence of the adaptive immune system. WT and 
RAG2 deficient mice were injected subcutaneously with 106 RMA-S cells in 100 µl PBS. When the tumor size 
exceeded 1 cm2, mice were sacrificed and single cell suspensions were prepared from blood and tumor. Expression of 
PD-1 (surface) and CTLA-4 (intracellular) on blood and tumor infiltrating NK cells, defined as CD3-NK1.1+, was 
analyzed by flow cytometry. Graphs indicate mean±SD of experimental groups of 3 treated animals and are 
representative of one out of two experiments performed. 
 
6.2.3.5. Expression od PD-1 and CTLA-4 in NK cell insensitive tumors 
RMA-S is considered as a NK cell sensitive tumor cell line due to its sensitivity to NK cell lysis owing to the 
low expression of MHC I [23]. Thereby, when injected at low cell numbers into congenic mice, RMA-S cells 
are efficiently rejected in a NK cell dependent manner, while MHC I sufficient RMA cells lead to tumor 
formation [23]. However, when inoculated at high cell numbers, RMA-S form solid tumors, which we found 
to be infiltrated by PD-1 and CTLA-4 positive NK cells. We compared NK cells from MHC I deficient 
RMA-S and MHC I suficient RMA tumors of a similar size to see if efficient target recognition influences 
PD-1 and CTLA-4 upregulation. We observed no differences (Figure 6.16). Similar data were obtained 
when we compared PD-1 and CTLA-4 induction on NK cells infiltrating B16 and B16.Rae1ε solid tumors, 
where more efficient recognition of B16.Rae1ε cells is based on the expression of the ligand for the 
activating receptor NKG2D. Those data indicate that missing-self and induced-self recognition do not 
influence PD-1 and CTLA-4 expression in tumor infiltrating NK cells and that other factors might play 
a main role in their induction. 
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Figure 6.16. Missing-self and induced-self recognition do not influence PD-1 and CTLA-4 expression by tumor 
infiltrating NK cells. Mice were inoculated subcutaneuosly with 106 tumor cells in 100 µl PBS. When the tumor size 
exceeded 1 cm2, mice were sacrificed and single cell suspensions were prepared. Expression of PD-1 (surface) and 
CTLA-4 (intracellular) on tumor infiltrating NK cells, defined as CD3-NK1.1+, was analyzed by flow cytometry. Graphs 
indicate mean±SD of experimental group of three animals and are representative of one out of two experiments 
performed. 
 
6.2.3.6. Expression of PD-1 and CTLA-4 in non-subcutaneous tumor models 
Induction of inhibitory receptors PD-1 and CTLA-4 on NK cells within the tumor microenvironment has 
been observed to depend on the tumor size. In tumors smaller than 1 cm2, expression was absent or very 
low. Bigger tumors are characterized by necrotic, and areas with low pH and low oxygen concentration. 
These conditions, and the factors produced by other cells in the microenvironment, can possibly favor the 
PD-1 and CTLA-4 upregulation. Metastases are usually smaller in size and also known to be better 
controlled by NK cells than large solid tumors. We aimed to analyse if NK cells found within the organs 
highly populated by metastases express PD-1 and CTLA-4. Two weeks after the intravenous injection of 
different tumor cell lines (RMA, RMA-S, B16, LL2) into congenic mice, we observed the metastasis 
formation in the lungs of inoculated animals. However, no PD-1 and CTLA-4 expression was detected on 
NK cells from either blood or lungs (data not shown). Similar data we obtained after tumor cell inoculation 
into peritoneum. Two weeks post-injection, no PD-1 or CTLA-4 positive NK cells were found in the blood 
or peritoneal lavage of inoculated mice (data not shown), indicating that the given phenotype of NK cells is 
feature of big solid tumors. 
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6.3. Expression of B7 family receptors and ligands by in vitro expanded NK cells 
6.3.1. In vitro induction of B7 family members 
Gene expression profiling of tumor infiltrating NK cells revealed that within the tumor tissue several 
B7 family members were induced on NK cells. For the most of selected candidates, the data obtained on 
the mRNA level were confirmed to correlate with the protein expression. High surface levels of PD-1 and 
substantional intracellular levels of CTLA-4 were detected in tumor infiltrating, but not blood NK cells 
(Figure 6.12). In contrast, the activating receptor CD28 was not found to be differentially regulated on the 
transcript level between blood and tumor infiltrating NK cells. However, while blood NK cells were 
CD28 negative, the receptor was induced on NK cells from the tumor tissue (Figure 6.12). Next, we aimed 
to analyze the biological functions of different B7 family members in NK cells to better understand possible 
consequences of their induction in the tumor. As a first step, we measured the expression of several 
B7 molecules on in vitro expanded NK cells. NK cells isolated from spleen and cultured for 7-10 days in 
the presence of 1700 U/ml rhIL-2, are preferentialy composed of the CD27high NK cell subset 
(Figure 6.17A), similar to the NK cells found in the tumor (Figure 6.1). They express high levels of B220, 
while MHC II expression was reduced compared to the freshly isolated NK cells (Figure 6.17A). Analysis 
of the B7 family expression revealed that expanded NK cells expressed CD28, CTLA-4 (intracellular), low 
levels of B7-1 and B7-2 and high levels of B7-H1, while PD-1 and PD-L2 were absent (Figure 6.17B). 
Compared to fresh NK cells, expansion in IL-2 did not change the surface levels of B7-1, B7-2 and B7-H1. 
These observations indicate that, although the culture in IL-2 did not precisely reproduce expression of 
B7 family members seen on NK cells in the tumor, it was capable of inducing CD28 and CTLA-4. Thus, 
in vitro expanded NK cells can be used for analysis of CD28 and CTLA-4 functional role in the regulation 
of NK cell effector responses. 
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Figure 6.17. Phenotype of in vitro expanded NK cells. NK cells were isolated from spleens by magnetic cell sorting 
using CD3+ cell depletion followed by DX5 positive selection. After one week of culture in the presence of 1700 U/ml 
rhIL-2  cells were analyzed by flow cytometry for (A) subset composition (CD11b/CD27 co-expression), IKDC markers 
(CD11c, B220, MHC II) and (B) expression of  depicted B7 family members. Cultured cells were compared with freshly 
isolated splenocytes. Representative histograms show the expression of depicted molecules on gated CD3-NK1.1+ 
cells. 
 
6.3.2. In vitro induction of PD-1 
Since the expansion of NK cells in IL-2 led to CD28 and CTLA-4, but not PD-1 induction, we aimed to 
investigate if the addition of other stimuli would potentiate its expression. Single cytokines or their 
combinations, triggering of different NK cell receptors, incubation with tumor cells or the induction of 
transcription factor HIF-1α, the main regulator of hypoxia induced responses, were some of the conditions 
that failed to induce PD-1 expression on NK cells (Table 6.3). Since freshly isolated NK cells cannot 
survive without IL-2 for more than several hours, these stimuli were used for the short term stimulation of 
freshly isolated NK cells (4-8 h) or long term stimulation of IL-2 expanded NK cells (24-48 h). Therefore, 
we cannot exclude the possibility that some of the stimuli would be able to induce PD-1 expression the  
whole splenocytes, since PD-1 might be induced indirectly, through the accessory cells responding to the 
primary stimulus. However, we did not observe PD-1 expression in any of the experimental conditions 
applied. 
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Stimulus
Cytokines  IL‐1β, IL‐2, IL‐4, IL‐6, IL‐9, IL‐10, IL‐12, IL‐13, IL‐15, IL‐18, IFNα, IFNβ
Tumor cells  RMA, RMA‐S, B16, B16.Rae1ε at diferent E/T ratios 
NK receptor triggering  NK1.1, NKG2D, 2B4, Ly49D 
TLR ligands  Poly I:C, CpG
PMA and Ionomycin Activation of PKC and Ca2+ flux 
Chronic stimulation  Plate bound Abs and irradiated tumor cells for 7 days 
HIF‐1α induction  DMOG ‐ prolyl‐4‐hydroxylase inhibitor, prevents HIF‐1α targeting for degradation
Combinations of stimuli 
Cytokine combinations
Cytokine + Tumor cells 
Cytokine + DMOG 
Tumor cells + DMOG 
 
Table 6.3. Experimental conditions used for analysis of PD-1 induction in vitro. Freshly isolated or IL-2 expanded NK 
cells and whole splenocytes were stimulated as indicated for a short term (4-8 h) or a long term (24-48 h) period. PD-1 
expression was analyzed by flow cytometry. No induction was observed for any of the given experimental setup. 
 
6.3.3. Regulation of CTLA-4 expression by in vitro expanded NK cells 
We showed that culture in IL-2 induces CTLA-4 expression by NK cells. In T cells, CTLA-4 is induced by 
the TCR and CD28 engagement and most of the protein is found intracellularly [190]. Treg constitutively 
express CTLA-4, which is stored within the cell, but is exposed on the cell surface upon activation. In both 
cases, surface CTLA-4 is internalized shortly after the exposure and either targeted for degradation or 
recycled back to the plasma membrane. To investigate if a similar cellular compartmentalization of CTLA-4 
exists in NK cells and how it is regulated, we applied several staining techniques for its detection 
(Figure 6.18).  
 
Figure 6.18. Staining strategies for CTLA-4 detection in NK cells. Intracellular staining protocol includes cell fixation 
and permeabilization of cell membranes, therefore both surface and intracellular protein is detected. Surface staining 
detects only the receptor exposed on the cell surface at the moment of staining. Prolonged surface staining detects 
any CTLA-4 molecule that reaches the surface within the last 4h of cell stimulation, which is the time period labeled 
αCTLA-4 mAb is added to the cell culture. 
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Intracellular staining detects the total protein content that can be distributed anywhere within the cell 
including the cell surface. Surface staining detects the receptor exposed on the cell surface in the moment 
of staining. Prolonged surface staining detects CTLA-4 that reaches the cell surface during a defined time 
period. In this case, fluorescently labeled αCTLA-4 mAb or isotype control was added to the culture for the 
last 4h of cell stimulation and can bind any CTLA-4 molecule that is expressed on the surface within 
a given time period. 
By applying surface staining, we did not detect CTLA-4 expression on freshly isolated, cultured NK cells or 
cultured and then restimulated NK cells using different stimuli (data not shown). This means that the 
amount of the receptor on the surface could be too low to be detected by a classical flow cytometry 
staining technique. Of importance, even small hardly detectable amounts of CTLA-4 on the cell surface 
can have a significant functional role due to its high binding affinity for the B7-1 and B7-2 ligands [200]. 
Indeed, prolonged surface staining revealed that under certain conditions, CTLA-4 was exposed on the 
surface of NK cells where it could participate in the ligand binding and influenced NK cell effector 
responses.   
 
6.3.3.1. Regulation of CTLA-4 surface expression by cytokines 
IL-12 is a cytokine secreted by activated macrophages and DCs that plays an important role in NK cell 
activation [302]. Its main effect is the induction of IFNγ that further activates macrophages and DCs. IL-18 
very efficiently synergizes with IL-12, which is the combination known to be one of the strongest inducer of 
IFNγ production by NK cells. In addition, IL-18 stimulates NK cell cytotoxicity [100]. We analyzed whether 
exposure to IL-12 or/and IL-18 might as well influence CTLA-4 expression by NK cells. As shown in Figure 
6.19A, stimulation of in vitro expanded NK cells with a combination of IL-2, IL-12 and IL-18 for 24 hours 
strongly induced CTLA-4 surface expression as detected by prolonged surface staining (see Figure 6.18 
for staining method). Single cytokines, IL-12 or IL-18, added to IL-2 did not have such an effect. In addition 
to the increased surface exposure, the triple cytokine combination (IL-2/12/18) elevated the levels of total 
CTLA-4 assessed by intracellular staining (6.19B). 
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Figure 6.19. Regulation of CTLA-4 expression by cytokine stimulation. NK cells were isolated from spleens by 
magnetic cell sorting via DX5 positive selection (A) or CD3+ cell depletion followed by DX5 positive selction (B). After 
one week of culture in the presence of 1700 U/ml rhIL-2, cells were stimulated with the indicated cytokines for 24h 
(IL-2 1700 U/ml, IL-12 5 ng/ml, IL-18 40 ng/ml). Prolonged surface staining (last 4h of stimulation) or intracelular (total) 
staining was used for the analysis of CTLA-4 expression on gated CD3-NK1.1+ cells. In the case of surface staining, 
dead cells were excluded by addition of 7-AAD. MFI (calculated as Geometric Mean of specific staining-Geometric 
Mean of isotype control) is depicted in each panel. Data are representative from one out of three experiments 
performed. 
To better understand how the CTLA-4 synthesis and trafficking are regulated, we analyzed kinetics of 
CTLA-4 expression upon IL-2/12/18 treatment by prolonged surface staining. Interestingly, although 
substantial amounts of the protein existed in IL-2 expanded NK cells (Figure 6.19B), increased surface 
expression was not detected earlier than 24h upon IL-2/12/18 stimulation (Figure 6.20A and Figure 6.19B 
showing the expression after 24h). That indicates that cytokines probably did not directly mobilize the 
receptor from the intracellular pool, but that putative secondary factor/s induced by cytokines might do so. 
Therefore, we analyzed whether the CTLA-4 surface expression depends on de novo transcription and/or 
de novo translation. As shown in Figure 6.20B, NK cells treated with transcription inhibitor actinomycin D 
(ActD) showed partial reduction, and cell treated with translation inhibitor cyclohexamide (CHX) complete 
absence of surface CTLA-4 expression. These data show that CTLA-4 surface exposure partially 
depended on de novo transcription and completely on de novo protein synthesis.  
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Figure 6.20. Requirements for CTLA-4 surface expression by in vitro expanded NK cells. NK cells were obtained by 
culture of non-adherent RAG2 deficient splenocytes in the presence of 1700 U/ml rhIL-2. After one week of culture NK 
cells were stimulated with the indicated cytokines (IL-2 1700 U/ml, IL-12 1 ng/ml, IL-18 10 ng/ml). (A) CTLA-4 
expression was measured by prolonged surface staining (last 4h of stimulation) at different time points after beginning 
of stimulation. Total stimulation time is depicted on the x-axis. (B) NK cells were left untreated or treated with 5 µg/ml 
actinomycin D (ActD), 10 µg/ml cyclohexamide (CHX) or adequate volume of absolute ethanol (EtOH) as a solvent 
control. CTLA-4 surface expression was measured by prolonged surface staining 24h after the beginning of 
stimulation. Graphs indicate mean±SD of triplicate culture. Graphs indicate mean±SD of triplicate cultures. 
 
6.3.3.2. Regulation of CTLA-4 surface expression by receptor triggering 
In addition to the stimulation by cytokines from the microenvironment, NK cells can be activated in a direct 
contact with other cells by recognition of the ligands for activating NK receptors. Thus, we analyzed if 
triggering of NK cell receptors can modulate CTLA-4 expression. When IL-2 expanded NK cells were 
stimulated with plate-bound mAbs directed against different NK receptors, no change in the total or 
surface expression of CTLA-4 was observed (Figure 6.21), although triggering of some receptors, as 
NK1.1, showed the tendency to induce CTLA-4. When receptor triggering was combined with the triple 
cytokine stimulation, synergy was obtained between IL-2/12/18 and NK1.1 engagement in enhancing 
CTLA-4 surface exposure, detected by the prolonged surface staining. 
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Figure 6.21. Regulation of CTLA-4 expression by receptor triggering. NK cells were obtained by culture of 
non-adherent RAG2 deficient splenocytes in the presence of 1700 U/ml rhIL-2. After one week of culture harvested NK 
cells were first incubated with αCD16/CD32 mAbs to block Fc receptors and subsequently stimulated with plate-bound 
Abs (10 µg/ml) for 24h in the presence of indicated cytokines (IL-2 1700 U/ml, IL-12 1 ng/ml, IL-18 10 ng/ml). CTLA-4 
expression was measured by prolonged surface staining (last 4h of stimulation). Graphs indicate mean±SD of 
triplicate culture. Graphs indicate mean±SD of triplicate ciltures. Ms – mouse; Ham - Hamster 
Interestingly, short exposure to cytokines, not sufficient to induce surface expression itself, can render NK 
cells sensitive to the NK1.1 mediated surface induction of CTLA-4. NK1.1 signals via the adaptor 
molecules CD3ζ and FcεRIγ [295]. On the other hand, Ly49D and NKG2D, that did not have any effect on 
CTLA-4 expression, are coupled to DAP12 and DAP12 or DAP10, respectively [303]. Therefore, we 
looked if another activating NK receptor that utilizes CD3ζ and FcεRIγ for signal transduction had similar 
effect as NK1.1. Indeed, short term NK cell stimulation with cytokines (IL-2/12/18) followed by triggering of 
NKp46, enhanced CTLA-4 surface expression similar to the levels obtained by NK1.1 engagement 
(Figure 6.22).  
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Figure 6.22. Regulation of CTLA-4 expression by CD3ζ and FcεRIγ coupled NK cell receptors. NK cells were obtained 
by culture of non-adherent RAG2 deficient splenocytes in the presence of 1700 U/ml rhIL-2. After one week of culture 
harvested NK cells were pre-treated with the indicated cytokines (IL-2 1700 U/ml, IL-12 1 ng/ml, IL-18 10 ng/ml) for 
12h. After removal of the cytokines by washing, cells were first incubated with αCD16/CD32 mAbs to block 
Fc receptors and subsequently stimulated with plate-bound Abs (10 µg/ml) for additional 12h in the presence of IL-2. 
CTLA-4 expression was measured by prolonged surface staining (last 4h of stimulation). Graphs indicate mean±SD of 
triplicate culture. Graphs indicate mean±SD of triplicate ciltures. Ms – mouse; Ham - Hamster 
In summary, our data indicate that cytokines commonly present in the inflammed tissues, namely IL-12 
and IL-18, synergized with IL-2 in the upregulation of CTLA-4 expression and potentiated its exposure on 
the cell surface. CD3ζ and FcεRIγ coupled receptors, NK1.1 and NKp46, further increased CTLA-4 
surface expression of IL-2/12/18 exposed NK cells. Thus,the recognition of cellular ligands in combination 
with cytokines from the microenvironment can modulate the expression of CTLA-4 receptor on the surface 
of activated NK cells.           
    
6.4. In vitro responses of NK cells to B7-1 
Our previous results showed that expression of CTLA-4 on NK cells can be modified by their exposure to 
cytokines (IL-2/12/18) and the engagement of activating receptors, such as NK1.1 and NKp46. These data 
indicate that situations that typically induce NK cell activation can in addition increase expression of 
inhibitory molecules, in this case the receptor CTLA-4. B7-1 and B7-2 are two described ligands of CTLA-4 
[200]. Compared to B7-2, B7-1 binds CTLA-4 with a higher affinity. During the course of immune 
response, expression of the ligand, B7-1, and the receptor, CTLA-4, is induced at a similar time point. 
Thus, B7-1 is considered to be preferential and physiologically more important ligand for CTLA-4 [181]. 
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Therefore, we analyzed how NK cell responses are controled by CTLA-4 upon recognition of B7-1. 
Of importance, B7-1 can be engaged by two other molecules, CD28 and B7-H1, that mediate activating or 
inhibitory effects, respectively [304]. In conditions where CTLA-4 expression has been observed on NK 
cells (tumor tissue, expansion in IL-2), CD28 and B7-H1 were also expressed (Figure 6.23). Thus, NK cell 
responses to B7-1 can be modulated through all three pathways. 
 
Figure 6.23. Expression of B7-1 binding receptors CD28, CTLA-4 and B7-H1 by IL-2 expanded NK cells. NK cells 
were isolated from spleens by magnetic cell sorting using CD3+ cell depletion followed by DX5 positive selection. After 
one week of culture in the presence of 1700 U/ml rhIL-2  cells were analyzed for the expression of CD28 and B7-H1 by 
surface staining and CTLA-4 by intracellular staining.  
 
6.4.1. Stimulation with B7-1 induces NK cell proliferation and IFNγ production 
Next, we determined the functional impact of NK cell stimulation with B7-1. In vitro expanded NK cells, 
which we found to express B7-1 receptors CD28, CTLA-4 and B7-H1, were stimulated with plate bound 
B7-1 or control IgG fusion protein. As shown in Figure 6.24A, B7-1 induced IFNγ production in a dose 
dependent manner, which accummulated in the cell culture supernatant. Short pulse with BrdU, that allows 
the analysis of the frequency of proliferating cells, revealed that NK cells stimulated with B7-1 proliferated 
more extensively than controls (Figure 6.24B). At the same time, NK cells survival was analyzed 
by annexin V/7-AAD co-staining. B7-1 stimulated cells contained a slightly higher proportion of apoptotic 
cells (Figure 6.24C), but differences were much lower compared to differences in proliferation rates. Thus, 
in addition to inducing IFNγ, B7-1 stimulated NK cell proliferation and slightly increased apoptosis. This 
effect can lead to the increasement in the number of NK cells that can further respond to stimulation. 
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Figure 6.24. Stimulation with B7-1 induces IFNγ production and proliferation by in vitro expanded NK cells. NK cells 
were obtained by culture of non-adherent RAG2 deficient splenocytes in the presence of 1700 U/ml rhIL-2. After one 
week of culture harvested NK cells were pre-treated with αCD16/CD32 mAb to block Fc receptors and subsequently 
stimulated with plate-bound B7-1 (B7-1-Fc) or control (c-Fc) IgG fusion protein (2 µg/ml) in the presence of 1700 U/ml 
IL-2. (A) Increasing concentrations of plate bound B7-1-Fc were used for stimulation of NK cells. After 8h the culture 
supernatant was harvested and released IFNγ was measured by ELISA. (B). Last 45min of stimulation cells were 
pulsed with BrdU. The frequency of cells that have incorporated BrdU was measured by flow cytometry. (C) Cells were 
stimulated with B7-1-Fc for 24h. Proportion of apoptotic cells was measured by labelling with annexin V and 7-AAD. 
Graphs indicate mean±SD of triplicate cultures. *, p<0.05 by t-test; B7-1-Fc, B7-1 IgG fusion protein; c-Fc, control IgG 
fusion protein 
 
6.4.2. B7-1 expression by tumor cells increases their susceptibility to NK cell lysis and potentiate 
IFNγ production 
Many potential NK cell targets express B7 costimulatory ligands, such as some tumor cell of hematopoetic 
origin or dendritic cells [221, 305]. B7-1 expressed on tumor cells can engage both the activating, CD28, 
or the inhibitory, CTLA-4 and B7-H1 pathway. We measured the NK cell cytotoxic responses against 
tumor cell lines transduced with B7-1, namely RMA-S.B7-1 and B16.B7-1 (Figure 6.25).  
 
Figure 6.25. B7-1 expression on transduced RMA-S lymphoma and B16 melanoma cell lines. Cells were harvested in 
the exponential phase of growth after 7 days of culture. B7-1 expression was analyzed by flow cytometry. 
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B7-1 expression on MHC I deficient RMA-S lymphoma strongly increases their susceptibility to NK cell 
lysis (Figure 6.26A). In addition to the increased cytotoxic response, their recognition by NK cell effectors 
induced IFNγ production (Figure 6.26B). In vivo, subcutaneous injection of RMA-S.B7-1 into congenic 
mice led to the complete rejection of inoculated cells (Figure 6.26C). Importantly, both WT and RAG2 
deficient mice were able to control high numbers of tumor cells (data not shown), indicating the central role 
of innate immune system in mediating the efficient rejection. Since in vitro studies showed that both 
cytotoxic and cytokine releasing effector responses are mobilized upon NK cell recognition of the B7-1 
expressing lymphoma cells, both mechanisms might play a role in their efficient rejection in vivo. 
 
 
Figure 6.26. NK cell responses to B7-1 expressing tumor cells. NK cells were isolated from splenocytes by magnetic 
cell sorting using CD3+ cell depletion followed by DX5 positive selection and further cultured for 7-10 days in the 
presence of 1700 U/ml rhIL-2. (A) NK cells were used as effectors in 4h 51Cr release assay against RMA-S lymphoma 
and B16 melanoma B7-1+ target cells. (B) NK cells were incubated alone or with the indicated tumor cells in a 1:2.5 
ratio for 8h in the presence of IL-2. The amount of IFNγ released in the cell culture supernatant was measured by 
ELISA. Graphs indicate mean±SD of triplicate ciltures.  
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(C) RAG2 deficient mice were injected subcutaneously with 106 tumor cells (RMA-S, RMA-S.B7-1, B16, B16.B7-1) in 
100 µl PBS. Tumor size was measured every 2 days starting from day 5 after tumor cell inoculation and expressed as 
product of three measured tumor dimensions. Graphs indicate mean±SD of triplicate culture (A and B) or mean±SD of 
experimental group of three animals (C). 
We observed that the effect of B7-1 expression depended on the nature of tumor cell expressing it. In 
contrast to RMA-S lymphoma, B16 melanoma cells are killed by NK cells more efficiently in vitro 
(Figure 6.26A). Expression of B7-1 slightly increased specific lysis of B16 tumor cells. In addition, NK cells 
produced IFNγ in response to B7-1 expressing melanoma (Figure 6.26B). However, in vivo inoculation of 
both B16 and B16.B7-1 cells led to the progressive tumor growth in RAG2 deficient mice (Figure 6.26C). 
These data indicate that B7-1 expression by itself does not determine the NK cell responses in vivo, but it 
is rather integrated in the complex network of interactions established by NK cells, their targets and the 
microenvironment. As shown in Figure 6.13, the microenvironment formed by the tumor in vivo might 
differentially regulate the expression of receptors recognizing B7-1. NK cells found within RMA-S, but not 
B16 subcutaneous tumors, expressed the activating receptor CD28, that might mediate positive responses 
to B7-1 expressing lymphoma (Figure 6.14). On the other hand, high expression of the inhibitory receptor 
B7-H1 was detected on B16 infiltrating NK cells and could be responsible for a poor response and 
progressive growth of B7-1 expressing melanoma. 
 
6.4.3. NK cell mediated trogocytosis of B7-1 from target cells 
If a target cell is efficiently recognized by a NK cell, the stable contact is formed, which typically results in 
NK cell activation. The resulting outcome is target cell elimination and/or triggering of cytokine and 
chemokine production by NK cells. We observed that in addition to the activation of cytotoxicity and IFNγ 
production, NK cells cultured with B7-1 positive target cells become B7-1 positive themselves. This finding 
raised the question whether B7-1 was upregulated or acquired from the targets through the close synapse 
formed between two cells. The process of intercellular exchange of intact membrane patches, including 
membrane molecules, is termed trogocytosis and is considered to occur very frequently between 
interacting cells [306-307]. The main characteristic of the process is very fast kinetics since it occurs within 
minutes from the beginning of the interaction. The event of exchange is triggered by specific receptors and 
requires the signal transduction in recipient cell. Importantly, membrane proteins are transferred in full size 
and in the right inside-out orientation and therefore, they can potentially perform their functions.  
We showed that co-culture with different B7-1 expressing tumor cell lines rendered NK cells B7-1 positive 
(Figure 6.27A). This process is very fast and already co-incubation with targets as short as 30 minutes 
resulted in a highly positive NK cell population (Figure 6.27B). The level of B7-1 expression correlated with 
the availability of B7-1 source, since increased numbers of tumor cells elevated the proportion of B7-1 
positive NK cells (Figure 6.27B). 
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Figure 6.27. NK cells express B7-1 after co-culture with B7-1 expressing target cells. NK cells were obtained by 
culture of non-adherent RAG2 deficient splenocytes in the presence of 1700 U/ml rhIL-2. Cells were used after 7-10 
days of expansion. (A) NK cells were cultured alone or with tumor cells in a 1:1 ratio in the presence of IL-2. After 4h, 
expression of B7-1 and B7-2 was measured by flow cytometry. (B) Representative dot plots show B7-1 staining after 
NK cell co-culture with B16 or B16.B7-1 tumor cells for 4h or 30min. (C) NK cells were cultured alone or with tumor 
cells at the indicated ratios. After 4h, expression of B7-1 was analyzed by flow cytometry. 
Apart from B7-1 transduced tumor cells, B7-1 and B7-2 ligands are endogenously expressed by APCs. NK 
cells were shown to establish interactions with DCs that lead to either NK and DC activation or DC 
elimination if they are not mature [66]. Mature DCs express high levels of costimulatory molecules 
including B7-1 and B7-2. We showed that NK cells cultured with mature but not immature DCs displayed 
elevated surface expression of both B7-1 and B7-2 (Figure 6.28). Therefore, similar to tumor targets, 
increased availability of the ligands on DCs correlated with their higher expression by NK cells after 
co-culture. 
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Figure 6.28. NK cells express B7-1 and B7-2 after co-culture with 
mature DCs. NK cells were obtained by 7 days culture of 
non-adherent RAG2 deficient splenocytes in the presence of 
1700 U/ml rhIL-2. DCs were generated from bone marrow of WT 
mice by culture in the medium supplemented with GM-CSF. Cells 
were harvested on day 6 and treated with 100 ng/ml LPS (mature 
DC, mDC) or medium only (immature DC, iDC) for 12 hours.  
NK cells were cultured alone or with iDC and mDC at  a 1:1 ratio 
in the presence of IL-2 and GM-CSF (1/5 of amount used for 
expansion). After 24h of co-culture the expression of B7-1 and 
B7-2 on CD3-NK1.1+ cells was measured by flow cytometry. 
Dead cells were excluded by 7-AAD staining. 
 
To investigate if B7-1 was indeed acquired from target cells or upregulated by NK cells, we used NK cells 
derived from B7-1 deficient mice as effector cells in the co-culture experiments. B7-1 ko NK cells had 
a comparable phenotype to WT NK cells (data not shown) both when analyzed fresh or after expansion in 
IL-2 for the expression of maturation markers (CD11b, CD27), activation markers (CD11c, B220, CD69, 
CD25) and B7 family members (CD28, CTLA-4, PD-1, ICOS, B7-H1, PD-L2, B7-2). After co-culture with 
B7-1 expressing tumor cells, both WT and B7-1 deficient NK cells displayed similar levels of B7-1 on the 
surface (Figure 6.29A left), which proved that B7-1 was acquired from tumor cells and not synthetized by 
NK cells themselves. After co-culture with DCs, both B7-1 and B7-2 were expressed at the comparable 
levels by WT and B7-1 ko NK cells (Figure 6.29A right), which proved that DCs are source of B7-1. As an 
additional confirmation of the B7-1 transfer is the observation that only B7-2 expression was detected on 
WT NK cells after co-culture with DCs derived from B7-1 deficient mice, while both B7-1 and B7-2 were 
expressed after incubation with WT DCs (Figure 6.29B). 
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Figure 6.29. B7-1 is transferred from target cells to NK cells. NK cells were isolated from spleens of WT and B7-1 
deficient (B7-1 ko) mice by magnetic cell sorting using CD3+ cell depletion followed by DX5 positive selection and 
further cultured for 7-10 days in the presence of 1700 U/ml rhIL-2. DCs were derived from bone marrow of WT and 
B7-1 ko mice by culture in the medium supplemented with GM-CSF. Cells were harvested on day 6 and treated with 
LPS (mature DC, mDC) or medium only (immature DC, iDC) for 12 hours. (A) WT or B7-1 ko NK cells were cultured 
alone or with either B16 and B16.B7-1 tumor cells (left) or WT iDC and mDC (right) at a 1:1 ratio. NK/tumor cell 
co-cultures were supplemented with IL-2 (1700 U/ml) and NK/DC co-cultures with IL-2 and GM-CSF (1/5 of amount 
used for expansion). After 4h of co-culture with tumor cells or 24h with DCs, expression of B7-1 and B7-2 on 
CD3-NK1.1+ cells  was measured by flow cytometry. Dead cells were excluded by 7-AAD staining. (B) WT NK cells 
were co-cultured with WT or B7-1 ko iDCs and mDCs as indicated for panel A. NK cell B7-1 and B7-2 expression was 
measured by flow cytometry as in A. 
 
In summary, NK cells were capable of trogocytosis of B7-1 ligand from the cells they interact with. In our 
in vivo experiments we found indications, that this process could take place in the tumor tissue as well. 
NK cells within B7-1 positive melanoma expressed higher levels of B7-1 compared to the NK cells 
infiltrating B7-1 negative tumors (Figure 6.30). Elevated levels of the B7 costimulatory ligands on the 
surface of NK cells can have multiple functional outcomes that include both positive (e.g. T cell 
costimulation through CD28) and negative effects (e.g. Treg support through CD28, effector T cell 
inhibition through CTLA-4 or induction of IDO). 
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Figure 6.30. NK cells infiltrating B7-1 positive melanoma 
tumor express elevated levels of B7-1. Mice were injected 
subcutaneously with 106 tumor cells (B16 or B16.B7-1) in 
100 µl PBS. The first group of mice were sacrified before and 
the second group after tumor exceeded 1 cm in diameter. 
Single cell suspensions were prepared from blood and tumor 
and expression of B7-1 and B7-2 on CD3-NK1.1+ cells was 
analyzed by flow cytometry. Graphs indicate mean±SD of 
experimental group of three animals. 
 
 
 
 
6.5. Regulation of B7-1 induced responses by CD28, CTLA-4 and B7-H1 
So far, we showed that in vitro expanded NK cells, similar to tumor infiltrating NK cells, expressed the 
B7 family receptors CD28, CTLA-4 and B7-H1, that all bind the same ligand, B7-1. In response to B7-1, 
NK cells proliferated and produced high amounts of IFNγ. Ectopic expression of B7-1 by RMA-S 
lymphoma and B16 melanoma tumor cells enhanced their sensitivity to NK cell lysis and stimulated 
NK cell IFNγ production. In T cells, that constitutively express CD28 and B7-H1, and upregulate CTLA-4 
when activated, CD28 delivers positive, and B7-H1 and CTLA-4 negative costimulatory signals in the 
context of the TCR activation [59, 304]. We analyzed how B7-1 induced responses of NK cells are 
regulated by the given receptors. For this purpose, we used NK cells deficient in CD28, CTLA-4 or B7-H1, 
which were derived from CD28 ko, OT-I transgenic (OT-I-Tg) CTLA-4 ko and B7-H1 ko mice, respectively. 
CTLA-4 ko mice develop severe autoimmune phenotype characterized by the activation and expansion of 
self-reactive T cells, which results in animal death at the age of 3-4 weeks [203]. OT-I-Tg mice contain 
only CD8+ T cells specific for ovalbumin peptide presented in the context H2-Kb. Although the signs of 
T cell activation are visible in OT-I-Tg CTLA-4 ko mice, disease progression is significantly slower [308], 
which allowed us to use NK cells derived from those mice at the age when NK cells are fully mature and 
the signs of immune activation are minimal (around age of 6 weeks). Freshly isolated or in vitro expanded 
NK cells from gene deficient mice had a phenotype comparable to the WT NK cells and expanded in IL-2 
with similar kinetics. No differences in the expression of maturation markers (CD11b, CD27), activation 
markers (CD11c, B220, CD69, CD25) and B7 family members (CD28, CTLA-4, PD-1, ICOS, B7-H1, 
PD-L2, B7-2) were observed (data not sown).  
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6.5.1. IFNγ production is positively regulated by CD28 and negatively by CTLA-4 and B7-H1 
When stimulated with the plate-bound B7-1 IgG fusion protein (B7-1-Fc), in vitro expanded NK cells 
produced IFNγ (Figure 6.25A). To investigate which of the receptors known to recognize B7-1 is 
responsible for this response, we used NK cells deficient for CD28, CTLA-4 or B7-H1 and measured their 
activation by B7-1-Fc. In response to plate-bound B7-1-Fc, CD28 deficient NK cells failed to produce IFNγ 
(Figure 6.31A), indicating that the positive response to B7-1 is completely CD28 dependent.  
 
 
Figure 6.31. CD28 stimulates NK cell IFNγ production in response to B7-1. (A,B) NK cells were isolated from spleens 
of WT and CD28 deficient (CD28 ko) mice by CD3+ cell depletion followed by DX5 positive selection. After one week 
of culture in the presence of 1700 U/ml rhIL-2, cells were incubated with 10 µg/ml αCD16/CD32 to block Fc receptors 
and then stimulated with the plate-bound IgG fusion proteins (2 µg/ml) or indicated mAbs (10 µg/ml). (C) NK cells were 
obtained by one week culture of non-adherent RAG2 splenocytes in the presence of 1700 U/ml rhIL-2. Cells were 
treated as in panel A and stimulated with the increasing amounts of B7-1-Fc and αNK1.1. After 8h of stimulation, 
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supernatants were harvested and amount of released IFNγ was measured by ELISA. Graphs indicate mean±SD of 
triplicate culture. Graphs indicate mean±SD of triplicate ciltures. B7-1-Fc, B7-1 IgG fusion protein; c-Fc, control IgG 
fusion protein 
Several other activating NK receptors were shown to induce IFNγ, among them NK1.1. When both the 
B7-1-Fc and αNK1.1 mAb were used for NK cell stimulation, the effects on IFNγ production seemed to be 
additive, as shown by CD28 ko NK cells responding to αNK1.1 and αNK1.1/B7-1-Fc combination 
(Figure 6.31B). We further extended these findings by analysis of WT NK cell response to the combination 
of these two stimuli.  When concentration of the B7-1 fusion protein was high, B7-1 delivered stimulus 
dominated and addition of αNK1.1 did not further increase IFNγ production (Figure 6.31C left). However, 
when the B7-1-Fc concentration was low and therefore the amount of stimulus limited, NK1.1 triggering 
contributed significantly to the response (Figure 6.31C right). As depicted in Figure 6.32, CTLA-4 and 
B7-H1 deficient NK cells showed elevated cytokine production in response to B7-1-Fc compared to WT 
NK cells. Therefore, similar to their function in T cells, CD28 positively, and CTLA-4 and B7-H1 negatively 
regulate NK cell IFNγ production. 
 
6.32. Negative regulation of NK cell IFNγ production by CTLA-4 and B7-H1. NK cells were isolated from spleens of 
WT and OT-I transgenic CTLA-4 deficient (CTLA-4 ko, panel A) or B7-H1 deficient (B7-H1 ko, panel B) mice by 
CD3+ cell depletion followed by DX5 positive selection. After one week of culture in the presence of 1700 U/ml rhIL-2, 
cells were incubated with 10 µg/ml αCD16/CD32 to block Fc receptors and then stimulated with plate-bound IgG 
fusion proteins (2 µg/ml). After 8h of stimulation, supernatants were harvested and the amount of released IFNγ 
measured by ELISA. Graphs indicate mean±SD of triplicate culture. *, p<0.05; **, p<0.01 by t-test; B7-1-Fc, B7-1 IgG 
fusion protein; c-Fc, control IgG fusion protein 
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6.5.2. Cytotoxicity is not regulated by CD28, CTLA-4 and B7-H1 
We observed that B7-1 positive RMA-S lymphoma and B16 melanoma tumor cell lines were more 
sensitive to NK cell lysis than their negative counterparts. We further analyzed the regulation of cytotoxic 
response by CD28, CTLA-4 and B7-H1 by using receptor deficient NK cells. Suprisingly, CD28, CTLA-4 
and B7-H1 deficient NK cells killed B7-1 transduced tumor cells equally efficient as WT NK cells 
(Figure 6.33).  
 
 
 
6.33. Cytotoxic response of CD28, CTLA-4 or B7-H1 deficient NK cells.  NK cells were isolated from spleens of WT 
and CD28 deficient (CD28 ko, upper panel), OT-I transgenic CTLA-4 deficient (CTLA-4 ko, middle panel) or B7-H1 
deficient (B7-H1 ko, lower panel) mice by CD3+ cell depletion followed by DX5 positive selection. After one week of 
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culture in the presence of 1700 U/ml rhIL-2, cells were used as effectors in 4h 51Cr release assay against RMA-S, 
RMA-S.B7-1, B16 and B16.B7-1 tumor cells. Graphs indicate mean±SD of triplicate cultures. 
 
6.5.3. Trogocytosis of B7-1 partially depends on CD28 expression 
As we previously showed (Figures 6.27-29), in the interaction with the B7-1 expressing target cells, B7-1 
ligand is transfered from the targets to NK cells. A previously described process of intercellular exchange 
of intact membrane patches including surface proteins is termed trogocytosis. Since trogocytosis is 
triggered by the receptor mediated recognition of the donor cell and requires the signal transduction in the 
acceptor cell [306-307], we analyzed if any of B7-1 recognition receptors is responsible for its transfer from 
the targets to NK cells. As an alternative, other receptor-ligand pairs might initiate the process and B7 
ligands might be exchanged as bystander molecules belonging to the tranfered membrane patch. 
 
Figure 6.34. Regulation of B7-1intercellular transfer by CD28. NK cells were isolated from spleens of WT and CD28 
deficient (CD28 ko, left panel), OT-I transgenic CTLA-4 deficient (CTLA-4 ko, middle panel) or B7-H1 deficient (B7-H1 
ko, right panel) mice by CD3+ cell depletion followed by DX5 positive selection. After one week of culture in the 
presence of 1700 U/ml rhIL-2, cells were co-cultured with B16 or B16.B7-1 tumor cell at 1:1 ratio. After 4h of 
incubation, expression of B7-1 on NK cells was analyzed by flow cytometry. Dead cells were excluded by 7-AAD 
staining.  
Co-culture of WT NK cells with B7-1 expressing targets (B16.B7-1 tumor cells or mature DCs) led to 
transfer of B7 ligand from target cells to NK cells. If CD28 deficient NK cells were used, levels of 
transferred B7-1 were reduced (Figure 6.34 left). This observation indicates that CD28 is partially involved 
in B7-1 trogocytosis. It is possible that certain amounts of B7-1 ligand were acquired through an active 
process mediated by CD28, and the rest was transferred passively as the part of the exchanged 
membrane patch. When CTLA-4 and B7-H1 deficient NK cells were co-cultured with B7-1 expressing 
tumor cells or B7-1 positive DCs, levels of acquired B7-1 ligand were comparable to the levels measured 
on WT NK cells (Figure 6.34 middle and right). Therefore, these two receptors were not involved in the 
active B7-1 trogocytosis from target cells. 
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6.6. Manipulation of NK cell anti-tumor responses in vivo 
Genetic expression analysis using whole genome microarrays, that we have performed, revealed that 
tumor infiltrating NK cells had a different transcription profile as compared to NK cells in the blood of tumor 
bearing animals. At the same time, differences observed between blood of naïve and tumor bearing 
animals were much less pronounced. We confirmed that most of the candidate genes we selected showed 
differential expression at the protein level too. Among those genes, B7 family receptors PD-1 and CTLA-4 
were expressed by NK cells only in the tumor. CTLA-4, but not PD-1, could be induced by NK cell 
expansion in IL-2. Functional analysis using in vitro expanded NK cells derived from OT-I transgenic 
CTLA-4 deficient mice, showed that CTLA-4 negatively regulated NK cell IFNγ production in response to 
B7-1, but not cytotoxicity. CTLA-4 blockade in vivo, in combination with agents, such as GM-CSF or Flt3L 
producing tumor vaccines, has been shown to mediate potent anti-tumor responses. CTLA-4 blockade is 
shown to affect both the T cell effector and Treg compartment. Similar to CTLA-4, disruption of 
PD-1:B7-H1 interaction by application of mAbs in vivo, was shown to enhance anti-tumor immune 
responses. Since NK cells within the tumor tissue expressed PD-1 and CTLA-4, we were aimed to analyse 
how the receptor blockade could affect NK cells and tumor growth in vivo. To avoid a posible effect of 
αPD-1 and αCTLA-4 mAb on the T cell compartement, for our experiments we used RAG2 deficient mice 
that lack T and B cells. 
 
6.6.1. αCTLA-4 mAb treatment does not improve the anti-tumor response in RAG2 deficient 
mice 
We first investigated whether the application of blocking αCTLA-4 mAb will affect the progression of 
subcutaneously inoculated tumor cells in RAG2 deficient mice. Mice were injected with B16, B16.B7-1 or 
B16.Rae1ε.B7-1 melanoma, RMA-S lymphoma or LL2 carcinoma tumor cells. A comparison of tumor 
growth of PBS and αCTLA-4 injected animals in different tumor models did not reveal significant benefits 
for αCTLA-4 treated animals (Figure 6.35). Moreover, neither ectopic expression of B7-1, the ligand of the 
B7 family receptors CD28, CTLA-4 and B7-H1, nor Rae1ε, the ligand of the activating receptor NKG2D, on 
B16 melanoma tumor cells, influenced the outcome of the experiment.  
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Figure 6.35. αCTLA-4 mAb treatment in RAG2 deficient mice. RAG2 deficient mice were injected with tumor cells 
subcutaneously (106 B16, B16.B7-1, RMA-S, LL2 or 5x106 B16.Rae1ε.B7-1). Mice were treated with i.p. injections of 
PBS or 250 µg αCTLA-4 mAb every three days starting from day -1 respective to the tumor cell inoculation. Tumor 
size was measured every 2 days and expressed as the product of three tumor dimensions. Graphs indicate mean±SD 
of experimental groups of 4-6 treated animals. 
  
6.6.2. Combination therapy of αCTLA-4 and IL-18 does not improve the anti-tumor response of 
RAG2 deficient mice 
We showed previously that stimulation with a combination of IL-2, IL-12 and IL-18 in vitro could increase 
CTLA-4 expression by NK cells. Here, we tested whether the IL-18 application in vivo might have a similar 
effect. RAG2 deficient animals with established RMA-S subcutaneous tumors, that do not express CTLA-4 
on NK cells withinn the tumor tissue, were treated systemically with IL-18 for two consecutive days. As 
depicted in Figure 6.36A, systemic injection of IL-18 did not induce CTLA-4 expression on blood NK cells, 
but elevated its expression in the tumor. Since IL-18 is known for its ability to enhance NK cell cytotoxicity 
and IFNγ production, we tested whether IL-18 application influences tumor growth control in RAG2 
deficient mice. At the same time, we blocked CTLA-4 by application of αCTLA-4 mAb. As shown in Figure 
6.35B, the therapeutic application of IL-18 or combination of IL-18 and αCTLA-4 did not influence RMA-S 
tumor growth in RAG2 deficient mice. 
Ana Stojanovic    Results 
‐ 118 ‐ 
 
 
Figure 6.36. Combination therapy with αCTLA-4 and IL-18 in RAG2 deficient mice. RAG2 deficient mice were injected 
with 106 RMA-S cells subcutaneously. (A) When tumor size exceeded 1 cm2, mice were treated with i.p. injections of 
PBS or 2 µg IL-18 for two consecutive days. On day 3 after the beginning of the treatment, mice were sacrificed and 
single cell suspension were prepared from blood and tumor. Expression of CTLA-4 in blood and tumor infiltrating NK 
cells was analyzed by flow cytometry after intracellular staining of the protein. (B) Mice were treated with i.p. injections 
of 2 µg IL-18 for 5 consecutive days starting from day 9 or/and 250 µg αCTLA-4 mAb every three days starting from 
day 8 respective to tumor cell inoculation. Tumor size was measured every 2 days and expressed as the product of 
three tumor dimensions. Graphs indicate mean±SD of experimental groups of 3 (A) and 5 (B) treated animals. 
 
6.6.3. Combination treatment of αCTLA-4 and IL-2 reduces tumor progression in RAG2 deficient 
mice 
NK cells expanded in vivo in the presence of IL-2 expressed CTLA-4 (Figure 6.17). IL-2 was shown to 
mediate NK cell activation and could enhance NK cell anti-tumor responses in vivo [102]. We tested 
whether IL-2 treatment combined with CTLA-4 blockade might further enhance control of tumor growth. 
We used B7-1 positive B16 melanoma tumor model and analyzed tumor growth and survival of treated 
animals. Figure 6.37A shows that IL-2 treatment alone slightly retained the tumor progression in RAG2 ko 
mice at the late stage of the tumor progression. Combination treatment of IL-2 and αCTLA-4 exert a similar 
effect, which was pronounced earlier compared to IL-2 treatment only. However, survival of mice treated 
with the IL-2/αCTLA-4 combination was not significantely prolonged compared to animals treated with IL-2 
only (Figure 6.37B).  
In contrast to the effects observed with B16.B7-1 tumor model, IL-2/αCTLA-4 treatment was not efficient 
when mice were inoculated with B16.Rae1ε.B7-1 tumor cells (Figure 6.37C). Since the Rae1ε expression 
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is already strong activating signal, NK cell effector functions might be not sensitive for further increasment 
with IL-2 and/or αCTLA-4 treatment in this model. 
 
Figure 6.37. Combination treatment with αCTLA-4 and IL-2 in 
RAG2 deficient mice. RAG2 deficient mice were injected with 
tumor cells subcutaneously as follows: panel A - 106 B16.B7-1, 
panel B – 2.5x106 B16.B7-1, panel C – 5x106 B16.Rae1ε.B7-1. 
Mice were treated with i.p. injections of 105 U of rhIL-2 for five 
consecutive days starting from day 0 or/and 250 µg αCTLA-4 
mAb every three days starting from day -1 respective to the 
tumor cell inoculation. Tumor size was measured every two 
days and expressed as the product of three tumor dimensions. 
Graphs indicate mean±SD of experimental groups of 4-6 
treated animals. (A, C). Animals were sacrificed when tumor 
diameter exceeded 1.5 cm (B). *, p<0.05; **, p<0.01 compared 
to PBS treated group, by t-test. Log-rank test was used for 
p-vaule calculation of survival curves (p=0.24 compared to IL-2 
group). 
 
6.6.4. αPD-1 treatment does not improve the anti-tumor response in RAG2 deficient mice 
Another B7 family receptor, PD-1, which we showed to be upregulated in the tumor infiltrating NK cells, is 
often expressed by many tumor cell lines, including RMA-S and B16 (data not shown). For testing the 
effect of PD-1 blockade in RAG2 deficient mice, we used LL2 carcinoma model. LL2 cells do not express 
PD-1, so the mAb treatment affected only the host cells. Although some mice receiving αPD-1 exibited the 
signs of possible immune activation at the tumor site, no reproducible differences were obtained between 
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control and αPD-1 treated animals. Representative tumor growth curves from one of the three experiments 
performed are shown in Figure 6.38. 
 
Figure 6.38. αPD-1 as a single reagent treatment in RAG2 deficient 
mice. RAG2 deficient mice were injected with 106 LL2 cells 
subcutaneously. Animals were treated with i.p. injections of PBS or 
300 µg αPD-1 mAb every three days starting from day -1 respective to 
the tumor cell inoculation. Tumor size was measured every 2 days and 
expressed as the product of three tumor dimensions. Graph indicates 
mean±SD of experimental groups of 3-5 treated animals. 
 
 
 
 
 
6.6.5. αPD-1 treatment combined with αCTLA-4 and IL-2 reduces survival of tumor bearing 
RAG2 deficient mice 
So far, our results indicated that IL-2 treatment in combination with αCTLA-4 blockade slightly prolonged 
survival of mice injected with B16.B7-1 melanoma tumor cells. When inoculated with LL2 carcinoma, 
αPD-1 treated mice often exerted the signs of inflamation at the tumor site. We decided to combine the 
blockade of both receptors with IL-2 treatment in mice bearing LL2. LL2 cells expanded in vitro did 
expressed neither PD-1 nor CTLA-4, but expressed low levels B7-H1 and B7-1. In addition, Rae1, the 
ligand for activating receptor NKG2D, was also expressed by LL2 carcinoma cells (Figure 6.39). 
 
Figure 6.39. Phenotype of in vitro expanded LL2 carcinoma cells. Expression of B7-1, B7-H1 and Rae1 on LL2 
carcinoma cells was analyzed by flow cytometry. Representative histogram plots show isotype control (grey 
histogram) compared to staining with specific mAb (black line).  
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As shown in the Figure 6.39, none of the applied treatments (IL-2, IL-2+αCTLA-4 and 
IL-2+αCTLA-4+αPD-1) significantly changed tumor growth kinetics in LL2 inoculated RAG2 deficient mice. 
In the previous experiments, we observed that the treatments with αPD-1 or αCTLA-4 had no effect on LL2 
tumor progression (Figure 6.34 and 6.37). In contrast, animals treated with a combination of all three 
reagents, IL-2, αPD-1 and αCTLA-4, showed reduced survival (Figure 6.39 right). We again observed the 
signs of the immune system activation at the timor site of triple reagent treated mice. This might be 
a consequence of the strong induction of the innate immune system. This overamplification of the 
response could be responsible for the early death of treated animals. 
 
Figure 6.40. Combination therapy of αPD-1, αCTLA-4 and IL-2 in RAG2 deficient mice. RAG2 deficient mice were 
injected with 106 LL2 cells subcutaneously. Animals were treated with i.p. injections of PBS, 105 U of rhIL-2 for five 
consecutive days starting from day 0, 250 µg αCTLA-4 mAb and 300 µg of αPD-1 mAb every three days starting from 
day -1 respective to the tumor cell inoculation. Tumor size was measured every 2 days and expressed as the product 
of three tumor dimensions. Animals were sacrificed when tumor diameter exceeded 1.5 cm or when mice become 
moribund. Graph of tumor growth kinetics indicates mean±SD of experimental groups of 4-6 treated animals. Log-rank 
test was used for p-vaule calculation of survival curves. *, p=0.017 compared to IL-2+αCTLA-4 group 
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7. Discussion 
 
7.1. Tumor infiltrating cells 
NK cells were shown to infiltrate solid tumors in both mouse models and cancer patients [309]. A high 
number of NK cells found in the tumor tissue correlated with better prognosis in the cases of lung, gastric 
or colorectal cancer [274-275, 310-311]. However, the frequency of NK cells among total infiltrated 
immune cells is not high and therefore the ratio relative to tumor cells is very low. In addition, NK cells 
were often not located in the direct contact with tumor cells, but rather in the proximity of the blood vessels 
within the stroma [309]. Other immune cells within the tumor tissue are composed mainly of suppressive 
myeloid cells, immature DCs, macrophages polarized toward M2 phenotype or regulatory T cells [312]. 
Therefore, the number of real effectors, such as NK cells and CD8+ T cells, that could eliminate tumor 
cells, is very low compared to the cells that rather support tumor progression. In addition to the tumor cells, 
certain immune cells were shown to be lysed by NK cells. Immature DCs or myeloid derived suppressor 
cells (MDSCs) can be eliminated by activated NK cells [66, 313]. Thus, within tumor tissue NK cells are 
confronted to multiple target cells whose elimination can be beneficial for the efficient control of tumor 
progression. 
Solid tumors are characterized by specific microenvironment formed within tumor tissue. Apart from 
suppressive cells, which are either recruited or converted upon infiltration, several other factors do not 
favor effective immune response. Low pH and oxygen concentration were shown to hamper normal 
function of effector cells, including NK cells [314-315]. Various studies of anti-tumor immune responses, 
especially after the application of therapeutics, were conducted using peripheral blood mononuclear cells 
(PBMCs) sampled from the patients (Table 3.5). Although in many cases specific anti-tumor responses 
were detected in vitro, benefits for tumor control were often not observed. A possible explanation for the 
failure of in vivo responses included the absence of efficient tumor tissue infiltration and the presence of 
multiple immunosuppressive mechanism exerted by the tumor. First, in vitro studies are typically 
performed under optimal cell culture conditions (pH, O2, humidity, etc), which are not met in the tumor 
tissue. Second, actual effector-to-target ratios in tumors are usually much lower than those used in the 
culture. And third, the microenvironment of the solid tumor is shaped by the presence of cytokines 
released by both tumor and infiltrated immune cells, which can differentially influence the studied 
responses and are not produced in in vitro systems. In addition, cells from peripheral blood might not 
precisely correspond to their tumor infiltrating counterparts. Indeed, several studies that analyzed effector 
functions of cells isolated from tumor tissue showed that their responses were impaired. Unresponsive 
tumor specific T cells were isolated from malignant melanomas [316], which recovered functional 
competence upon ex vivo stimulation, indicating that they were inhibited in the tumor microenvironment 
and that the process was reversible. Functional incompetence of tumor infiltrating T cells (TITs) was found
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to directly correlate with the level of expression of the inhibitory B7 family receptor PD-1 [241]. A higher 
frequency of PD-1+ T cells was detected in melanoma lesions as compared to blood or healthy tissue of 
patients. In addition, PD-1+ TITs expressed another inhibitory B7 family receptor, CTLA-4. The possible 
mechanism underlying non-optimal T cell activation within the tumor tissue includes the alternation in the 
proximal TCR signaling machinery given by the decreased expression of CD3ζ or tyrosine kinases Lck 
and Fyn [317]. An aberrant activation of distal signaling molecules has been also reported: defects in the 
expression of NF-kB family proteins were correlated with the impairment in Th1 cytokine production and 
decreased CTL function [318]. Tumor infiltrating CD8+ T cells showed a defective conjugate formation with 
tumor cells ex vivo due to the defective expression and activation of adhesion molecules [319]. 
In summary, studies that analyzed the tumor microenvironment and phenotypical and functional properties 
of T cells from blood and tumor of tumor bearing mice and cancer patients revealed a functional 
impairment of cells infiltrated into the tumor tissue. Since the failure of the numerous clinical trials was 
correlated with the unresponsiveness of the effector cells in the tumor, it is of importance to analyze the 
phenotype and function of the immune cells infiltrating the tumor tissue and their possible contribution to 
the outcome of novel treatment strategies. 
 
7.2. Tumor infiltrating NK cells 
While treatment strategies targeting T cells as the main anti-tumor effectors must rely on tumor antigen 
specificity, NK cells are considered as non-specific cytotoxic effectors that should be capable or 
recognizing a broad range of transformed cells. Of importance, data obtained in mouse models indicated 
that the activation of T cell anti-tumor responses to effectively reduce the tumor burden required an intact 
NK cell compartment [13, 69, 266]. Several clinical observations provided information about NK cells in 
tumor patients with regard to their numbers, activation state and functionality. An association of defective 
NK cell activity and severe cancer progression was reported. Decreased NK cell responses were detected 
in patients with lung, breast, colon and liver cancer as well as in the cases of melanoma, chronic myeloid 
(CML) and acute myeloid (AML) leukemia [148, 276, 320-322]. In several mouse tumor models NK cell 
progression to the last maturation stage in bone marrow was blocked at high tumor load, leading to the 
accumulation of immature NK cells [323]. At the same time, NK cells from spleen of tumor bearing mice 
did not show defects in cytotoxicity, while IFNγ production was reduced in response to PMA/Ionomycin but 
not IL-12 stimulation. Recently, Brenner and colleagues showed that in the transgenic mouse model of 
spontaneously arising lymphoma effector functions of tumor infiltrating NK cells became progressively 
paralyzed with increasing tumor load [324].  
Due to the low NK cell numbers found within the tumor tissue and their functional impairment, studies 
aimed at the enhancement of anti-tumor responses of endogenous and/or adoptively transferred NK cells. 
As discussed in the section 3.2.5.2, those approaches included the facilitation of NK cell migration to the 
tumor site, their proliferation, cytotoxicity and cytokine production. Independently whether endogenous or 
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adoptively transferred NK cells are expected to directly or indirectly mediate tumor rejection, the influence 
of the tumor microenvironment on their activity must be taken into consideration in order to design the 
efficient strategy of their use in anti-tumor therapy.  
 
7.2.1. Subset composition of tumor infiltrating NK cells 
Our study aimed at the comprehensive analysis of the phenotype of tumor infiltrating NK cells including the 
expression of surface markers used to define their maturation stage, subset composition, activation status 
and functional competence. Importantly, we analyzed NK cells that infiltrated the tumor tissue without any 
exogenous manipulation. Our findings revealed that subcutaneous solid tumors of different origin are 
preferentially infiltrated with the CD27high NK cell subset (Figure 6.1). CD27high tumor infiltrating NK cells 
were composed of both the immature CD11blow and the more mature CD11bhigh population. CD27 
expression on TINs directly correlated with the expression of c-Kit and CD127 (IL-7Rα), which are defined 
as markers of immature NK cells, and inversely correlated with the expression of markers for mature NK 
cells, KLRG1 and CD43. Fully mature CD27lowCD11bhigh NK cells were present in the tumor at a lower 
frequency compared to blood, where they represented the dominant subset. When NK cell subsets 
defined by CD27 expression were analyzed for their functional properties, it was found that fully mature 
CD27high NK cells were more competent to proliferate, lyse target cells, produce IFNγ and migrate toward 
certain chemokines [114]. In this respect, infiltration of tumor with CD27high NK cells can be seen as 
beneficial for successful anti-tumor responses. 
Several mechanisms might be responsible for the prevalence of CD27high NK cell subset in the tumor. 
First, it is possible that all subpopulations equally infiltrate the tumor tissue where CD27low cells 
subsequently upregulate CD27. CD27 is a receptor of the TNF family shown to costimulate NK cells [68]. 
It is responsible for the potent response to tumor cells that express its ligand CD70 [69]. Since in our tumor 
model, tumor cells do not express CD70, CD27 expression by NK cells might be relevant for the 
interaction with other CD70 expressing cells. For example, CD70 expression by DCs contributes to T cell 
activation [67]. Since the NK/DC interaction is known to result in their reciprocal activation, engagement of 
CD70 on DC by the CD27 receptor on NK cells might contribute to this effect. Alternatively to the CD27 
upregulation on CD27low cells, CD27high NK cells could be the subset preferentially recruited to the tumor. 
Co-expression of the maturation markers that correlate with CD27, as well as the previously reported 
enhanced migration abilities of CD27high subset compared to CD27low counterparts, favors this hypothesis. 
As an example, CD27high NK cells express chemokine receptor CXCR3, which is downregulated in the 
tumor [280]. Using gene deficient NK cells, authors showed that the migration of NK cells to the 
subcutaneous lymphoma in vivo, depended on CXCR3. Thus, CXCR3 downregulation on CD27high NK cell 
subset in the tumor might be the consequence of its engagement. 
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7.2.2. Relation of tumor infiltrating NK cells to IKDCs 
Interferon producing killer dendritic cells (IKDCs) were initially defined as a cell population with the 
properties of both NK and DCs [131-132]. They were described to produce both IFNγ and exert cytotoxic 
responses, but unlike classical NK cells, they were capable of producing IL-12. Another characteristic 
considered to be the main feature of DCs, antigen presentation, was also performed by IKDCs. 
The presence of IKDCs within the tumor tissue might be beneficial, since they were shown to mediate 
potent anti-tumor responses [139]. Phenotypically, IKDCs were defined as a CD11c+B220+NK1.1+ cell 
population that express MHC II upon activation. However, it is still controversial whether IKDCs have 
independent origin and biological futures from those of DCs and NK cells. IKDCs express NKp46, which is 
exclusively expressed by NK cells [325], as well as other NK cell receptors including NKG2D and Ly49 
receptors [134-135]. Importantly, they depend on IL-15 and common γc chain for their development and 
homeostasis. Since there is no specific marker that can precisely separate them from the other cell types, 
it is not excluded that IKDCs could be composed of several different cell populations. Their high similarity 
to NK cells raised the hypothesis that IKDCs represent activated NK cells, which acquired APC functions. 
Indeed, detailed analysis of NK1.1+ cells within CD11c+B220+ population in the studies of Vosshenrich 
et al. [135], revealed that both in vitro and in vivo activation of NK cells led to the upregulation of CD11c, 
B220, MHC II and costimulatory molecules, giving rise to IKDC-like cells with the ability to produce IFNγ 
and present antigens to T cells. In addition, among NK cells, defined as CD19-CD3-NK1.1+, no bimodal 
expression of CD11c and B220 could be observed. B220low NK cells could produce similar amounts of 
IFNγ as B220high NK cells and could upregulate B220 upon stimulation induced proliferation. 
Our analysis of tumor infiltrating NK cells, which we defined as CD3-NK1.1+, revealed an unchanged 
expression of CD11c compared to NK cells found in blood of tumor bearing animals (Figure 6.2). 
Expression of B220 was enhanced and, unlike blood NK cells, TINs were MHC II+. In addition, NK cells 
within the tumor expressed costimulatory molecules B7-1 and B7-2 albeit at the low levels. Thus, similar to 
the cell population defined as IKDCs, the subpopulation of the tumor infiltrating NK cells could be 
considered as NK1.1+CD11c+B220highMHC II+. However, whether those cells represent IKDCs cannot be 
concluded, since IKDCs are primarily defined by their dual functional property of IFNγ/IL-12 production 
and performance of cytotoxicity and antigen presentation. Although MHC II expression indicated the ability 
for Ag presentation and high intracellular levels of perforin and granzyme B that we detected in TINs 
(Figure 6.3), cytotoxic potential, further functional studies are necessary to characterize the IKDC nature of 
this cell population.  
Several studies reported that NK cells were able to present antigens and prime both CD4+ and CD8+ T cell 
responses [138]. NK cell potential for T cell priming was acquired upon recognition and elimination of 
sensitive targets. Similar to these observations, IKDCs can perform their APC functions only after the 
encounter of tumor or virus infected cells [137]. Since perforin deficient IKDCs cannot prime T cell 
responses, the elimination of the target is a prerequisite for antigen presentation. Triggering of specific 
activation pathways in NK cells represents the additional mechanism that could upregulate MHC II and 
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costimulatory molecules allowing the subsequent T cell activation by NK cells [138]. Cross-linking of 
NKp30, NKp46 and CD16, but not NKG2D, in human NK cells induced an APC-like phenotype. Thus, it is 
possible that a subpopulation of tumor infiltrating NK cells, activated by tumor cell recognition, or/and by 
other mechanisms within the tumor, acquired phenotypical and functional properties of APCs or IKDCs. 
In support for this hypothesis is an observation of Blasius and colleagues, who observed that 
CD11c+B220+ NK cells were enriched within the CD27high NK subset [134], which were also described as 
more efficient effectors than CD27low NK cells [120]. The enrichment of the CD27high NK cells in the tumor 
compared to blood might explain their higher B220 expression, while the upregulation of MHC II and 
costimulatory molecules might indicate that they are activated within the tumor tissue. 
 
7.2.3. Transcription profile of tumor infiltrating NK cells 
In addition to the phenotypical analysis of the markers that were previously described as the indicators of 
NK cell maturation and activation status, we took advantage of a more global approach and performed 
gene expression profiling of blood and tumor infiltrating NK cells (Figure 6.5). Some of the molecules that 
we have already shown to be expressed by CD27high NK cells in the tumor elevated compared to blood, 
such as c-Kit and CD127 (Figure 6.1), were also found to be differentially regulated at the mRNA level. 
This correlation indicated the high reliability of our microarray experimental data. The most striking 
observation of the experiment was that tumor infiltrating NK cells showed pronounced differences when 
compared with blood NK cells of tumor bearing animals (Figure 6.6). The differentially expressed genes 
between blood and tumor infiltrating NK cells comprised several groups functionally relevant for anti-tumor 
responses, as discussed in the section 6.2.1. Briefly, four main features were noticed. First, we observed 
that NK cells in tumor were activated, which was supported by the upregulation of cytokine receptors, 
several chemokines and chemokine receptors, some components of the cytotoxic pathway or regulatory 
molecules that drive cell division. Second, NK cells displayed responses to unfavorable environment within 
the tumor tissue. The examples are prevention of cell cycle progression or the metabolic changes as 
a consequence of hypoxia, which are driven primarily by the upregulation of transcription factor HIF-1α 
and its target genes [290]. The third group of the observed changes might be contributed to the direct 
actions of tumor microenvironment towards the downregulation of NK cell function. Several candidate 
genes from this group were chosen for validation and their differential regulation was confirmed to persist 
at the protein level too. Those include NK cell activating receptors and inhibitory molecules of the 
B7 protein family. Finally, NK cells exerted some features that might support rather than hamper tumor 
progression. Upregulation of VEGF, PDGF and angiopoietin are some of the examples of molecules that 
facilitate tumor angiogenesis. In addition, chemokines produced by NK cells might attract anti-tumor 
effectors but also suppressive cell types. Similarly, the enzymes that modulate extracellular matrix can 
support NK cell migration but also facilitate metastases formation by tumor cells. Thus, many functions of 
activated NK cells might be used by tumor and converted for the purposes of its own progression. 
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7.2.4. Activating receptors expressed by NK cells in the tumor 
NK cells isolated from the tumor tissue negatively regulated expression of several activating NK cell 
receptors at both transcript and protein level. We confirmed that the surface expression of NKp46, 2B4 
and CD48 was reduced on TINs compared to blood NK cells in RMA-S tumor bearing mice (Figure 6.9). 
Although we observed a constant tendency, the decrease in surface expression of NK1.1 was not always 
significant. Of importance, NKp46 and 2B4 can directly recognize RMA-S tumor cells. NKp46 recognizes 
viral hemaglutinins as well as unknown ligand(s) on several tumor cell lines including RMA-S [291]. 
In addition to MHC I deficiency that removes the inhibition and increases RMA-S sensitivity to NK cell 
lysis, the positive signal that triggers the cytotoxic pathway is deliverd through NKp46. Therefore, the 
reduction of NKp46 might be one of the mechanisms used by the tumor to evade the direct recognition and 
elimination by NK cells. It was already shown that tumors, which express ligands for the activating receptor 
NKG2D, use a similar strategy of evasion. Proteolytic shedding of MICA from the cell surface was reported 
to cause a systemic downregulation of NKG2D surface expression, thereby impairing the lysis of tumor 
cells [326]. In our model, expression of NKG2D was unchanged, indicating that the tumor could selectively 
target the receptor responsible for its recognition. The important difference between these two strategies is 
that the NKG2D expression was inhibited at the protein level, while NKp46 was regulated at the 
transcription level. 
2B4 can mediate both activating and inhibitory functions [297]. It recognizes CD48, which is widely 
expressed on hematopoetic cells. RMA-S tumor cells express high levels of CD48 and can be directly 
recognized by 2B4 expressed on NK cells. 2B4 plays a very important role in the cross-talk of NK cells 
with other immune cells. Homotypic NK/NK interaction was shown as essential for the generation of NK 
cell effector function [298], while heterotypic NK/T cell interaction supports T cell activation [299]. 
Therefore, downregulation of 2B4 might impact anti-tumor response on multiple levels, including direct 
tumor recognition and support of NK and T cell effector responses. 
NKp46 and NK1.1 are coupled to the adaptor molecules CD3ζ and FcεRIγ, that contain ITAM motifs in 
their cytoplasmic tails [36, 327]. Upon receptor engagement, tyrosine residues of ITAMs are 
phosphorylated and Syk and ZAP70 kinases are recruited. Dowstream of Syk/ZAP70, different signaling 
branches are activated including SLP76/LAT, PI3K, PLCγ, MAPK and release of Ca2+ (Figure 7.1). 
We observed that several signaling molecules involved in the depicted pathways were differentially 
expressed by tumor infiltrating NK cells, including most upstream kinases that phosphorylate ITAM motifs. 
This is similar to the previously observed modulation of proximal TCR signaling components in tumor 
infiltrating T cells [317]. In addition to the downregulation of receptors themselves, the downregulation of 
their signaling components can further contribute to the impairment of NK cell trigerring through ITAM 
coupled receptors. Of note, members of the MAPK pathway were rather upregulated in tumor infiltrating 
NK cells, which can be of importance for other receptors that utilize this signaling branch. One example is 
CD28, which did not appear to be regulated at the transcript level, but was upregulated at the protein level 
by TINs compared to blood NK cells.  
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Figure 7.1. The signaling pathway downstream of the activating receptor NKp46 (obtained from KEGG database). 
NKp46 receptor is coupled to the ITAM bearing adaptor molecules CD3ζ and FcεRIγ, which are phosphorylated by 
Src kinases Lck and/or Fyn upon receptor engagement. Syk and ZAP70 are recruited to the phosphorylated ITAMs 
and initiate further signaling events. Molecules represented by blue boxes were negatively regulated at the transcript 
level in tumor infiltrating NK cells, while several members of the MAPK pathway were upregulated (red box).  
 
7.2.5. Inhibitory receptors expressed by NK cells in tumor 
The downregulation of the activating NK cell receptors in TINs was accompanied by an upregulation of 
inhibitory receptors. The main group of inhibitory receptors of NK cells recognize different MHC I 
molecules. In mice, they belong to the C-type lectin-like family of Ly49 receptors [328]. The BL6 mouse 
strain expresses several Ly49 members – Ly49A, Ly49C, Ly49D, Ly49G2, Ly49H and Ly49I. Ly49D and 
Ly49H belong to the subgroup of activating receptors. Only Ly49C and Ly49I bind to the H-2b MHC I 
alleles and their cognate ligands are expressed by the BL6 strain. According to the results of our genetic 
expression profiling, Ly49A was downregulated in TINs and other Ly49 receptor family members were not 
regulated at the transcript level (Table 6.2). In contrast, TINs displayed enhanced surface protein levels of 
Ly49A when compared to the blood NK cells of tumor bearing animals (Figure 6.10). Ly49A mediates NK 
cell inhibition by the recruitment of protein and lipid phosphatases that dephosphorylate proximal signaling 
components downstream of activating receptors [328]. However, due to the absence of the cognate ligand, 
the functional significance of its increased expression in the tumor is not clear.  
When we analyzed the cell surface expression of other Ly49 members, we observed that Ly49C/I or H 
(recognized by the same mAb) as well as Ly49D and Ly49G2 were sensitive to the enzymatic digestion 
with hyaluronidase and collagenase when expressed by blood or spleen, but not tumor infiltrating NK cells 
(Figure 6.10). We assume that those receptors could be protected from digestion by mechanisms that are 
functional in the tumor but not in other organs. It would be important to investigate whether the expression 
of Ly49 receptors is modified in a similar way in other conditions, such as viral and bacterial infections. 
Regulation of Ly49 receptor expression is mainly studied in respect to the acquisition of a specific Ly49 
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repertoire during development, which is regulated at the transcription level [329]. However, little is known 
about the regulation of the level of surface expression during the course of NK cell effector responses, 
including both transcriptional and post-transcriptional regulation. Cell intrinsic mechanisms could exist to 
preserve Ly49 receptor expression in the environment rich in the activity of ECM degrading enzymes, such 
as the tumor tissue. Cell surface expression of the H-2b specific inhibitory molecules Ly49C/I might raise 
the threshold for NK cell activation and allow the protection of cells with low expression of MHC I on the 
cell surface. This mechanism would possibly lead to the decreased elimination of tumor cells with reduced 
MHC I expression or MHC Ilow iDCs that accumulate in tumor beds and cause aberrant T cell activation.  
 
7.2.6. Expression of B7 family members in tumor infiltrating NK cells 
B7 family is a group of molecules that regulate T cell responses at multiple levels [59]. The interactions 
established between B7 family members determine the threshold for the activation through TCR, drive 
effector responses or mediate their shutdown. Interactions between family members are established at the 
T/APC interface and control priming of naïve T cells, or between T cells and peripheral tissues controlling 
their effector functions. Naïve T cell activation requires a minimum of two signals – triggering of TCR and 
costimulation delivered by the B7 family receptor, CD28. NK cell activation is considered similar as they 
require either the simultaneous absence of inhibition (e.g. low MHC I expression) and presence of 
stimulation (e.g. through NKp46) or stimulation through activating and cytokine receptors (e.g. NKG2D and 
IL-15R) [330]. There are also examples of costimulation of two activating receptors (e.g. NK1.1 and 
NKG2D) [331]. When T cells get activated, a number of molecules are engaged to control the level of 
activation including several B7 family members as ICOS, CTLA-4 or PD-1. So far, it is not known if such 
mechanisms, which regulate the activity once the responses are triggered, exist in NK cells. Several 
B7 family members are also expressed by NK cells, but their function is poorly investigated. It was 
previously shown that activated, but not resting NK cells express activating B7 receptor ICOS, which 
mediated the lysis of ICOS-L expressing target cells [72]. 
By analysis of transcript profiles of blood and tumor infiltrating NK cells we observed an upregulation of 
multiple members of the B7 family in TINs (Figure 6.11). Flow cytometric analysis confirmed the 
expression of CD28, PD-1, B7-H1, PD-L2, ICOS-L, B7-1 and B7-2 on the surface and CTLA-4 
intracellularly (Figure 6.12). Of importance, CD28, PD-1 and CTLA-4 were expressed only in tumor 
infiltrating but not in blood NK cells of either naïve or tumor bearing mice. The expression of B7 molecules 
by TINs depended on the tumor type (Figure 6.13). TINs found in lymphomas were preferentially 
CD28highPD-1high, while NK cells in melanoma and carcinoma were CD28low/-PD-1-B7-H1high. Importantly, in 
all tested tumor models NK cells within the tumor expressed CTLA-4. Differential expression of 
B7 molecules was observed only in the solid tumors that exceed the size of 1cm2 (data not shown). 
NK cells from lung and peritoneum of mice bearing lung metastases or tumor cells growing in the 
peritoneum did not express PD-1 and CTLA-4. In solid tumors of the given size, features that include 
Ana Stojanovic    Discussion 
‐ 130 ‐ 
 
biochemical conditions, such as hypoxia and low pH, presence of suppressive cells and cytokine 
combinations secreted by both tumor and other infiltrating cells could contribute to the induction of specific 
TIN phenotype. In line with this hypothesis is the fact that the induction of PD-1 was observed only in the 
tumor and was unsuccessful in vitro, even when the combinations of multiple stimuli were used 
(Table 6.3). In addition, systemic application of IL-18 induced CTLA-4 expression by NK cells only in the 
tumor, but not in blood or spleen (Figure 6.35A). This indicates that additional factor/s in the tumor 
synergize with IL-18 to mediate CTLA-4 induction.  
It appears that distinct pathways regulate PD-1 induction in different cell types. In T cells, PD-1 is induced 
upon the TCR triggering or cytokine stimulation through the common γc chain [332]. Simultaneous 
triggering of BCR with αCD40 induces PD-1 expression on B cells [221]. Macrophages display elevated 
PD-1 expression in mouse models and patients with sepsis [333], while PD-1 can be induced on DCs by 
Listeria infection or TLR2, TLR3, TLR4 and NOD engagement in vitro [334]. Recently, Brauner and 
colleagues showed that NK cells infiltrating the diabetic pancreas in NOD mice expressed PD-1 [335]. 
Furthermore, pancreatic NK cells were hyporesponsive compared to spleen NK cells and could be 
rescued by overnight culture in IL-15 and IL-18. PD-1+ T cells from tumor or blood of chronically infected 
patients and mice, macrophages from humans and mice with sepsis and pancreatic NK cells from diabetic 
mice exerted hyporesponsiveness that correlated with PD-1 expression. We showed that NK cells in the 
tumor expressed PD-1 (Figure 6.12). The expression was detected on all NK cells and increased with the 
tumor size (data not shown). To investigate whether PD-1 might be a marker for nonfunctional tumor 
infiltrating NK cells further functional analyses have to be performed. Due to the low cell numbers that can 
be obtained from the tumor tissue, we could not conduct experiments that would test this hypothesis. 
We, however, observed that the culture in IL-2 or IL-15 after isolation from the tumor tissue results in 
downregulation of PD-1 (data not shown), indicating reversibility of the phenotype acquired in the tumor.  
Expression of the inhibitory B7 family receptor CTLA-4 was highly increased at the transcript level in TINs 
compared to blood NK cells in mice with tumors (Figure 6.11). The expression at the mRNA level 
correlated with the protein expression (Figure 6.12). Intracellular staining revealed that CTLA-4 was 
expressed only in tumor but not in blood and spleen of tumor bearing animals. In contrast to PD-1, CTLA-4 
was inducible in vitro by NK cell expansion in IL-2 (Figure 6.17). Intracellular content of the protein could 
be further increased by stimulation with IL-12 and IL-18 (Figure 6.19). While short-term incubation with 
fluorescently labeled Ab failed to detect any CTLA-4 on the cell surface, prolonged incubation revealed 
that a certain amount of CTLA-4 reaches the NK cell surface (Figure 6.19). The surface expression is 
positively regulated by the stimulation with IL-12, IL-18 and αNK1.1 or αNKp46 (Figure 6.22). 
Of importance, all factors that we found to regulate CTLA-4 expression in vitro, can influence its 
expression in the tumor tissue as well. Still unidentified NKp46 ligand is expressed by RMA-S cells [291]. 
IL-18 and IL-12 are secreted by macrophages and dendritic cells that also infiltrate the tumor [336]. In fact, 
CD11b+ cells, among them macrophages, comprise the main pool of hematopietic cells infiltrating the 
tumor. NK cell ability to respond to various signals from the microenvironment is beneficial for maximizing 
Ana Stojanovic    Discussion 
‐ 131 ‐ 
 
the responses against infected or transformed cells. At the same time, the induction of negative regulators, 
such as CTLA-4, may serve as a mechanism to keep NK cell responses under control.  
 
7.3. Regulation of NK cell effector functions by B7 family members 
We showed that TINs expressed the B7 family receptors PD-1, CD28, CTLA-4 and B7-H1 and aimed at 
the analysis of their function in the context of NK cell responses. In vitro expanded NK cells in 
the presence of rhIL-2 expressed CD28, CTLA-4 and B7-H1 (Figure 6.17). Since all three molecules 
recognize the same ligand, B7-1, we determined their role in B7-1 induced responses of NK cells. 
Stimulation of in vitro expanded NK cells with the B7-1 IgG fusion protein induced NK cell proliferation and 
IFNγ production (Figure 6.24). By using NK cells derived from gene deficient mice, we showed that IFNγ 
production was triggered through CD28 and it was negatively regulated by CTLA-4 and B7-H1 (Figure 
6.30-31). In T cells, CD28 engagement leads to the phosphorylation of the tyrosine residues in its 
cytoplasmic tail, which drives the recruitment of several signaling molecules [171]. CD28 dependent 
production of IL-2 and IFNγ in T cells is mediated via PI3K and Grb2 pathways, which are shown to 
associate with CD28. A similar activation pathway in NK cells is used by the NKG2D receptor that is 
coupled to the DAP10 adaptor molecule [303]. DAP10 and CD28 share the YMNM motif in their 
cytoplasmic domain known to recruit PI3K and Grb2. Therefore, CD28 on NK cells might use a similar 
signaling pathway described to operate in T cells leading to IFNγ production. Indeed, PI3K was already 
described as a key player in NK cell effector function including IFNγ production. Stimulation of activating 
NK receptors in the absence of the p110δ, PI3K catalytic subunit, results in a decreased IFNγ release 
[337]. Similarly, ICOS induced IFNγ is reduced in the presence of a PI3K inhibitor [72]. 
As already described in the section 3.3.2.1, several mechanisms are used by CTLA-4 to inhibit T cell 
responses (Figure 3.13) [196]. Among cell intrinsic mechanisms, delivering of negative signal and 
competition for the ligands with CD28 have been reported to contribute to CTLA-4 mediated inhibition. 
Both mechanisms might underlay CTLA-4 mediated inhibition of NK cells. Using CD28 deficient NK cells, 
we observed that B7-1 stimulation of NK cells that lead to IFNγ production, entirely depended on positive 
signals delivered by CD28 (Figure 6.30). The response is negatively regulated by CTLA-4 and B7-H1 
indicating the direct inhibition of the CD28 mediated response (Figure 6.31). Both CTLA-4 and B7-H1 have 
a higher affinity for B7-1 compared to CD28 [304] and could efficiently sequester the ligand. In addition, 
CTLA-4 can recruit phosphatases that interfere with proximal CD28 signaling. Binding of PI3K and CD3ζ 
to the CTLA-4 cytoplasmic tail was also reported [195]. While these interactions might promote some of 
the positive effects mediated by CTLA-4, as increased survival, they can also sequester signaling 
molecules from other activating receptors. PI3K is recruited by CD28 and NKG2D, and CD3ζ by NK1.1 
and NKp46, which are all potent inducers of IFNγ. Therefore, it would be of interest to investigate whether 
CTLA-4 co-engagement with the given receptors might influence their responses. We also showed that 
two receptors, namely CD28 and NK1.1, can synergize in the induction of IFNγ when the level of CD28 
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stimulation is low (Figure 6.30). In these situations, cooperation of two receptors might be crucial to induce 
response and, at the same time, more sensitive to inhibition. Therefore, the levels of CTLA-4 mediated 
suppression that we measured in vitro might be even more pronounced in in vivo conditions when the low 
levels of stimuli are provided by the microenvironment. 
Among the cell extrinsic mechanisms underlying CTLA-4 inhibition of T cells, TGF-β mediated suppression 
was described. In activated T cells, simultaneous cross-linking of αCD3 and CTLA-4 leads to the 
production of TGF-β [338]. Importantly, we found increased transcript levels of TGF-β in TINs compared to 
blood NK cells in tumor bearing animals. Future investigation will be conducted to investigate whether 
CTLA-4 mediated this effect. TGF-β was shown to impede NK cell dependent IFNγ production [287]. Thus, 
it is possible that the induction of TGFβ represents additional mechanisms used by CTLA-4 to suppress 
NK cell IFNγ production.  
B7-H1 has recently been reported to bind to B7-1 and inhibit T cell proliferation, cytokine production and 
expression of activation markers induced by CD3 cross-linking [304]. It is unknown how B7-H1 delivers the 
inhibitory signal. The intracellular domain of B7-H1 is short, but highly conserved in all so far investigated 
species [225], which indicates that it might be preserved due to the function it mediates. The evidence for 
B7-H1 signaling came from the studies of Kuipres et al, who showed that the incubation of DCs with 
soluble PD-1 IgG fusion protein led to the IL-10 and IDO induction [339]. Further investigation is necessary 
to show how B7-H1 inhibits CD28 driven IFNγ production and whether IL-10 and IDO might be induced 
upon its engagement. In the later case, a negative regulation mediated by B7-H1 can be indirect and can 
also affect other cells within the tumor tissue. 
While all three molecules, CD28, CTLA-4 and B7-H1, regulated B7-1 driven IFNγ production, none of 
them influenced the cytotoxic responses against B7-1 expressing target cells (Figure 6.32). Similar to our 
studies, proliferation and IFNγ production induced by B7-1+ tumor cell lines has been contributed to CD28 
in studies of Kelly et al. [61]. However, the enhanced lysis of B7-1 expressing targets observed by 
Chambers and colleagues was not affected by CD28 and CTLA-4 deficiency of NK cell effectors [58]. The 
same group showed that the efficient elimination of B7-2 positive tumor cells both in vivo and in vitro did 
not depend on CD28 [56]. Our data revealed that the third receptor that recognizes B7-1, B7-H1, also did 
not mediate enhanced cytolysis. Of note, it is possible that intrinsic differences of B7-1 transduced cells 
might lead to their higher sensitivity to NK cell lysis compared to the control cells. Therefore, it is of 
importance to show that the expression of B7-1 is responsible for the better recognition of transduced 
cells, by using the B7-1 blockade or tet-inducible system. In the case of positive results, the existence of 
the fourth receptor for B7-1 can be postulated. However, it is also possible that the engagement of B7-1 by 
any of the so far known receptors induces reverse signaling already shown to take place in DCs [183], 
which might lead to cell death by unknown mechanisms. The use of NK cells deficient in all three known 
B7-1 receptors would be required to test presented hypotheses.  
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7.4. B7 family members on NK cells - possible implications for the anti-tumor responses 
B7 family members were already exploited as the potential biomarkers for the activation status of 
anti-tumor effector cells and as the potential targets for anti-tumor immune therapy [269]. PD-1 is 
considered as a marker for functionally exhausted unresponsive effector T cells found in chronic viral 
infection of mice and human as well as in melanoma lesions of cancer patients [211, 241]. Disruption of 
PD-1:B7-H1 interaction with mAbs was shown to restore T cell responsiveness and mediate tumor 
rejection in the mouse tumor models [234, 243-244, 340]. Both αPD-1 and αB7-H1 mAbs target multiple 
cells (T effector cell, Treg, macrophages, tumor cells, etc) and multiple interactions (PD-1:B7-H1, PD-
1:PD-L2, B7-H1:B7-1). Therefore, they can have diverse effects. As an example, in a sepsis model, when 
compared to WT, PD-1 deficient macrophages exert higher phagocytic capacity and produce higher levels 
of proinflammatory cytokines including IFNγ and IL-12 [333]. On the contrary, Listeria infection induces 
PD-1 expression on DCs, which reduces their ability to produce IL-12 and TNFα [334]. We showed that 
B7-H1 negatively regulated IFNγ production in NK cells. Thus, application of αPD-1 or αB7-H1 mAb could 
affect NK cell responses as well. Therefore, NK cells can contribute to the better outcome of αB7-H1 mAb 
treatment by increased IFNγ production.  
Several studies revealed that αCTLA-4 treatment of tumor bearing mice had a potential to generate or 
enhance anti-tumor T cell responses leading to tumor regression [264, 341-342]. However, the efficacy of 
αCTLA-4 monotherapy strongly depended on immunogenicity of the tumor and the stage of the tumor 
growth when the treatment was applied. In the majority of the studies, CTLA-4 blockade was beneficial 
when combined with other regimens, such as peptide immunization [343], tumor cell vaccine [344] or 
peptide vaccine combined with DC stimulation via αCD40 [345]. So far, the expression of CTLA-4 by NK 
cells was not reported and the application of αCTLA-4 mAb as a component of an anti-tumor therapy was 
assumed to affect only the T cell compartment. The study of Peggs and colleagues, who combined the 
receptor blockade with GM-CSF producing tumor vaccine, showed that both the T effector and the Treg 
compartment responded to αCTLA-4 treatment to achieve tumor growth control [346]. Of importance, the 
efficacy of the treatment completely depended on NK cells, since their depletion abrogated the positive 
effects of the vaccine [266]. The authors speculated that NK cells were required to kill tumor cells at early 
time points of tumor progression providing the antigens that could be uptaken and processed by DCs that 
subsequently prime T cell responses. Another evidence of possible involvement of NK cells in the 
αCTLA-4 mediated tumor regression came from the studies conducted with B7-1 transduced prostate 
cancer cell line [342]. Although expressing no or low MHC I on the surface, those tumor cells were 
efficiently rejected upon CTLA-4 blockade in vivo. We demonstrated that NK cells expressed CTLA-4 in 
the tumor tissue and could be the additional direct targets of αCTLA-4 treatment. By use of CTLA-4 
deficient NK cells, we showed that in the absence of CTLA-4, NK cells produced more IFNγ when 
stimulated with the B7-1 IgG fusion protein (Figure 6.31) or B7-1 expressing tumor cells (data not shown). 
In addition, B7-1 induced NK cell proliferation (Figure 6.24), which was previously shown to depend on 
CD28 [61]. Therefore, the functional blockade of CTLA-4 on NK cells is expected to result in their 
enhanced proliferation and IFNγ production. 
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We observed that repeatedly given αCTLA-4 mAb did not influence tumor progression in RAG2 deficient 
mice inoculated subcutaneously with different tumor cell lines. These data are in agreement with 
a previous study of van Elsas et al. showing that αCTLA-4 monotherapy did not affect the progression of 
poor immunogenic B16 melanoma in WT animals [266]. We also observed no beneficial effects when the 
combination therapy of IL-18 and αCTLA-4 was administrated to the RAG2 deficient RMA-S tumor bearing 
mice, although IL-18 was shown to be a potent anti-tumor agent mediating its effect via NK cells [347]. 
The reason for non-effectiveness of the treatment might be explained by the observations of the previous 
reports showing that IL-18 potentiated NK cell anti-tumor responses against FasL but not perforin sensitive 
tumors [92, 102]. Therefore, we cannot exclude the possibility that IL-18/αCTLA-4 therapy might be 
successful in different tumor models. We showed that IL-2 treatment in vitro positively regulated CTLA-4 
expression (Figure 6.19). Therefore, simultaneous CTLA-4 blockade with IL-2 application might represent 
the desired strategy when NK cell responses are to be harnessed against tumor. When we combined 
αCTLA-4 treatment with IL-2 in the B7-1 expressing melanoma model, we observed a modest but 
significant delay in the tumor growth, which also resulted in the prolonged survival of treated mice. IL-2 
can have multiple effects on NK cell anti-tumor responses including better infiltration of the tumor and 
enhanced proliferation and cytotoxicity. Since we administrated IL-2 during the first five days of tumor 
progression, we cannot exclude that repeated treatment or higher dosage would induce more potent 
responses to tumor. In addition, tumors other than melanoma might be more sensitive to the treatment.  
We showed that the main effect of CTLA-4 in NK cells was the regulation of IFNγ production, while 
cytotoxic responses against B7-1 transduced tumor cells were not affected by the receptor. These 
observations implicate that CTLA-4 blockade in vivo might not affect the direct lysis of B7-1+ target cells. 
On the other hand, multiple cells expressing B7-1/2 in the tumor might trigger the IFNγ production by NK 
cells. Since downregulation of B7-1/2 is one of the mechanisms used by tumors to evade T cell responses, 
they are rarely expressed by tumor cells. However, myeloid cells that represent the main population 
infiltrating the tumor, usually express the ligands. Importantly, IFNγ production is the most common result 
of the direct, cell contact dependent, or the indirect, cytokine mediated, activation of NK cells by myeloid 
cells, namely DCs and macrophages. Owing to the very important role of IFNγ to bridge innate and 
adaptive immune responses that finally results in the efficient activation of T cells, suppression of its 
production during an ongoing anti-tumor response is not desirable. NK cells are seen as the important 
cytotoxic effectors that lyse tumor cells at early time points and provide antigens for DCs to initiate T cell 
responses [348]. However, recognition of target cells and the interaction with DCs also induce IFNγ 
release that is necessary for efficient T cell priming. Therefore, increased IFNγ production provided by NK 
cells during an ongoing anti-tumor response is essential for an efficient T cell mediated tumor control 
[349]. Our in vitro data indicate that the induced expression of CTLA-4 on NK cells in all solid tumor tested 
and elevated B7-H1 expression detected in melanoma and carcinoma, might suppress B7-1 induced NK 
cell IFNγ production. Expression of CD28 in TINs further supports the hypothesis that IFNγ might be 
induced via the interaction with B7-1 expressing cells. In RAG2 deficient mice that we used for testing the 
efficiency of CTLA-4 blockade in NK cell mediated anti-tumor responses, only a modest improvement of 
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tumor growth control was seen with IL-2/αCTLA-4 combination. The beneficial effects might be 
a consequence of higher numbers of NK cells in the tumor and/or their higher cytotoxic capacity due to the 
IL-2 mediated activation. Indeed, a significant reduction in tumor size was achieved by IL-2 single 
treatment at the very late stages of tumor progression. Additional CTLA-4 blockade might further increase 
IFNγ release, which might act on several different aspects. IFNγ was shown to increase tumoricidal 
activity of various immune cells including innate effectors as macrophages and neutrophils [94]. It can 
directly act on the tumor cells by promoting anti-proliferative and anti-apoptotic effects or on tumor 
vasculature by preventing angiogenesis [350-351]. Some of those actions might be involved in tumor 
growth delay by the combined IL-2/αCTLA-4 treatment. However, the crucial effectors whose anti-tumor 
action is to be directly or indirectly potentiated by NK cell derived IFNγ, which are T cells, were missing in 
our system. Therefore, for the final prove that CTLA-4 blockade on NK cells plays the important role in the 
enhancement of anti-tumor responses, mice with targeted deficiency of CTLA-4 in NK cells should be 
created and analyzed. 
So far, we tested the blockade of the inhibitory receptor CTLA-4 in the combination with agents that 
directly activate NK cells, namely IL-2 and IL-18. In addition, NK cells can be also activated by myeloid 
cells, macrophages and DCs, in a cell contact dependent manner or via various cytokines [66]. Therefore, 
agents that induce DC or macrophage activation can be also considered as a choice for priming NK cell 
responses. Indeed, CpG oligonucleotides, which bind TLR4, are proven to be potent activators of myeloid 
cells and initiators of events that prime potent anti-tumor responses [352]. Our preliminary results 
indicated that CpG could induce a significant tumor growth delay in T and B cell deficient mice. Further 
studies will be conducted to investigate whether the CpG treatment combined with CTLA-4 blockade in 
therapeutic settings could mediate the eradication of established tumors. Our future studies will be aimed 
at the optimization of therapeutic protocols that could lead to maximal NK cell activation against tumor and 
include the facilitation of NK cell responses in combination with prevention of their inhibition within the 
tumor tissue. 
 
7.5. B7 family expression by NK cells - crucial issues for NK cell based anti-cancer 
therapy 
Despite the knowledge about NK cell anti-tumor responses, the clinical efficacy of trials targeting NK cells, 
has been modest. The most effective use of NK cells is in situations when the tumor burden is relatively 
low, such as in patients with minimal residual disease, post surgery or following relapse. Studies in mice 
indicate that NK cells have a very limited capacity to affect established malignancies. The high percentage 
of human tumors show a deficient expression of MHC class I molecules and cannot be efficiently targeted 
by CTLs [273]. However, those tumors might be selected for NK cell based therapy. NK cell infiltration of 
solid tumors in human patients is variable. Although higher numbers of NK cells found within the tumor 
tissue correlated with a better prognosis, their level of activation is often not sufficient to efficiently control 
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the tumor growth [275-276]. Our studies shed some light on the possible mechanisms that might impede 
the effective NK cell response within established solid tumors. Global expression profile of tumor 
infiltrating NK cells provided the data for a detailed study of NK cell functional state within the tumor. 
We confirmed the downregulation of activating receptors and the upregulation of inhibitory receptors of the 
B7 family on NK cells in the tumor. Our data suggest that NK cell IFNγ production might be the main target 
of inhibition within the tumor tissue, with the potential to prevent effective T cell activation and T cell 
mediated tumor regression. In agreement with the emerging evidence from other studies, strategies based 
on the combination therapies are expected to be the most effective anti-tumor treatments. The knowledge 
about the phenotype and function of tumor infiltrating NK cells will be essential for their efficient implication 
in the novel treatment strategies.  
CTLA-4 blockade in cancer patients was shown to be beneficial for late stage cases of melanoma and 
renal cell carcinoma [268, 353]. When CTLA-4 blockade was combined with peptide vaccine, no additional 
clinical benefits were observed. A combination of CTLA-4 blocking mAb with GM-CSF producing tumor 
vaccine induced large tumor necrosis and long-term freedom from progression after the resection of 
necrotic tumor masses in melanoma patients. However, the patients who showed clinical benefits usually 
developed immune-related adverse events, including rush, vitiligo, colitis, diarrhea, hypophysitis, hepatitis 
and nephritis due to the breakage of self-tolerance and activation of self-reactive T cells. Therefore, 
it would be important to investigate whether CTLA-4 blockade can be combined with NK cell activating 
agents in the dose and application regimen that would produce clinical benefits without adverse effects. 
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9. Abbreviations 
 
β2m     β2 microglobulin 
µg      Microgram 
µl      Microliter 
µM     Micromolar 
7-AAD     7-Aminoactinomycin D 
Å     Angström 
ACK      Ammonium chloride potassium phosphate 
ADCC     Antibody dependent cell mediated cytotoxicity 
Ag      Antigen 
ALL     Acute lymphoid leukemia 
AML      Acute myeloid leukemia 
ANOVA     Analysis of variance 
AP-1 and AP-2    Activator protein-1 and 2 
APC      Allophycocyanin 
APC(s)      Antigen presenting cell(s) 
BC     Breast cancer 
BCG     Bacillus Calmette-Guérin 
BCR      B cell receptor 
BM      Bone marrow 
BMT     Bone marrow transplantation 
BP     Binding protein 
BrdU      Bromodeoxyuridine 
BTNL2     Butyrophilin-like protein 2 
CAECAM1    Carcinoembryonic antigen-related cell adhesion molecule 1 
CAM      Cell adhesion molecule(s) 
CD      Cluster of differentiation 
cDNA     complementary DNA 
cFc     control fusion protein 
CFSE     Carboxyfluorescein succinimidyl ester 
CML     Chronic myeloid leukemia 
CMV     cytomegalovirus 
CNS     Central nervous system 
CR     complete response 
cRNA     complementary RNA 
CTL(s)      Cytotoxic T lymphocyte(s) 
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CTLA-4     Cytotoxic T lymphocyte associated antigen-4 
Cy     Cyanine 
d      Day(s) 
DAP10     DNAX-associated protein of 10 kDa 
DAP12      DNAX-associated protein of 12 kDa 
DC(s)     Dendritic cell(s) 
ddH2O      Double distilled water 
DEN     Diethylnitrosamine 
DEPC     Diethylpyrocarbonate 
DFS     Disease-free survival 
DMBA     7,12-Dimethylbenz(a)anthracene 
DMEM     Dulbecco/Vogt modified Eagle's minimal essential medium 
DMOG     Dimethyloxaloylglycine 
DMSO      Dimethylsulfoxide 
DNA      Desoxyribonucleic acid 
DNAM-1    DNAX accessory molecule-1 
dNTP     Deoxyribonucleotide triphosphate 
E:T     effector to target ratio 
EAE     Experimental autoimmune encephalomyelitis 
ECM      Extracellular matrix 
EDTA      Ethylenediaminetetraacetic acid 
ELISA      Enzyme-linked immunosorbent assay 
ERK     Extracellular-signal-regulated kinase 
FACS™     Fluorescence-activated cell sorting 
Fas      Fibroblast associated 
FasL      Fas ligand 
FcR     Fc receptor 
FCS      Fetal calf serum 
FITC      Fluorescein-isothiocyanate 
Flt3     FMS-like tyrosine kinase 3 
FVAX     Flt3L expressing cancer vaccine 
g      Gram(s) 
GATA-3     GATA-binding protein-3 
GM-CSF     Granulocyte-macrophage colony stimulating factor 
Grb2     Growth factor receptor-bound protein 2 
GVAX     GM-CSF producing cancer vaccine 
Gzm     Granzyme 
h      Hour(s) 
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HD     Hodgkin’s lymphoma 
HER-2      Human epidermal growth factor receptor-2 
HLA     Human leukocyte antigen 
HSC     Hematopoietic stem cell 
HVEM     Herpesvirus entry mediator 
i.p.      Intraperitoneal 
i.v.     Intraveneous 
ICAM      Intercellular adhesion molecule 
ICOS     Inducible  T cell costimulator 
ICOS-L     Inducible T cell costimulator ligand 
iDC     Immature dendritic cells 
IDO      Indoleamine-pyrrole 2,3-dioxygenase 
IFN      Interferon 
Ig     Immunoglobulin 
IgC     Immunoglobulin constant 
IGIF     IFNγ inducible factor 
IGV     Immunoglobulin variable 
IKDC(s)     Interferon producing killer dendritic cell(s) 
IL      Interleukin 
IMDM     Iscove's modified Dulbecco's medium 
Iono     Ionomycin 
ITAM      Immunoreceptor tyrosine-based activation motif 
ITIM      Immunoreceptor tyrosine-based inhibitory motif 
ITSM     Immunoreceptor tyrosine-based switch motif 
JNK     c-Jun N-terminal kinase 
KEGG     Kyoto Encyclopedia of Genes and Genomes 
KIR(s)     Killer-cell immunoglobulin-like receptor(s) 
KLRG1     Killer cell lectin-like receptor subfamily G member 1 
KO     Knock out 
L     Ligand 
L     Liter 
LAK(s)     Lymphokine activated killer cell(s) 
Lin     Lineage 
LIR     Leukocyte immunoglobulin-like 
LN      Lymph node 
LPS      Lipopolysaccharide 
M     Molar concentration 
mAb(s)     monoclonal antibody(ies) 
MACS®     Magnetic cell sorting 
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MCA     methylcholanthrene 
MCAM      Melanoma cell adhesion molecule 
MCMV      Murine cytomegalovirus 
MCP-1      Monocyte chemoattractant protein-1 
mDC(s)     Mature dendritic cell(s) 
MDSCs     Myeloid derived suppressor cell(s) 
MFI      Mean fluorescence intensity 
MHC      Major histocompatibility complex 
MIC      MHC class I chain related 
min      Minute(s) 
mg     Miligram 
ml      Mililitre 
mM     Milimolar 
mRNA     Messenger RNA 
MS     Multiple sclerosis 
MULT1     Murine UL-16-binding protein-like transcript 1 
NCAM      Neural cell adhesion molecule 
NCR(s)     Natural cytotoxicity receptor(s) 
NF     Nuclear factor 
NFAT     Nuclear factor of activated T cells 
NHL     Non-Hodgkin’s lymphoma 
NK      Natural killer 
NKG2      NK group 2 member 
NKP     NK cell precursor 
NOD     Non-obese diabetic 
NOS     Nitric oxide syntase 
OR     Overall response 
OS     Overall survival 
OVA      Ovalbumin 
ORA     Over-representation approach 
PAMP      Pathogen-associated molecular patterns 
PBL      Peripheral blood lymphocytes 
PBMC     Peripheral blood mononuclear cells 
PBS      Phosphate buffered saline 
PCM     Primary cell medium 
PD-1      Programmed cell death-1 
pDC      Plasmacytoid DC 
PDGF     Platelet derived growth factor 
PD-L     Prrogrammed cell death 1 ligand 
 ‐ 155 ‐ 
 
PD-L1 and PD-L2    Programmed cell death-1 ligand-1 and 2 
PE      Phycoerythrin 
PerCP-Cy5.5     Peridinin-chlorophyll-protein-complex-cyanine 5.5 
pH      Potential hydrogeni 
PI3K      Phosphoinositide 3-kinase 
PLC     Phospholipase 
PMA     Phorbol 12-myristate 13-acetate 
Poly I:C     Polyinosinic-polycytidylic acid 
PP2A     Protein phosphatase 2 
PR     Partial response 
PRF     Perforin 
PRR(s)     Pattern Recognition Receptor(s) 
R     Receptor 
RA     Rheumatoid arthritis 
Rae-1      Retinoic acid early inducible-1 
RAG      Recombination activation gene 
RCC     Renal cell carcinoma 
RNA      Ribonucleic acid 
ROS     Reactive oxygen species 
rpm      Rounds per minute 
RPMI     Roswell park memorial institute medium 
RT      Room temperature 
s.c.      Subcutaneous 
SD     Stable disease 
SD      Standard deviation 
SH-2      Src homology-2 
SHIP      SH2-containing inositol polyphosphate 5-phosphatase 
SHP-1 and SHP-2    SH2-containing protein-tyrosine phosphatase-1 and 2 
SLE     Systemic lupus erythematosus 
TAP     Transporter associated with antigen processing  
TCR      T cell receptor 
TF     Transcription Factor 
TGFβ     Transforming growth factor β 
TGN     Trans-Golgi network  
Th     T helper 
TIN(s)     Tumor infiltrating NK cell(s) 
TIT(s)     Tumor infiltrating T cell(s) 
TLR      Toll-like receptor 
TNF     Tumor necrosis factor 
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TPA     12-O-tetradecanoylphorbol-13-acetate 
TRAIL      TNF–related apoptosis inducing ligand 
TRAMP     Transgenic adenocarcinoma mouse prostate 
Treg      Regulatory T cell 
TREM     Triggering receptor expressed on myeloid cells 
TREML2    Triggering receptor expressed on myeloid cells-like 2 
TRIM     T-cell receptor-interacting molecule 
U     Unit 
ULBP      UL16-binding protein 
UV     Ultraviolet 
VEGF     Vascular endothelial growth factor 
W/     With 
W/O     Without 
WT      Wild type 
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